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Abstract 
Alzheimer’s disease (AD) is a devastating condition characterised by significant 
cognitive impairment and memory loss. Transgenic mouse models are increasingly 
being used to further our knowledge of the cause and progression of AD, and identify 
new targets for therapeutic intervention. These mice permit the study of specific 
pathological hallmarks of the disease, including intracellular deposits of 
hyperphosphorylated tau protein and extracellular amyloid plaques. In order to 
characterise these transgenic mice, robust biomarkers are required to evaluate 
neurodegenerative changes and facilitate preclinical evaluation of emerging therapeutics. 
In this work, a platform for in vivo structural imaging of the rTg4510 mouse model of 
tauopathy was developed and optimised. This was combined with a range of other 
clinically relevant magnetic resonance imaging (MRI) biomarkers including: arterial spin 
labelling, diffusion tensor imaging and chemical exchange saturation transfer. These 
techniques were applied in a single time-point study of aged rTg4510 mice, as well as a 
longitudinal study to serially assess neurodegeneration in the same cohort of animals. 
Doxycycline was administered to a subset of rTg4510 mice to suppress the tau 
transgene; this novel intervention strategy permitted the evaluation of the sensitivity of 
MRI biomarkers to the accumulation and suppression of tau. Follow-up ex vivo scans 
were acquired in order to assess the sensitivity of in vivo structural MRI to the current 
preclinical gold standard. 
High resolution structural MRI, when used in conjunction with advanced computational 
analysis, yielded high sensitivity to pathological changes occurring in the rTg4510 
mouse. Atrophy was reduced in animals treated with doxycycline. All other MRI 
biomarkers were able to discriminate between doxycycline-treated and untreated 
rTg4510 mice as well as wildtype controls, and provided insight into complimentary 
pathological mechanisms occurring within the disease process. 
In addition, this imaging protocol was applied to the J20 mouse model of familial AD. 
This mouse exhibits widespread plaque formation, enabling the study of amyloid-
specific pathological changes. Atrophy and deficits in cerebral blood flow were 
observed; however, the changes occurring in this model were markedly less than those 
observed in the rTg4510 mouse. This study was expanded to investigate the early-onset 
AD observed in individuals with Down’s syndrome (DS) by breeding the J20 mouse 
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with the Tc1 mouse model of DS, permitting the relationship between genetics and 
neurodegeneration to be dissected. 
This thesis demonstrates the application of in vivo multi-parametric MRI to mouse 
models of neurodegeneration. All techniques were sensitive to pathological changes 
occurring in the models, and may serve as important biomarkers in clinical studies of 
AD. In addition, in vivo multi-parametric MRI permits longitudinal studies of the same 
animal cohort. This experimental design produces more powerful results, whilst 
contributing to worldwide efforts to reduce animal usage with respect to the 3Rs 
principles. 
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3
 (1.9) 
 
𝐹𝐴 =  √
1
2
 
√(𝜆1 −  𝜆2)2 + (𝜆1 −  𝜆3)2 + (𝜆2 −  𝜆3)2 
√𝜆1
2 + 𝜆2
2 +  𝜆3
2 
 (1.10) 
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𝐶𝑜𝑛𝑡𝑟𝑎𝑠𝑡 =  𝑆𝑖𝑔𝑛𝑎𝑙ℎ𝑖𝑝𝑝𝑜𝑐𝑎𝑚𝑝𝑢𝑠  − 𝑆𝑖𝑔𝑛𝑎𝑙𝑡ℎ𝑎𝑙𝑎𝑚𝑢𝑠 (3.1) 
 
𝑆𝑁𝑅 =  
𝑀𝑒𝑎𝑛 𝑠𝑖𝑔𝑛𝑎𝑙 
𝑁𝑜𝑖𝑠𝑒
 (3.2) 
 
𝐶𝑁𝑅 =  
𝑀𝑒𝑎𝑛 𝑠𝑖𝑔𝑛𝑎𝑙𝐴 –  𝑀𝑒𝑎𝑛 𝑠𝑖𝑔𝑛𝑎𝑙𝐵
𝑁𝑜𝑖𝑠𝑒
 (3.3) 
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Abbreviations 
11C-PiB Pittsburgh compound B 
18F-FDG Flurodeoxyglucose 
2D Two dimensional 
3D Three-dimensional 
3D Three-dimensional 
ACh Acetylcholine 
ACh Acetylcholine 
AChEI Acetylcholinesterase inhibitor 
AChEIs Acetylcholinesterase inhibitors 
AD Axial diffusivity 
AD Alzheimer’s disease 
ADNI Alzheimer’s Disease Neuroimaging Initiative 
APOE Apolipoprotein 
APP Amyloid precursor protein 
APT Amide proton transfer 
ASL Arterial spin labelling 
Aβ-42 Amyloid-β1-42 
CBF Cerebral blood flow 
CEST Chemical exchange saturation transfer 
CNR Contrast-to-noise ratio 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CT Computer tomography 
DNA Deoxyribonucleic acid 
DS Down’s syndrome 
DTI Diffusion tensor imaging 
DTPA Diethylene-triamine-penta-acetic acid 
EPI Echo planar imaging 
ETL Echo train length 
FA Fractional anisotrophy 
FAIR Flow-sensitive alternating inversion recovery 
FDG 18F-FDG 
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FDR False discovery rate 
FID Free induction decay 
FSE Fast spin echo 
FT Fourier transform 
FTD Frontotemporal dementia 
GE Gradient echo 
hAPP Human amyloid precursor protein 
hMAPT Human microtubule associated protein tau 
i.p. Intraperitoneal 
Ind. Indiana 
Lon. London 
LP Lumbar puncture 
MAPT Microtubule associated protein tau 
MCI Mild cognitive impairment 
MD Mean diffusivity 
MIP Maximum intensity projection 
mL Millilitre 
mm Millimetre 
MMSE Mini mental state examination 
MR Magnetic resonance 
MRA Magnetic resonance angiography 
MRH Magnetic resonance histology 
MRI Magnetic resonance imaging 
NFTs Neurofibrillary tangles 
NMDA N-methyl-D-aspartate 
NMR Nuclear magnetic resonance 
NSA Number of signal averages 
PET Positron emission tomography 
PS1 Presenilin 1 
PS2 Presenilin 2 
P-tau Phosphorylated tau 
RD Radial diffusivity 
RF Radiofrequency 
ROI Region of interest 
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SD Standard deviation 
SE Spin echo 
SEM Standard error of the mean 
SNR Signal-to-noise ratio 
SPIO Superparamagnetic iron oxide 
SUV Standard uptake value 
Swe. Swedish 
T Tesla 
T1 Longitudinal magnetisation relaxation time constant 
T2 Transverse magnetisation relaxation time constant 
TBM Tensor-based morphometry 
TBV Total brain volume 
Tc1 Transchromic 1 
TE Echo time 
TEeff Effective echo time 
TOF Time-of-flight 
TR Repetition time 
T-tau Total tau 
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Chapter 1: Alzheimer’s disease 
This chapter gives a broad overview of Alzheimer’s disease (AD): from reviewing the existing 
hypotheses that try and explain the cause of the disease, to describing the current available biomarkers 
for the diagnosis of AD. A summary of different mouse models of AD is also provided.  
1.1 Overview: Alzheimer’s disease and the current challenges 
In 1906, at the 37th Meeting of the Psychiatrists of South West Germany, Dr. Alois 
Alzheimer presented the neuropathological and clinical findings of his most recent case. 
The patient, Auguste D, presented with “a peculiar severe disease of the cerebral 
cortex,” with symptoms including “paranoia, progressive sleep and memory 
disturbance, aggression, and confusion’’. Auguste D died of her symptoms at the age of 
55.  
 
Figure 1.1 Alois Alzheimer’s historical case reported the symptoms of Auguste D, pictured above. 
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Alzheimer’s subsequent publication in 1911 provided detailed post-mortem analysis of 
Auguste D’s brain, showing various abnormalities including ‘senile plaques’ – 
extracellular deposits of amyloid-β – and neurofibrillary tangles of hyperphosphorylated 
tau (NFTs) (1, 2). These discoveries were crucial in uncovering key aspects of the 
disease, and plaques and tangles are now widely regarded as the histopathological 
hallmarks of Alzheimer’s disease (AD). 
 
 
Figure 1.2 Drawings of histological preparations of postmortem AD brains, taken from Alois Alzheimer’s 
1911 publication. Alzheimer employed Bielschowsky's silver stain protocol to stain senile plaques and NFTs in 
the cortex of AD patients. (A) Beginning of the disease; (B) Advanced stage; and (C) Terminal state of the 
disease.  
 
It has been over one hundred years since Alois Alzheimer’s initial observations of the 
disease that would come to bear his eponym. Yet, there is still no known cure for this 
debilitating disease. AD is now known to be the most common form of dementia: a 
broad category of neurodegenerative diseases associated with the progressive decline of 
brain function. The rest of this chapter will focus on the advancements that have been 
made in our understanding of AD. 
1.2 Causes of Alzheimer’s disease 
The underlying cause of the vast majority of AD cases is unknown. However, a small 
proportion of early-onset AD cases are found to cluster in families, and can be 
attributed to genetic mutations in one of three genes:  those encoding amyloid 
precursor protein (APP) (3), presenilin 1 (PS1) (4) and presenilin 2 (PS2) (5). APP 
mutations cause an increase in amyloid-β production and aggregation, as well as 
increasing the extracellular concentration of the amyloid-β1-42 species, which is believed 
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to be the initiating molecule in the pathogenesis of AD (6, 7). Mutations in the 
presenilins are linked to abnormal APP processing, and are also believed to increase the 
extracellular concentration of amyloid-β1-42 (8). Estimates of the prevalence of early-
onset forms of AD vary widely, but most recently it has been suggested that 1% - 5% of 
AD cases are inherited in an autosomal dominant fashion (9).  
In contrast, the majority of AD cases are late-onset (“sporadic”) forms of AD, without 
obvious familial aggregation. A number of genes have been identified which are 
associated with a greatly increased risk of developing late-onset AD, without invariably 
causing it. The ε4 allele of the apolipoprotein ε (APOE) gene is the strongest known 
genetic risk factor for late-onset AD. In comparison to non-carriers, individuals who are 
heterozygous for one ε4 allele are 3 – 4 times more likely to develop AD; the risk factor 
for homozygous carriers is even further increased (10). In addition, a number of other 
genetic variants have been associated with increased risk of AD including: CLU and 
CR1 (11); ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP (12).  It is likely 
that, over time, more genetic determinants will be implicated in AD (13). Other than the 
age of onset, the clinical and histological features of early-onset AD are 
indistinguishable from late-onset, sporadic forms of AD (14). 
With no definitive genetic cause for the majority of sporadic AD cases, a number of 
hypotheses have been proposed which attempt to outline the cause of the disease.  
1.2.1 The cholinergic hypothesis 
In an effort to identify a neurochemical abnormality in the brains of AD patients, 
systematic biochemical evaluation of post-mortem AD brains commenced in the late 
1960s (15). In 1976, marked deficits of the neurotransmitter acetylcholine (ACh) were 
identified in AD patients compared to elderly controls (16, 17). These findings resulted 
in the first theory proposed to explain AD: the cholinergic hypothesis of AD. The 
cholinergic hypothesis proposes that a loss of cholinergic function in the central 
nervous system (CNS) significantly contributes to cognitive decline in AD patients (18). 
This discovery has led to the development of treatment strategies which aim to increase 
the levels of ACh, with hope of restoring cognitive function. Acetylcholinesterase 
inhibitors (AChEIs), which increase neural levels of ACh by inhibiting the 
acetylcholinesterase enzyme from breaking down acetylcholine, have shown beneficial 
40 
 
effects on cognitive functions and memory in AD patients (19, 20). AChEIs currently 
make up the majority of FDA-approved AD therapies (Table 1.1) (21) 
Despite these encouraging results, the cholinergic hypothesis is subject to much 
criticism. Post-mortem analysis of the brains of patients with early stage AD identified 
no loss in ACh activity (22), suggesting that a cholinergic marker would be unsuitable 
for early detection of AD. These findings also question the therapeutic validity of 
treating individuals with early stage AD with AChEIs (23). In addition, AChEIs only 
offer mild symptomatic relief of AD, and are not able to reverse or restore neuronal 
function (23). Researchers are now investigating other possible mechanisms which may 
shed light on the cause of AD. 
 
Table 1.1 Current FDA-approved drugs for the treatment of AD  
Therapeutic target Drug Trade name(s) 
AChEIs Rivastigmine Exelon 
 Galantamine Razadyne, Reminyl 
 Tacrine Cognex 
 Donepezil Aricept 
NMDA-receptor antagonist Memantine Namenda 
 
1.2.2 Amyloid cascade hypothesis 
With increasing research into the biochemical changes underpinning AD, the amyloid 
cascade hypothesis emerged in 1992 when Hardy and Higgins proposed that deposits of 
amyloid-β were the main causative agent in AD. Their hypothesis stipulates that 
amyloid plaques, formed by aggregates of amyloid-β generated by the proteolytic 
cleavages of APP, are central to AD pathogenesis (24). Once present in the brain, the 
plaques initiate a succession of neuropathological events including NFTs, neuronal cell 
loss, and ultimately dementia (Figure 1.3) (24).  
The amyloid cascade hypothesis emerged after increasing evidence implicated the role 
of amyloid-β in AD. The discovery that the senile plaques first described by Alois 
Alzheimer in 1906 contained amyloid-β (25) was the first piece of evidence implicating 
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amyloid-β as a causative agent in AD. It was later shown that the primary constituent of 
amyloid plaques was amyloid-β1-42 – the species believed to initiate the disease (6, 7). 
The subsequent discovery that mutations in the APP, PS1 and PS2 genes cause early 
onset AD provided further proof of amyloid-β’s role in the development of AD, as all 
of these mutations affect the processing and accumulation of amyloid-β (3). In addition, 
the universal occurrence of AD within the Down’s syndrome (DS) population has been 
attributed to triplication of the APP gene, which lies on chromosome 21 (26, 27). It is 
believed that the extra copy of the APP gene is sufficient to cause the early-onset AD in 
individuals with DS (28). This combination of biochemical, neuropathological and 
genetic findings provides compelling evidence in support of the amyloid cascade 
hypothesis, which has been the subject of substantial research in the field over the past 
two decades. This is reflected in the next generation of disease-modifying AD drugs, the 
majority of which are targeting the production, aggregation and clearance of amyloid-β 
(29). However, a number of these emerging drugs have since failed to produce a 
therapeutic effect in clinical trials (30). These results suggest that amyloid build-up 
cannot solely define AD, putting the validity of the amyloid hypothesis into question. 
Indeed, some people develop amyloid plaques without suffering cognitive impairment; 
these cases are called ‘asymptomatic AD’ (31). 
It is doubtful that the complex pathophysiology of AD can be explained by a simple 
linear disease model such as the amyloid cascade hypothesis (32). It is likely that there 
are other causative agents besides amyloid-β that are underpinning AD.  
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Figure 1.3 The amyloid cascade hypothesis, adapted from the work by Karran et al. (33) 
 
1.2.3 The tau hypothesis 
One such potentially causative agent is tau, the other major histological hallmark of AD. 
Tau’s inherent role in the human brain is as a cytoplasmic protein that binds to tubulin 
during its polymerisation, stabilising microtubules and facilitating intracellular transport 
(34). In AD, tau becomes abnormally phosphorylated, forming hyperphosphorylated 
NFTs. In recent years, tau has been implicated as the major causative agent 
underpinning cognitive decline in AD (35). 
The tau hypothesis has a number of advantages over the amyloid hypothesis for 
defining AD. The work by Braak and Braak identified NFT pathology in post-mortem 
brains, in the absence of amyloid plaques (36); these findings suggest that NFT 
accumulation is the initiating event in AD (37). NFT burden has also been shown to 
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correlate with the severity of cognitive decline and the duration of dementia (38, 39); 
this correlation is not mimicked with amyloid plaques. In addition to AD, NFTs are 
also central to a number of other degenerative diseases in the absence of amyloid 
plaques, such as Pick’s disease, frontotemporal dementia (FTD) and progressive 
supranuclear palsy (40). The implication of tau in other dementias strengthens its role as 
a key pathological agent in AD. 
There are no known mutations in the microtubule associated protein tau (MAPT) gene 
that cause early-onset AD; however, a number of mutations in the MAPT gene cause 
other dementias, e.g. autosomal dominant FTD chromosome-17 type (41). Individuals 
with FTD typically exhibit a similar pattern of neuropathological alterations to AD, 
including cortical atrophy, loss of neuronal cells and behavioural alterations (42).  
As an AD treatment strategy, there are a number of therapeutic approaches that tau-
directed compounds typically target, including: 1) modulating tau phosphorylation by 
inhibiting tau phosphorylation kinases; 2) stabilization of microtubules, and 3) 
compounds that prevent tau aggregation (43, 44). A number of these tau-mediating 
therapies have shown promise in preclinical studies, and are currently moving into 
clinical trials (45-47). 
In addition to dementias, hyperphosphorylation of tau is observed during hibernation. 
It has been suggested that tau phosphorylation in the adult mammalian brain may to 
represent a naturally occurring process that is associated with neuroprotective 
mechanisms (48); hibernating animals may therefore represent an valuable model to 
study the regulation of tau phosphorylation.  
1.2.4 Other hypotheses 
Another compelling hypothesis for the cause of AD states that glutamate dysfunction 
can account for many of the neurochemical and behavioural alterations observed in AD 
(49). Glutamate is the most abundant excitatory neurotransmitter in the CNS which 
helps regulate synaptic plasticity, neuronal growth, cognition and memory (50). 
Disturbances in the glutamatergic system have been associated with the 
pathophysiological processes in AD (51, 52).  
Glutamate activates a number of different receptors in the brain, including the N-
methyl-D-aspartate (NMDA) receptors. It is believed that chronic, low-level stimulation 
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of these NMDA receptors by glutamate leads to neurodegeneration; a phenomenon 
termed ‘excitotoxicity’ (50). The reason for the increased sensitivity of the glutamatergic 
system is still unknown, but a number of different mechanisms have been proposed, 
including: oxidative stress, mitochondrial dysfunction and impaired metabolism, in 
addition to the presence of amyloid plaques and NFTs (53-55). 
Therapeutic strategies targeting the glutamatergic system have shown some promise in 
clinical trials. Memantine, for example, is an FDA-approved NMDA receptor 
antagonist which addresses the hyperactivity of these receptors (Table 1.1) (56). 
Memantine may delay the deterioration of the patient in mild to moderate cases of AD 
(57). 
1.3 Diagnosis of Alzheimer’s disease 
An accurate and early diagnosis of AD requires careful clinical evaluation, and is crucial 
for planning treatment strategies and supportive counselling. An initial memory 
complaint or subtle personality change usually causes a patient to seek medical advice in 
the first instance.  
Typically, a clinician will explore the patient’s medical records in order to ascertain 
whether they have a family history of AD, and therefore may carry an increased risk of 
developing the disease. For early-onset forms of AD, the increased risk of developing 
the disease is 50%. It has been estimated that individuals with a family history of  late 
onset (“sporadic”) AD carry a 20% chance of developing the disease, compared with 
10% across the wider population (58). Secondly, a neuropsychological test is employed 
in order to assess the patient’s memory, language and problem solving abilities. The 
mini mental state examination (MMSE) is the most frequently used, and uses a 30 point 
questionnaire to measure cognitive function (59). As well as helping diagnose AD (and 
other forms of dementia), the MMSE can indicate the progression and severity of the 
disease.  Patients may undergo additional blood and urine tests, in order to rule out any 
other cause for their memory problems. Brain imaging techniques may be utilised in 
order to get a more definitive diagnosis of AD, although these are not routinely 
employed (60). 
Often, the current clinical assessment for AD (described in Section 1.3) is inconclusive, 
resulting in a diagnosis of mild cognitive impairment (MCI). MCI can be considered an 
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intermittent phase between the normal aging process and the earliest features of 
dementia. MCI patients carry a high risk for developing dementia with over half of 
those diagnosed converting to AD and other forms of dementia within 5 years (61). 
There are 4 different subgroups of MCI; an algorithm is used by clinicians to aid their 
classification (Figure 1.4) (62). If memory is impaired then the patient is designated as 
having amnestic MCI. A memory component is a strong indicator that the patient will go 
on to develop AD over other forms of dementia.  
In recent years, increasing emphasis is being placed on the development and 
implementation of biomarkers of AD: direct or surrogate measurement of 
pathophysiological or functional characteristics of the tissue which can be measured in 
vivo (63, 64). Biomarkers may offer heightened sensitivity to the early pathological 
events in AD which precede cognitive impairment, and facilitate early diagnosis of the 
disease.  
 
Figure 1.4 The algorithm used to classify subgroups of MCI, adapted from the work by Petersen et al. (62) 
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1.4 Biomarkers of Alzheimer’s disease 
While the MCI classification is useful for identifying individuals who carry a heightened 
risk of converting to AD, the diagnostic criteria will ideally move into the asymptomatic 
stage of the disease. The pathological processes of AD are now believed to begin up to 
20 years before the onset of cognitive impairment (65, 66). This prolonged prodromal 
stage of the disease provides a critical opportunity for therapeutic intervention, prior to 
the irreversible destruction of neuronal tissue (62, 67). Thus, the identification and 
validation of biomarkers of AD is increasingly important, for improving the predictions 
of those who are at risk of converting from normal cognition to MCI, and finally AD.  
Humpel et al. outlined a list of criteria which biomarkers of AD should ideally fulfil 
(64): 
1. Reflect physiological aging processes 
2. Reflect basic pathophysiological processes of the brain 
3. React upon pharmacological intervention 
4. Display high sensitivity 
5. Display high specificity for the disease as compared with related disorders 
6. Allow measurements repeatedly over time 
7. Allow reproducibility in laboratories worldwide 
8. Should be measurable in non-invasive, easy-to-perform tests 
9. Should not cause harm to the individuals being assessed 
10. Tests should be inexpensive and rapid 
11. Samples should be stable to allow easy and cheap transport 
12. Easy collection of fluids not only in hospitals 
13. Changes should be at least twofold to allow differentiation of controls 
14. Define good cut-off values to distinguish diseases 
15. Data published in peer-reviewed journals 
16. Data reproduced by at least two independent researchers 
While researchers have yet to identify an AD biomarker which satisfies all of the above 
criteria, several biomarkers have shown sensitivity to early neuropathological changes in 
AD, and may be useful for the early diagnosis of the disease and evaluating the efficacy 
of candidate drugs (63).  
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1.4.1 Cerebrospinal fluid  
It is now known that molecular changes in the brain can be detected in the 
cerebrospinal fluid (CSF) (68). Candidate CSF biomarkers include: total tau (T-tau) as a 
marker of neuronal degradation, amyloid-β1-42 (Aβ-42), as a marker of amyloid-β 
metabolism and plaque formation; and phosphorylated tau (P-tau) as a marker for tau 
phosphorylation and the formation of NFTs (69).  
A number of studies have reported a marked increase in CSF T-tau and P-tau, alongside 
decreases in Aβ-42 (69, 70). This pattern of changes is unique to AD, and therefore may 
find relevance in the differential diagnosis of AD over other forms of dementia (71). 
The performance of these biomarkers is high, with reported sensitivity and specificity of 
CSF biomarkers to discriminate between AD patients from healthy controls of 80 – 
90% (69, 70). CSF biomarkers are believed by some to be the most sensitive biomarkers 
of AD neuropathology (68). 
In order to extract CSF for biomarker analysis, a lumbar puncture (LP) must be 
performed (69). In the clinical scenario, a LP is often avoided due to the post-LP 
headache, thought to arise due to loss of CSF volume and the leaking of fluid into 
nearby tissue (72). An alternative, non-invasive method for quantifying amyloid-β and 
tau deposition in the brain is therefore highly desirable. 
1.4.2 Positron emission tomography 
One such method is positron emission tomography (PET). PET is a nuclear imaging 
technique which permits the quantification and distribution of a radiolabelled tracer to 
be assessed in vivo. These tracers can be engineered to bind to amyloid plaques and 
NFTs, which may allow the detection of these causative agents in the brain prior to the 
onset of cognitive decline (73, 74).  
The most widely used PET compound for amyloid imaging is the 11C-labelled tracer 
Pittsburgh compound B (11C-PiB) (75). 11C-PiB is a radioactive analogue of thioflavin T; 
a histological stain which is traditionally used to identify amyloid oligomers – a 
precursor to amyloid plaques (76). It has been demonstrated that the regional uptake of 
11C-PiB closely mirrors the post-mortem distribution of amyloid-β, supporting its 
application as a method for in vivo detection of amyloid plaques (77). In addition, high 
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levels of 11C-PiB uptake have been shown to be a strong predictor for conversion from 
MCI to AD (78, 79). 
 
 
Figure 1.5 PET scan of an AD patient and healthy control, showing high retention of the tracer in the AD 
brain. SUV represents the standard uptake value: red = high uptake, blue = low uptake. Reproduced from 
Nordberg et al. (80) 
 
However, the very short half-life of 11C (20 minutes) introduces some practical 
limitations to working with 11C-PiB, as the radioisotope must be produced in close 
proximity to the PET scanner in order to label the compound and inject the patient in 
sufficient time (81). In order to overcome these difficulties, several other tracers have 
been developed for in vivo amyloid imaging, such as florbetaben, florbetapir and 
flutemetamol (81). These agents are all labelled with the radioisotope 18F, which has a 
half-life of 110 minutes. Preliminary work using these compounds suggests high 
sensitivity and specificity to amyloid-β (81). 
A number of tau radiotracers are currently being developed for in vivo tau quantification; 
these include the compounds 18F-808 (82) and 18F-THK-5015 (83). As tau burden 
correlates with cognitive decline in AD (84), tracers which permit in vivo quantification 
of the distribution of tau pathology may potentially enable ante-mortem Braak staging 
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of the disease (85). Both of the aforementioned tracers have enabled the differentiation 
of AD patients from healthy controls, with high uptake in regions vulnerable to NFT 
deposition (82, 83).   
Another popular PET tracer for investigating neurodegeneration in AD patients is 
flurodeoxyglucose (18F-FDG). 18F-FDG is a glucose analogue, and can be used to 
measure brain metabolism. It is believed that cerebral glucose metabolism measured 
with 18F-FDG reflects synaptic activity (86); in AD, regional reductions in glucose 
metabolism have therefore been attributed to an impairment in synaptic activity that 
accompanies neurodegeneration (63). Hypometabolism detected using 18F-FDG has a 
distinct topographical pattern which is distinct from other dementias, enabling the 
differential diagnosis of AD over other forms of dementia (87, 88). It has been shown 
that 18F-FDG can identify MCI patients who will convert to AD, and may be useful in 
the early diagnosis of the disease (89, 90). 
 
 
Figure 1.6 18F-FDG PET scan of (A) a healthy control subject, and (B) a patient with an MCI diagnosis. 
Regional decreases in 18F-FDG uptake can be observed in the frontal parietal and temporal cortex of the MCI 
patient. SUV represents the standard uptake value: red = high uptake, blue = low uptake. Reproduced from 
Mosconi et al. (91). 
 
However, the short half-life of the PET radioisotopes (both 11C and 18F) has restricted 
the widespread and routine use of PET for early diagnosis of AD. In addition, the use 
of PET tracers in longitudinal studies is problematic, owing to the exposure risks 
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associated with radioactive isotopes; the radiation dose is greatly increased when an 
anatomical computed tomography (CT) scan is acquired simultaneously, to enable 
improved localisation of tracer uptake in the brain (92).  
1.4.3 Magnetic resonance imaging 
Structural MRI is an alternative method for assessing AD-related neuropathological 
changes.  
Structural MRI is able to accurately detect grey matter loss in characteristically 
vulnerable brain regions, such as the hippocampus and entorhinal cortex (93). These 
alterations have been shown to be indicative of progression from MCI to AD and other 
forms of dementia (94). The characteristic topographical pattern of atrophy in the AD 
brain can also be readily visualised using structural MRI, aiding differential diagnosis of 
the disease (93). 
 
 
Figure 1.7 Structural MRI scans of (A) a healthy control subject, (B) a patient diagnosed with amnestic MCI, 
and (C) and AD patient. Atrophy in the medial temporal lobes can be readily visualized in the aMCI and AD 
images. Reproduced from Vemuri et al. (95) 
 
The structural changes which can be visualised using structural MRI have been shown 
to reflect neuronal loss, decreased synaptic density and cell shrinkage (96).  As structural 
changes quantified using MRI correlate well with NFT deposition (97), they can be 
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considered a measure of tau-related neurodegeneration (98). It therefore may find 
clinical relevance in the therapeutic assessment of tau-mediating therapies. 
Recently, advanced image processing techniques have been developed to support the 
analysis of structural MRI datasets, enabling the detection to atrophy in an automated 
and unbiased fashion (93). These techniques have facilitated high throughput analysis of 
large cohort data sets, such as those generated within the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI); a shared resource of AD research data which includes PET and MRI 
scans, alongside cognitive testing and genetics (99). Advanced image processing 
techniques have also enabled the detection of structural MRI changes up to 10 years 
prior to the development of AD, in the prodromal phase of the disease (100).  
Other MRI techniques are increasingly being used to study AD-related changes. 
Diffusion tensor imaging (DTI), for example, is a technique that has shown sensitivity 
to microstructural changes in the white matter of the AD brain (101). More information 
about other MRI techniques which may offer sensitivity to neurodegenerative changes 
can be found in the proceeding chapters. 
1.5 The dynamic biomarker model 
In 2010, Jack et al. proposed a dynamic biomarker model for the AD pathological cascade: a 
schematic depiction plotting the sensitivity of the aforementioned biomarkers against 
time (Figure 1.8) (63, 98). According to this model, biomarkers of amyloid deposition 
show the earliest abnormalities prior to tau-related and neurodegenerative changes. This 
was achieved using measurements of Aβ-42 in the CSF and PET with 11C-PiB, with the 
former offering the earliest sensitivity to AD-related changes. Biomarkers of 
neurodegeneration, including CSF measurements of tau, structural MRI and FDG-PET, 
were abnormal later in the disease. 
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Figure 1.8 Dynamic biomarkers of the AD pathological cascade model. Amyloid-β is identified by CSF 
Aβ42 or PET amyloid imaging. Neuronal injury and dysfunction is identified by CSF tau or FDG-PET. 
Neurodegenerative atrophy is measured by structural MRI. Reproduced from Jack et al. (98) 
 
Jack et al. acknowledge that the observations made by Braak and Braak, described in 
Section 1.2.3, do not fit their model. Braak and Braak stated that NFT deposition 
precedes amyloid-β accumulation in AD -- a finding which is not reflected in the 
dynamic biomarker model. In defence of their model, Jack et al. stated that the genetic 
mutations in the APP, PS1 and PS2 giving rise to early-onset forms of AD are 
supportive of amyloid disturbances as the initiating event. Alternatively, it is also 
possible that these early, low levels of tau are below the detection threshold of the 
current available biomarkers. In support of the latter theory, Jack et al. released another 
version of their dynamic biomarker model, which acknowledges that tau pathology may 
be the first pathophysiological process to arise in many AD individuals, although it is 
below the detection threshold of the currently available biomarkers (Figure 1.9) (98).  
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Figure 1.9 Updated biomarkers of the AD pathological cascade model, which proposes that tau pathology 
precedes amyloid-β alterations but at a sub-threshold biomarker detection level. Reproduced from Jack et al. (98). 
 
1.6 Mouse models of Alzheimer’s disease 
Mouse models of AD are valuable tools for furthering our understanding of the 
different mechanisms underpinning the human condition. The most commonly used 
AD mouse models harbour mutations in human transgenes associated with early-onset 
forms of the human disease: APP, PS1 and PS2. Although these mutations are not 
representative of the majority of sporadic forms of the disease, they enable the 
replication of AD neuropathology in the mouse.  
There are many different mouse models of AD, each exhibiting a unique pattern of 
AD-related neuropathological changes. Some of the more frequently used models are 
detailed in Table 1.2.   
1.6.1 hAPP mouse models 
The most widely used mouse models of AD are based on transgenic expression of 
human APP (hAPP) (102). There are over 20 known APP mutations associated with 
early-onset AD, each named according to the geographical location from which the 
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Table 1.2 Summary of the most commonly used mouse models, adapted from previous work by Hall et al. (102) 
Mouse model Genes Mutations 
Plaques 
(months) 
Tangles 
(months) 
Neuronal loss 
(months) 
Synaptic loss 
(months) 
Cognitive 
impairment 
(months) 
Primary 
paper 
hAPP models PDAPP APP Ind. 6   8 3 (103) 
 J20 APP Ind., Swe. 5  3 8 4 (104) 
 Tg2576 APP Swe. 11   4 - 5 10 (105) 
 APP23 APP Swe. 6  14 - 18  3 (106) 
 TgCRND8 APP Ind., Swe. 3  6 6 3 (107) 
 R1.40 APP Swe. 13.5     (108) 
Aβ BRI-Aβ42 BRI-A  3     (109) 
hAPP/PS1 PS/APP APP, PS1 
Swe., PS1 M146L 
(A>C) 
6  22  3 (110) 
 
APPswe/PS1Δ 
E9 
APP, PS1 
Swe., PS1: Δ 
E9 
6    6 (111) 
 5XFAD APP, PS1 
Swe., Flo., Lon., PS1 
M146L (A<C), PS1 
L26V 
1.5  9 9 4 – 5 (112) 
hTau Tg2576/Tau(P301L) APP, MAPT Swe., MAPT P301L 6 – 7 3    (113) 
 rTg4510 MAPT MAPT P301L  2.5 5 8 2.5 - 4 (114) 
 3xTg 
APP, PS1, 
MAPT 
Swe., MAPT P301L, 
PS1 M146V 
6 12   4 (115) 
 htau MAPT -  9 10 - 14  6 (116) 
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affected family originated (117). The Swedish (Swe.), London (Lon.) and Indiana (Ind.) 
are the most frequently replicated in mouse models of AD.  
The PDAPP mouse, which was generated by Games et al. in 1995, is considered to be 
one of the oldest mouse models of AD (103). This mouse exhibits a number of 
cognitive abnormalities which manifest prior to plaque pathology; this includes deficits 
in spatial working memory from 4 months, followed by a decline in recognition 
memory from 6 months. Plaque deposition is observed from 6 months. The Tg2576, 
developed the following year by Hsaio et al., develops a similar pattern of age-related 
learning defects and plaque formation (105). 
Unusually, these mice do not typically exhibit significant neuronal loss; a defining 
feature of the clinical condition (118, 119). A number of other hAPP mouse models 
have also been unable to replicate the neuronal loss (120). Of the hAPP transgenic mice 
which do exhibit neuronal loss, such as the APP23  and J20 models, it is marginal and 
does not reflect the substantial neuronal loss observed in AD patients (121). These 
findings suggest that hAPP mice may not be the most suitable models for the study of 
AD. 
1.6.2 Amyloid-β mouse models 
AD mouse models can also be used to study the pathophysiological effects of different 
amyloid-β series. McGowan et al. have developed a transgenic mouse (the BRI-Aβ40 
mouse) that expresses amyloid-β1-42 in the absence of APP overexpression, in order to 
study the neurotoxic effects of amyloid-ββ1-42. BRI-Aβ40 mice develop age-related 
plaque pathology; these findings support the hypothesis that amyloid-β1-42 is the 
initiating molecule in the pathogenesis of AD. 
Conversely, mice overexpressing amyloid-β1-40 do not develop plaques, providing further 
proof of amyloid-β1-42’s role in the development of AD (109). 
1.6.3 Presenilin mice 
There are 184 mutation in PS1, and 14 mutations in PS2 that are known to cause early-
onset AD (117); the former are both more abundant and more severe, making them the 
focus of AD mouse models (122). Transgenic PS1 mice have been created, which 
permit the study of the effects of PS1 on APP processing (102). These mice exhibit 
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increased levels of amyloid-β1-42, although they do not develop amyloid plaque pathology 
or cognitive abnormalities (123).  
When PS1 mice are crossed with mice transgenic for hAPP, however, the development 
of AD neuropathology is substantially increased, in comparison to the singly transgenic 
hAPP mice (121). The PS/APP mouse, for example, was generated by crossing the 
Tg2576 mouse with a mouse expressing mutant PS1 (124). The double transgenic 
progeny develop plaque pathology from 6 months; a significantly younger age than the 
single transgenic Tg2576 mice (124). 
An even more aggressive line is the 5XFAD which encompasses 5 AD-related 
mutations, including: 3 hAPP mutations (the Swedish, Florida and London mutations) 
and 2 mutations in PS1 (112). The 5XFAD mouse rapidly develops amyloid pathology, 
with plaques detectable from 1.5 months. Unlike the aforementioned mouse models, 
where neuronal loss is marginal, the 5XFAD also exhibits gross neuronal loss (112). 
These findings suggest that the combination of multiple mutations induces neuronal 
loss in the mouse that is more representative of the clinical condition (125). 
1.6.4 Tau mouse models 
The models discussed so far faithfully encapsulate the characteristic amyloid plaques in 
AD. However, they are limited models of AD owing to the absence of tau pathology, 
and little or no neuronal loss. 
In order to model tau pathology in the mouse, transgenic models expressing mutant 
human MAPT (hMAPT) have been developed. The rTg4510 is a widely studied mouse 
model of tauopathy which carries a mutation in hMAPT (114). This mouse develops 
robust NFT pathology and exhibits many additional features of AD such as cognitive 
impairment, synaptic dysfunction and neuronal loss (114). It is worth noting that this 
mouse could arguably be considered a model of FTD; however, the NFT pathology 
which the rTg4510 mouse exhibits closely mimics that seen in AD patients (114). The 
rTg4510 mouse is therefore widely accepted as a valuable model for dissecting the role 
of tau in AD (14). 
An alternative model which is commonly used to study the neuropathological effects of 
tau is the htau mouse, which develops pathology from the overexpression of non-
mutated human tau. Htau mice exhibit AD-like neuropathology including age-related 
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NFT deposition, cognitive impairment and neuronal loss in a spatiotemporal 
distribution similar to that found in AD (116). These findings suggest that amyloid-β 
may not necessarily be a prerequisite for tau pathology to develop from wild-type tau, as 
seen in AD (116).  
Recently, mice that exhibit amyloid plaques and NFTs have been generated, by 
combining APP mutations (with or without PS1) with mutant forms of tau. These mice 
deliver a combination of plaque and tangle pathology not seen in other lines, permitting 
the exploration of interactions between amyloid-β and tau (102). For instance, the 3xTg 
line develops age-related AD neuropathology, including cognitive deficits, amyloid 
plaques and NFTs (115).  
1.6.5 Promoter sequences 
Although many of the models described here exhibit pathological similarities, their 
temporal profile can differ. This can be due to a number of factors: 1) the different 
genetic mutation; 2) the genetic background on which the transgene is maintained; and 
3) the type of promoter used (125).  
A promoter is a short construct of deoxyribose nucleic acid (DNA) that initiates the 
transcription of a gene, and defines where in the body the gene is expressed. Several 
different promoters are used in mouse models of AD, and outlined in Table 1.3. 
Table 1.3 Commonly used promoters in mouse models of AD; adapted from Hall et al. (102)  
Promoter 
Brain region 
expressed 
Cell types Expression begins by: 
PDGF-B Widespread (126) Neurons (126) E15 (126) 
Thy-1 Widespread (127, 128) Neurons (127) P7 (127) 
Prp Widespread (129, 130) 
Neurons, astroctyes, 
oligodendroyctes, 
microglia (129) 
E12.5 (131) 
 CaMKII-α 
Forebrain 
(hippocampus, cortex) 
(132) 
Neurons, glia, synaptic 
junction fractions, post-
synaptic densities (132) 
P5 (133) 
 
The promoters used are typically not native to the mouse genome, but heterologous: that 
is, taken from another species. They are chosen for their strength or pattern of 
expression. This often results in expression of the transgenic protein at higher levels 
than normal, and elevated levels of plaque or NFT deposition (125). 
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1.6.6 Mouse models of Alzheimer’s disease: concluding remarks 
The ideal mouse model of AD would develop the entire spectrum of clinical and 
pathophysiological features seen in the human condition, including amyloid plaques and 
NFTs, neuronal loss, synaptic dysfunction, cognitive deficits and progressive, age-
related neurodegeneration. Different mouse lines encapsulate elements of this 
pathological cascade, and are useful surrogates for patient populations in preclinical 
drug trials targeting one or more of these features. 
While no mouse exists that recapitulates all the aspects of AD, the complementary use 
of several models will support growing research into the neurobiology of AD. 
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Chapter 2: Magnetic Resonance Imaging 
In this section, I have provided a brief overview of nuclear magnetic resonance (NMR) physics, and 
introduced the fundamental MRI pulse sequence and contrast mechanisms. I have also introduced the 
basic concepts underpinning a number of different imaging techniques that are applied in this thesis.  
2.1 Introduction 
MRI is a powerful non-invasive imaging technology which utilises strong magnetic 
fields and radio waves to produce detailed anatomical images of the body. Since its 
inception in the 1970s, MRI has established itself as one of the most powerful tools for 
routine clinical diagnosis, as well as a valuable modality in biomedical research.  
 
 
Figure 2.1 (A) Anatomical scan of the human brain, acquired using a 7 Tesla MRI scanner. This was 
acquired at 0.44 mm3 isotropic resolution. (B) Magnifications of the marked regions, showing exquisite soft 
tissue contrast, including the folia in the cerebellum. Adapted from Stucht et al. (134). 
MRI exploits the principles of NMR to produce an image. NMR is a physical 
phenomenon in which nuclei in a magnetic field absorb and re-emit electromagnetic 
radiation. It has been known for over 70 years that atomic nuclei which are placed 
inside a magnetic field and irradiated with radiofrequency (RF) energy of a certain 
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wavelength will produce a signal (a voltage in a coil); this is due to the interactions of 
the nuclei with the magnetic field. These early discoveries were unearthed by Felix 
Block and Edward Purcell, who received the Nobel Prize in 1952 “for their 
development of new methods for nuclear magnetic precision measurements and 
discoveries in connection therewith” (135). 
 
 
Figure 2.2 An extract from Felix Bloch’s notebook, describing his famous experiment. Here, 1cm3 of water 
was placed inside a small glass bulb, around which were wrapped an RF transmitter and receiver coil. The bulb 
was placed inside a magnetic field, before a pulse of RF was delivered to the sample. Image reproduced from ‘The 
discovery of NRM’ (136). 
 
It is now known that atomic nuclei possess their own form of angular momentum 
called nuclear spin, I. This can be visualised as the motion of the nucleus rotating about 
its axis. The overall spin of an object depends on the number of protons and neutrons it 
possesses. For atoms with the same proton and neutron number, I = 0. Conversely 1H, 
the source of signal in most MRI experiments, has no neutrons, thus the proton has 
two possible spin states: either + ½ or – ½. These orientations are specified by the 
quantum number, m. When these spin states are placed inside an external magnetic field, 
B0, they align either parallel (m = + ½) or antiparallel (m = - ½) to the B0 field (Figure 
2.3). The nuclei of spins in the m = + ½ state have lower energy than spins in the m = - 
½ state. 
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Figure 2.3 A proton takes two possible orientations when placed in an external magnetic field 
 
The proportion of spins in the + ½ and – ½ states are determined by the Boltzmann 
distribution: 
 𝑁𝑎𝑛𝑡𝑖−𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙
𝑁𝑝𝑎𝑟𝑎𝑙𝑙𝑒𝑙
=  𝑒(
−∆𝐸
𝑘𝑇 ) (1.1) 
  
ΔE is the energy difference between the two states, k is the Boltzmann constant and T 
is the temperature in Kelvin. This relation shows that thermal energy will result in the m 
= + ½ state is slightly more populated; in a standard 1.5 T scanner at body temperature 
of 37oC, this is typically an excess of 4 protons per million in the lower energy state.  
 
 
Figure 2.4 Schematic representation of the imbalance of spins; the lower energy level is slightly more populated.  
This unequal distribution results in a net magnetization, M0, in the presence of B0. It is 
the manipulation of this net magnetization that is the source of signal in all MR 
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experiments. As B0 is conventionally defined to be orientated in the z direction of a 
Cartesian coordinate system, net magnetization is also orientated in the z direction (Mz). 
 
Figure 2.5 In the presence of the main B0 field, more spins reside in the m = + ½ there is net magnetization 
along the z direction. 
 
Spins will precess when placed in an external magnetic field, due to their angular 
momentum. The rate of precession is proportionate to the strength of the magnetic 
field B0, and expressed by the Larmor equation: 
 
𝜔0 =  
𝛾𝐵0
2𝜋
 (1.2) 
 
𝜔0 is the Larmor frequency and 𝛾 is the gyromagnetic ratio – a constant for each nuclei. 
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Figure 2.6 Schematic illustrating the spin precession of a nuclei in the presence of an external magnetic field at 
the Larmor frequency, 𝝎𝟎. 
 
The net tissue magnetisation parallel with B0 is too small (e.g. 1μT at 1.5T) to be 
detected whilst at equilibrium. In order to detect the magnetization induced within a 
sample by the B0 field, it must be brought out of this alignment using a pulse of energy, 
which causes protons to transition from the lower energy level to the higher energy 
level. When Mz is tilted into the xy plane, a signal can be recorded by a receiver coil 
which only measures magnetization in the xy plane. The energy required for these 
transitions is defined in Equation 3. 
 
𝐸 = ℎ𝑣 =  
𝛾ℎ𝐵𝑜
2𝜋
 (1.3) 
 
E is the energy required to excite a proton from the m = + ½ state to the m = - ½ state; 
h is Plank’s constant; B0 is the external magnetic field strength and 𝛾 is the gyromagnetic 
ratio.  
In order for transitions to occur, energy must be applied at the Larmor frequency in 
order to selectively excite the nuclei under investigation. This energy is supplied in the 
form of an electromagnetic pulse, which causes the protons to temporarily transition 
into the higher energy state before returning to ground level. These electromagnetic 
pulses will typically be in the RF part of the spectrum. This excitation causes the M0 to 
move out of the B0 direction. The extent of deviation from the B0 field depends on 
magnitude and duration of the RF pulse. If the RF pulse has exactly enough energy to 
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tilt the magnetization from Mz (parallel to the B0 field) to Mxy, then it is called a 90
o RF 
pulse. 
 
Figure 2.7 Schematic describing the tilting of net magnetization from the z direction into the transverse (xy) 
plane, following a 90o RF pulse. (A) In a reference frame rotating at the Lamor frequency, the net magnetization 
is parallel with the B0 field in the z direction. (B) An RF pulse is applied, which begins tilting the magnetization 
into the xy plane. (C) The magnetization has been tilted into the xy plane, where it generates a sinusoidal current 
in a receiver coil; this coil will detect magnetization which has a component in the xy plane. 
 
When Mz has been tilted into the xy plane, it generates a voltage in a receiver coil, which 
rapidly decays once the RF pulse has been switched off and the magnetization gradually 
returns parallel to the Bo field. The signal that is produced is known as the free induction 
decay (FID) (Figure 2.8A). It is often more convenient to look at the signals in the 
frequency domain instead of the time domain; so, a Fourier transform (FT) is 
performed on the time-domain signal, converting it into a frequency domain signal 
(Figure 2.8B). 
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Figure 2.8 (A) A signal induced in the receiver coil – the free induction decay. Fourier transfer of this time 
domain signal produces a frequency domain signal, with the peak frequency at the Lamor frequency. 
 
The loss of net signal, or ‘relaxation’ has two components: 1) the T1 or ‘spin-lattice’ 
relaxation, and 2) T2 or ‘spin-spin’ relaxation; both will be discussed in the next section. 
2.2 T1 Relaxation 
T1, or ‘spin-lattice’ relaxation, is the rate at which the excited protons return to the 
equilibrium magnetisation. The term spin-lattice is used as this relaxation mechanism 
involves an exchange of thermal energy between the excited spins and the lattice: the 
molecules that make up the surrounding structure. Following exposure to an RF pulse, 
nuclei dissipate their energy and gradually regain M0 magnetization; this typically takes 1 
– 5 seconds to occur in biological tissue at clinical field strengths. The T1 time constant 
is the time it takes for 63% of the Mz magnetization to recover, at a time t, following a 
90o RF pulse, and is described by Equation 4. 
 
𝑀𝑥𝑦 =  𝑀𝑧  ∙  (1 − exp ( 
−𝑡
𝑇1
))  (1.4) 
 
Different tissue types in the body have different T1 relaxation times. For instance, fats 
have a very short T1 (typically 260 ms in a standard 1.5T clinical scanner) whilst fluids 
such as CSF have a relatively long T1 (2600 ms). The T1s of most other tissues in the 
body fall within the range of fat and fluid. As described earlier, T1 relaxation occurs 
when the spins exchange their energy with their surrounding molecular framework. 
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However, the higher energy state is a relatively stable position for the spins to be in and 
it does not occur spontaneously. As described earlier, in order for transitions to occur 
between spin states, energy must be applied at the Larmor frequency. In the absence of 
a B1 field (once the RF pulse has been switched off), they must be stimulated to relax by 
emissions of energy through contact with their neighbouring protons, nuclei or 
molecules. This contact takes the form of an oscillating magnetic field from the 
molecular environment in which a spin resides. This oscillating magnetic field refers to 
the rotation, vibration and translation of the molecules, and is termed molecular tumbling. 
Water molecules can broadly exist in three states:  
1. Free to move (unbound)  
2. Bound to a macromolecule by a single bond, which permits rotation (structured) 
3. Bound by two bonds, prohibiting movement (tightly bound) 
 
These three different states have a differing range of tumbling frequencies. Free water is 
evenly likely to tumble at many different frequencies, which makes it very inefficient at 
T1 relaxation. The T1s of free water are therefore very long. In solid structures, the 
tightly bound water molecules are much more likely to tumble very slowly, producing an 
oscillating magnetic field which is much lower than the Larmor frequency. Equally, they 
are inefficient at stimulating the transitions and have long T1s. Incidentally, structured 
water contained within soft tissues in the body provides the ideal environment for T1 
relaxation: these tissues are most likely produce an oscillating magnetic field at the 
Larmor frequency, and are efficient at T1 relaxation.  
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Figure 2.9 Graph showing the tumbling rates of water in different molecular environments and how it affects 
the T1 relaxation time; structured water has the most efficient T1 relaxation as it tumbles at the Larmor 
frequency. Adapted from Dowsett et al. (137). 
 
2.2.1 Measuring T1 relaxation time 
The standard method for measuring T1 is known as inversion recovery. An 180
o RF pulse is 
applied, which inverts the M0 magnetization along the –z axis to give –M0 magnetization 
immediately after the RF pulse. After a time period, during which –M0 magnetization 
decays due to spin-lattice relaxation, a second RF pulse is applied at 900 and the M0 
magnetization is recorded. This is repeated using different time period delays, which are 
known as inversion times (TIs).  
When measuring T1 relaxation, the delay between successive inversion pulses must be 
sufficiently long in order for Mz magnetization to completely recover before the next 
pulse is applied; this delay is called the repetition time (TR). TR is typically set to 
approximately 5 times the T1 of the tissue under investigation.  
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Figure 2.10 Schematic illustrating the measurement of T1 relaxation. (A) An 1800 RF pulse is applied, 
which inverts Mz magnetization into the –z axis, producing –Mz magnetization. (B) T1 relaxation is the time it 
takes for 67% of Mz to recover. 
 
2.3 T2 relaxation 
T2, or ‘spin-spin’ relaxation is the rate at which Mxy magnetization returns to a net zero 
magnetisation following exposure to an RF pulse. The term ‘spin-spin’ is used because 
this relaxation mechanism involves interactions between adjacent spins. Immediately 
after an RF pulse has been applied, the spins are aligned in one direction in the Mxy 
plane. In this state, the spins are said to be phase coherent. However, this coherence is 
temporary: when two neighbouring protons come together, they begin to interact with 
each other via their oscillating magnetic fields. These inter- and intra-molecular 
interactions cause slight changes in the magnetic field that each proton experiences, 
causing its Larmor frequency to change. This causes the spins to move out of phase, 
and the Mxy magnetization is reduced. The T2 time constant is the time it takes for 63% 
of the Mxy magnetization to decay, at a time t, following a 90
o RF pulse, and is described 
by Equation 5. 
 
𝑀𝑥𝑦  =  𝑀𝑜  ∙ exp (
−𝑡
𝑇2
) (1.5) 
 
T2 relaxation typically increases as the molecular tumbling rate increases. Free water 
molecules that are tumbling very rapidly will be exposed to fluctuating magnetic fields 
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which averages to zero. This produces a fairly homogeneous local field and little 
dephasing, resulting in long T2 relaxation times. Conversely, bound water molecules will 
experience a static magnetic field inhomogeneity and dephase more rapidly. This will 
result in shorter T2 relaxation times. 
 
 
Figure 2.11 Graph showing the tumbling rates of water in different molecular environments and how it affects 
the T2 relaxation time; tightly bound water molecules have the shortest T2 relaxation times as they behave more 
like a static magnetic field inhomogeneity. Adapted from Dowsett et al. (137) 
 
Inhomogeneities in the B0 magnetic field also cause dephasing of the spins and 
contribute to the decay of Mxy magnetisation. The decay rate constant associated with 
the combination of spin-spin dephasing and field inhomogeneities is known as T2*. 
However, the T2 relaxation time only represents the decay rate constant associated with 
dephasing of the spins due to spin-spin interactions. When measuring T2 relaxation, the 
dephasing due to the B0 field must therefore be taken into account. 
2.3.1 Measuring T2 relaxation time 
When measuring T2 relaxation, a 90
o RF pulse is applied which tilts magnetization into 
the xy plane. After a short time, during which Mxy magnetization is lost due to spin-spin 
interactions and inhomogeneities in the B0  field, a 180
0 refocusing pulse is applied. This 
flips the protons around an axis in the transverse plane; as a result, the slower spins are 
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now ahead of the faster ones. The spins then begin to regain common alignment and 
come back into phase at the echo time, TE. The application of the 180o RF pulse 
effectively causes the dephasing of the spins due to time-invarying field inhomogeneities 
to be reversed.  
 
 
Figure 2.12 Schematic showing (A) the flipping of magnetization into the xy plane following a 90o RF pulse. 
(B) The spins rapidly dephase due to spin-spin interactions and B0 field inhomogeneities. (C) A 180o RF pulse 
refocuses the spins in the opposite direction, where (D) they gradually regain common alignment and come back 
into phase. 
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This is repeated using different TEs; the time it takes for 63% of Mxy to decay is the T2 
relaxation time. 
 
 
Figure 2.13 T2 relaxation is the time is takes for 63% of Mxy magnetization to decay. 
 
2.4 Generating an MRI image 
When generating an imaging using MRI, the FID is rarely measured directly. Instead, 
echoes are created and measured. An echo refers to a signal that is formed or regenerated 
sometime after the initial excitation.  As spins begin to dephase following an initial RF 
pulse, an echo can be generated by bringing the dephasing spins back into alignment.  
The two most fundamental imaging pulse sequences in MRI are gradient echo (GE) and 
spin echo (SE), which will be discussed in this section. But first, a brief description of 
how spatial information is encoded in an MRI image will be provided. 
2.4.1 Spatial encoding 
Spatial information is encoded in MRI using a combination of RF pulses and gradient 
coils. These gradient coils are used to spatially encode the positions of protons by 
varying the magnetic field linearly across the imaging volume. For instance, a gradient 
applied along the z axes will cause the magnitude of the B0 field to increase linearly in 
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the z direction, from –z to +z. At z = 0, the field experienced by the nuclei is the B0 
field; these protons will resonate at the Larmor frequency. However, moving along the z 
direction, the nuclei will experience greater or smaller field strength. This will cause 
these protons to resonate faster or slower, according to Equation 2. A RF pulse at the 
Lamor frequency will then only excite the protons resonating at z = 0, enabling selective 
excitation of this region.  
An MR system incorporates three sets of gradients: Gx, Gy and Gz. These are oriented so 
that gradients can be produced in the x, y and z directions. These three sets of gradients 
give MRI its three dimensional quality. 
2.4.2 Gradient echo 
In the GE sequence, a RF pulse is applied with a flip angle α. This is typically between 
0o and 90o. A negatively pulsed frequency-encode gradient is immediately applied, which 
causes rapid dephasing of the spins. A second frequency-encode gradient is then applied 
with opposite polarity which causes the spins to rephase. A signal is subsequently 
acquired at a specified TE, when the positive gradient area matches that of the negative 
gradient area. The time between RF pulses is called the repetition time (TR) and 
determines how much Mz magnetization recovers before the next excitation. In gradient 
echo imaging, the consequence of using a low angle excitation pulse is greater Mz 
magnetization for a given TR.   
The positive gradient only compensates for the dephasing caused by the negative 
gradient, and does not refocus rephasing due to the B0 field inhomogeneities. Therefore, 
the decay of transverse magnetization is due to T2* relaxation. 
Imaging the GE enables the acquisition of an echo in a short timeframe – potentially far 
quicker than SE, which will be discussed next. 
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Figure 2.14 Basic GE pulse sequence. Gss is the slice-selection gradient; GPE is the phase-encoding gradient; 
GFE is the frequency-encoding gradient. Adapted from McRobbie et al. (138). 
 
2.4.3 Spin echo 
SE imaging was mentioned briefly in Section 2.3.1. This section will provide a more 
thorough description of this pulse sequence. 
The SE sequence employs a 900 excitation pulse, which tilts the magnetization into the 
transverse plane. Immediately following this pulse, all spins are in phase and are 
precessing together. This phase coherence is temporary, as magnetic field 
inhomogeneities cause the protons to precess at different rates and fall out of phase 
with one another. Spins exposed to a lower local magnetic field will slow down, while 
others will speed up in the presence of a higher local magnetic field. This causes the 
signal to decay due to T2* relaxation. 
In order to overcome this rapid dephasing and bring the spins back into alignment, a 
1800 RF pulse is applied at ½ TE. This flips the protons around an axis in the transverse 
plane, so that the faster protons are now located behind the slower ones. This causes 
transverse magnetization to reappear, and a T2 echo can be measured without T2* 
effects. The signal is acquired at the specified TE. 
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Figure 2.15 Basic SE pulse sequence. Gss is the slice-selection gradient; GPE is the phase-encoding gradient; 
GFE is the frequency-encoding gradient. Adapted from McRobbie et al. (138). 
 
One advantage of SE imaging as opposed to GE imaging is that the B0 field 
inhomogeneities are corrected, which produces an echo which follows true T2 
relaxation, not T2*. However, SE imaging takes substantially longer, as it employs more 
than one RF pulse per acquisition, as well as longer TR times. 
It is now possible to dramatically speed up SE imaging by applying more than one 180o 
rephasing pulse after each 90o excitation pulse. The number of successive 1800 pulses is 
called the echo train length (ETL). Depending on how many rephasing pulses are applied, 
SE imaging can be made substantially faster. This technique is called fast spin echo (FSE). 
2.5 Image contrast  
When generating an anatomical image using MRI, the scan parameters TR and TE can 
be manipulated in order to emphasize certain image contrast properties. The signal, S, 
in a SE sequence is influenced by the following properties: 
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𝑆 ∝ 𝜌 ×  [1 − exp (− 
𝑇𝑅
𝑇1
) × exp (− 
𝑇𝐸
𝑇2
) ] (1.6) 
 
𝜌 is the spin density, and represents the number of protons per unit volume. This 
formula indicates that altering the TR and TE parameters will have a substantial effect 
on whether the image exhibits T1- or T2-weighted contrast.  
2.5.1 T1-weighted images 
In T1-weighted images, contrast is based on the differences in T1 relaxation time of the 
different tissues. In order to produce a T1-weighted image, either a GE or SE sequence 
can be employed. In both cases, the TR must be kept relatively short to capture the T1 
contrast, which develops during the early growth phase of longitudinal relaxation. The 
TE must also be kept short in order to limit the amount of T2 contrast which is allowed 
to develop, as this can influence image contrast. A short TE value will minimise this 
effect. 
In T1-weighted (and high proton density) images, fat-containing tissues appear bright 
owing to their short T1 relaxations times. White matter has a shorter T1 relaxation time 
than grey matter, and so appears brighter in these images. The ventricle containing CSF, 
however, appear dark owing to the long T1 relaxation times associated with fluids. T1-
weighted images are known as ‘anatomy scans’ owing to the range of different contrasts 
which are exhibited between tissue types. 
2.5.2 T2-weighted images 
In T2-weighted images, contrast is based on the differences in T2 relaxation time. In 
order to produce a T2-weighted image, a SE sequence is employed in order rephase the 
protons and remove T2* effects. A long TR is chosen to minimise T1 contributions, and 
a long TE is chosen to allow sufficient time for T2 contrast to develop.  
In T2-weighted images, fluids such as CSF have a long T2 and appear bright whilst 
water- and fat-based tissues are mid-grey. T2-weighted images are known as ‘pathology 
scans’, because most diseased tissues have higher water content than normal; as a result, 
they appear hyperintense in T2-weighted images.  
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Figure 2.16 Illustration of different tissue contrast in (A) T1-weighted images, and (B) T2-weighted images. 
Adapted from Dowsett et al. (137) 
 
More specialised pulse sequences can generate contrast that is sensitive to diffusion and 
perfusion; however, the precise mechanisms that lead to contrast generated by these 
sequences are beyond the scope of this thesis. 
2.5.3 The effect of contrast agents 
Exogenous contrast agents can be introduced in order to improve the visibility of 
internal structures. The most commonly used MRI contrast agents employ the 
paramagnetic element gadolinium. When gadolinium is placed inside a magnetic field, it 
generates a local magnetic field 1000 times that of water protons. This causes magnetic 
field inhomogeneities, resulting in: a) accentuated transitions between spin states, and 
shortening of T1; and b) rapid dephasing of protons, and shortening of T2 and T2*. 
Gadolinium-based contrast agents have the strongest effect in T1-weighted images, 
because the T1 relaxation time in the tissue is most strongly influenced by the presence 
of gadolinium. 
Gadolinium is highly toxic, so it is introduced to the body in the form of a chelated 
compound. For instance, the contrast agent Magnevist consists of a gadolinium chelated 
to a diethylene-triamine-penta-acetic acid (DTPA); this eliminates the toxicity of 
gadolinium whilst maintaining its paramagnetic properties.  
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One novel use of gadolinium-based contrast agents proposed by Johnston et al. is as a 
tissue stain for so-called magnetic resonance histology (MRH) (139). The use of contrast 
agents in such a way reduces the T1 relaxation time of the tissue under investigation, 
improving the efficiency of signal available due to faster recovery of Mz magnetization. 
MRH enables post-mortem tissues to be imaged with enhanced structural detail, which 
highlights cellular features for investigation of processes involved in development and 
disease (140). 
Superparamagnetic iron oxide (SPIO) particles are another class of MRI contrast agents. 
SPIO particles are a lot larger than gadolinium-based contrast agents, and produce a 
large magnetic field inhomogeneity when they are introduced into the body. SPIO 
particles increase the dephasing rate of protons, which decreases the T2 and T2* 
relaxation time. Therefore, they have the greatest effect in T2-weighted images, and 
manifest as tissue signal loss. 
2.6 Diffusion, perfusion, chemical exchange and flow 
So far, this chapter has provided an overview of the basic imaging sequences, contrast 
mechanisms, and the physics underpinning MRI. This final section will focus on 
different ways that MRI is increasingly being used to image specific structural, 
biochemical or functional properties. 
2.6.1 Diffusion tensor imaging 
Diffusion tensor imaging (DTI) exploits the intrinsic properties of directionality of 
water diffusion in the brain in order to examine the tissue microstructure. 
The movement of water molecules can be characterized by Brownian motion. When 
water is unconstrained, the direction of motion of a given molecule is completely 
random and is said to be isotropic (Figure 2.17A). However, in tissue water, the 
Brownian motion of water is impeded by cell membranes, resulting in directional 
anisotropy (Figure 2.17B). DTI provides information about the orientation and 
anisotropy of the diffusion of water in different tissue types. 
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Figure 2.17 Schematic illustrating (A) isotropic diffusion properties of water and (B) anisotropic diffusion 
properties of tissue water which is restricted by physical barriers. The eigenvalues λ1, λ2, λ3 are used to characterize 
the overall directionality of diffusion. Adapted from Alexander et al. (141). 
 
Water diffusion in tissues is measured using diffusion-sensitized magnetic field gradients 
applied in multiple directions, to produce images with directional diffusion-weighting. 
This information can be mathematically modelled to extract the diffusion tensor, which 
provides quantitative measures of water diffusion for each voxel. 
The diffusion tensor is made up of the eigenvalues λ1, λ2 and λ3. Diffusion is considered 
isotropic when the eigenvalues are nearly equal (e.g.  λ1 ~ λ2 ~ λ3.). Conversely, the 
diffusion tensor is anisotropic when the eigenvalues are significantly different in 
magnitude (e.g., λ1 > λ2 > λ3). These eigenvalues, or combinations of them, are used to 
characterise diffusion measures. 
Axial diffusivity (AD) describes the diffusion rate along the main axis of diffusion, and 
is defined by the largest eigenvalue, λ1. Radial diffusivity (RD) describes the rate of 
diffusion in the transverse direction, and is quantified as the mean of λ2 and λ3. Mean 
diffusivity (MD) provides an average of all three eigenvalues (λ1, λ2, λ3) to define the 
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molecular diffusion rate. Fractional anisotropy (FA) quantifies the fraction of diffusion 
that is anisotropic by comparing the relative difference between the largest eigenvalue λ1 
to the others. The exact mathematical calculations are shown below: 
 
𝑅𝐷 =  𝜆1 (1.7) 
 
 
𝐴𝐷 =  
𝜆2 +  𝜆3
2
 (1.8) 
 
 
𝑀𝐷 =  
 𝜆1 +  𝜆2 +  𝜆3
3
 (1.9) 
 
 
𝐹𝐴 =  √
1
2
 
√(𝜆1 −  𝜆2)2 + (𝜆1 −  𝜆3)2 + (𝜆2 −  𝜆3)2 
√𝜆1
2 + 𝜆2
2 +  𝜆3
2 
 (1.10) 
 
DTI is particularly useful when studying fibrous tissues such as cerebral white matter. 
The direction of greatest diffusivity (RD) is assumed to be parallel to the local direction 
of white matter. 
2.6.2 Arterial spin labelling 
Arterial spin labelling (ASL) is a non-invasive MRI technique that uses arterial blood as 
an endogenous tracer to measure cerebral blood flow (CBF). In pulsed ASL (pASL), the 
arterial blood water is labelled before it enters the tissue of interest using an inversion 
pulse; which inverts the net magnetization of the blood water protons from Mz to –Mz. 
After a short delay, termed the inversion time (TI), the labelled blood flows into the tissues 
where it exchanges with the bulk tissue water and reduces the tissue magnetization.  
A control image is also acquired, with no labelling of the arterial blood water. In the 
initial application of ASL, the control pulse is applied above the head to account for 
signal changes caused by the labelling pulse itself (142). The control image and the 
labelled image are subtracted which eliminates signal contributions from the static 
tissue; the remaining signal reflects perfusion of the tissue of interest. 
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Figure 2.18 Schematic diagram showing (A) the labelling of the arterial blood with an inversion RF pulse 
(shown in orange) before an image was acquired of the tissue of interest, and (B) the acquisition of a control image 
with no labelling of the arterial blood water. Adapted from McRobbie et al. (138). 
 
2.6.3 Chemical exchange saturation transfer 
Chemical exchange saturation transfer (CEST) probes the dynamic relationship between 
different proton environments. As described in Section 2.2.1, water molecules can exist 
in bound and free states. In a typical NMR spectrum, bound protons within the 
macromolecular pool have broad resonance lines (Figure 2.19). 
Water protons resonate at a frequency of 4.75 ppm. However, the short T2 of the 
bound proton pool means they are off-resonance, and not visible directly with MRI. 
However, they can influence the signal of the free water pool. This is because the free 
water protons are in constant exchange with bound protons contained within 
macromolecules such as lipids, amines, amides and hydroxides (143). 
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Figure 2.19 Schematic showing the resonance frequencies of water protons and the macromolecular pool. Water 
protons (shown in blue) resonate at or near the Larmor frequency (𝝎𝟎) while the macromolecular pool (shown in 
grey) has a much broader resonance spectrum.  Adapted from McRobbie et al. (138). 
 
The bound pool can be selectively excited using an off-resonance RF pulse, with no 
immediate effect on the free water pool. However, the exchange of protons between 
the bound and free pool causes the transfer of this saturation into the free water pool, 
which attenuates the MR signal. For instance, in order to probe the exchange of amide 
protons to the free water pool, an off-resonance RF pulse is applied at 8.25 ppm. This 
corresponds to a frequency shift of 3.5 ppm, or 445 Hz at 3T. After a delay termed tsat, 
this effect is visible in the NMR spectrum (Figure 2.20). This technique is called amide 
proton transfer (APT). 
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Figure 2.20 (A) An RF pulse is applied which specifically saturates the amide protons at their resonance 
frequency (8.25 ppm). (B) Following a time tsat this saturation is transferred to water (4.75 ppm). Adapted from 
van Zijl et al. (143). 
2.6.4 Magnetic resonance angiography 
Magnetic resonance angiography (MRA) exploits the motion sensitivity of certain MRI 
pulse sequences to illuminate blood flow within vessels. MRA employs short TRs and 
TEs which saturate the spins from the stationary tissues. Unsaturated spins in the blood 
move into the imaging slice with full magnetization, producing high contrast. This 
technique is called time-of-flight (TOF) MRA.  
 
 
Figure 2.21 Schematic showing the time-of-flight effect. Following saturation of the stationary tissues, the 
previously excited blood moves out of the imaging plane and is replaced by blood with full Mz magnetization. 
Adapted from Gadian et al. (144). 
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Alternative MRA methods employ gadolinium-based contrast agents administered 
intravenously which shorten the T1 relaxation time of the blood, increasing its signal in 
T1-weighted images. These techniques are called contrast-enhanced MRA. 
MR angiograms are typically viewed using a maximum intensity projection (MIP). A MIP is a 
volume rendering method for three-dimensional (3D) data, which shows only the 
brightest voxel along the projection. As the blood vessels appear hyperintense in MRA, 
a MIP is useful for accentuating this contrast. 
 
 
This chapter was compiled with the help of the following seminal texts: 
D. W. McRobbie et al., MRI from Picture to Proton (Cambridge University Press, 2006). 
D. Gadian, NMR and its applications to living systems (Oxford Science Publications, 1995). 
D. J. Dowsett et al., The Physics of Diagnostic Medicine (Hodder Arnold, 2006). 
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Chapter 3: Optimising the in vivo structural 
sequence for high resolution structural mouse brain 
imaging 
3.1 Aims 
The overall aim of this thesis is to develop and apply in vivo MRI techniques to 
transgenic mouse models of neurodegeneration, with the intention of characterising 
pathological changes longitudinally, and uncovering novel phenotypes. 
This chapter focuses on optimising a structural MRI sequence for high resolution in vivo 
mouse brain imaging.  The suitability of the optimised sequence for tensor-based 
morphometry (TBM) was then assessed through subsequent application to the rTg4510 
mouse model of tauopathy at a single timepoint (8.5 months of age), in order to 
characterise neurodegenerative changes occurring in this model. The development of 
this sequence lays the foundations for the proceeding chapters, where in vivo structural 
MRI has been applied in a longitudinal study of neurodegeneration in the rTg4510 
mouse with comparisons made to the preclinical gold standard for single timepoint 
imaging: high resolution ex vivo MRI of post-mortem mouse brain using contrast agents.  
In this work, I acquired the T2 maps and wrote the two-tier optimisation script in order 
to calculate optimum scan parameters. I also was involved in the experimental set-up, 
acquisition of the structural scans of the rTg4510 mice and wildtype controls, and post-
processing of the results. Following in vivo scanning, I perfuse-fixed all of the mice 
before dispatching the tissues to my collaborators for histology. I also manually 
segmented the cortex and hippocampus, in order to investigate correlations between the 
MR findings and histology. 
I would like to acknowledge: Simon Richardson at the UCL Centre for Advanced Biomedical 
Imaging, for his help producing the 3D printed head holder; and Nick Powell at the UCL Centre for 
Medical Image Computing, for developing the image processing software. 
Sections of this work have been peer-reviewed and published in NeuroImage (145). 
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3.2 Introduction 
Alzheimer's disease (AD) is devastating neurodegenerative disease, characterised by 
progressive memory impairment and cognitive decline. A number of factors have been 
implicated in the multifaceted pathogenesis, including local inflammation (146), protein 
accumulation (147), abnormal mitochondrial function (148) and haemodynamic 
alterations (149) with amyloid plaques and NFTs being the classical hallmarks of the 
post-mortem AD brain. In the past decade, structural MRI has emerged as an integral 
part of the diagnosis and study of AD, owing to its ability to detect patterns of atrophy 
in the AD brain (93). These changes are now believed to precede the onset of the 
clinical symptoms of the disease (98), strengthening the role of MRI as a valuable tool in 
AD research, where early detection may increase the success of emerging therapeutics.  
Transgenic mouse models are increasingly being used to further our knowledge of the 
cause and progression of neurodegenerative diseases such as AD. While no mouse 
recapitulates all characteristics of the human condition, such models do permit the 
study of specific pathological features in experimentally controlled conditions. This is 
particularly advantageous in AD where human clinical research can often be 
confounded by uncontrollable variables such as lifestyle choices and other co-morbidity; 
mice allow the precise impact of genes and their role in AD to be fully explored.  
There are currently over 100 different mouse models of AD (150), all which express 
one of more of the key neuropathological hallmarks of the disease (14). Some of the 
most commonly used mouse models of AD are detailed in Chapter 1.6. As previously 
described, mice containing mutations in the APP gene are the oldest and most widely 
studied AD models, and are used to investigate the role of APP, amyloid-β 
and amyloidosis in neurodegeneration (102). These mice are also valuable tools in 
preclinical drug discovery, where many emerging therapeutics focus on decreasing 
amyloid-β production and aggregation. However, the failure of these compounds to 
produce a therapeutic effect in clinical trials (30) has resulted in a shift in interest 
towards tau-mediating therapies. 
Tau is thought to play a critical role in the neurodegenerative process in AD: aggregates 
of hyperphosphorlylated tau forming NFTs are a major histological hallmark of AD and 
correlate with clinical disease progression (151). In the absence of amyloid-β, NFTs are 
also implicated in several other neurodegenerative diseases (e.g. FTD), further 
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supporting the role of tau in the dementing process (152). A mouse model of 
tauopathy (rTg4510) has recently been developed that specifically expresses tau in 
the forebrain but without amyloid plaques, enabling dissection of the unique role of tau 
in AD pathology (114, 153). Behavioural and histological studies of the rTg4510 mouse 
have demonstrated cognitive deficits in learning and motor tasks and marked atrophy of 
brain regions known to be selectively vulnerable to AD such as the 
hippocampus and frontal cortex(114). 
Structural MRI, with high spatial resolution, is increasingly being used to study mouse 
models of AD; however there is limited information on the optimum scan parameters 
for acquisition of mouse brain structural data sets. In particular,  within the discussion 
and justification of the chosen structural MRI parameters in the relevant literature there 
is no mention of the specific demands of advanced imaging processing techniques (such 
as TBM) (154, 155).   These demands include:  
1. High resolution, isotropic voxels to reduce partial volume effects and improve 
localisation of deformations to sub-regional structures;  
2. Whole brain coverage for global morphological analysis and application of 
existing mouse brain atlases; 
3. High contrast between tissue boundaries to enable voxel-wise tests to detect 
regions of change.  
 
In this chapter, I have developed and implemented a structural MRI sequence for in vivo 
mouse brain imaging, which is suitable for advanced image processing techniques. The 
sequence permits the acquisition of high resolution, isotropic voxels encompassing the 
whole mouse brain within a 1 hour 30 minute acquisition time. The demand for 
isotropic voxels meant that I selected a three-dimensional (3D) rather than two-
dimensional (2D) sequence (where artefacts may be introduced by imperfect slice 
profiles with such thin slices (150μm)). Furthermore, I choose a SE rather than GE 
sequence in order to avoid artefacts that occur due to signal “drop out” in GE images. 
Such artefacts are caused by local magnetic field inhomogeneities that occur at 
boundaries of material with different magnetic susceptibility, and are known to be 
particularly problematic at the high field strengths employed for rodent imaging (156).  
The scan parameters within the 3D SE sequence were optimised for high contrast 
between the hippocampus and its surrounding grey and white matter structures, as the 
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hippocampus suffers gross atrophy in clinical cases of AD and is frequently 
compromised in AD mouse models. Importantly, this phenotype appears to present in 
the rTg4510, where marked atrophy of the hippocampus has been previously reported 
(157).  
When planning the 3D structural sequence, the field-of-view (FOV) was first adjusted 
in order to encompass the whole mouse brain. This would permit global analysis of 
morphological changes, and facilitate the application of pre-existing mouse brain atlases 
for future automated parcellation analyses. Hence, a FOV of 
19.2 mm × 16.8 mm × 12.0 mm was selected, which was sufficient to avoid aliasing in 
the images due to the mouse’s ears; this can result in undesirable wraparound artefacts. 
Next, a resolution of 150μm3 was selected; this was based on previous work by Lau et 
al. where voxel-wise analysis techniques were successfully applied to in vivo mouse brain 
data sets at 156.25 μm3 resolution (155). Together, the selected FOV and resolution 
would permit the acquisition of suitable mouse brain data sets within an imaging time of 
approximately 30 mins – 90 mins (depending on the TR – see below).  With these 
parameters fixed, I proceeded to optimise the TR and TE in order to yield maximum 
contrast between the hippocampus and the surrounding tissue by using a “two tiered” 
optimisation approach; this is detailed in the Methods section. 
In this work, I have optimised the TR and TE for optimum contrast to distinguish the 
hippocampus from its surrounding grey and white matter structures. The optimised 
sequence was subsequently applied to a cohort of rTg4510 mice and wildtype controls 
at 8.5 months of age. Previously published in vivo structural analysis in the rTg4510 
mouse has identified marked atrophy within the hippocampus and cortex, and 
expansion of the ventricles (157). As such, this earlier study provides a comparison 
through which to validate my imaging and analysis protocol to detect structural 
differences between cohorts of mice.  I sought to verify and expand upon these 
previous findings, and use TBM to characterise discrete structural changes occurring in 
this model. 
This work demonstrates the suitability of the optimised structural MRI sequence for 
detecting morphological changes in the rTg4510 using TBM analysis; with scope to 
apply atlas-based structural parcellation in future studies. 
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3.3 Methods 
3.3.1 Animals  
For T2 mapping 
A wildtype C57BL/6J mouse was imaged in vivo. 
Single time-point imaging study 
Generation of homozygous rTg4510 transgenic mice has been reported previously 
(153). Female rTg4510 mice were licensed from the Mayo Clinic (Jacksonville Florida, 
USA) and bred for Eli Lilly by Taconic (Germantown, USA). Mice were imported to 
the UK for imaging studies at the Centre for Advanced Biomedical Imaging (CABI), 
London. All studies were carried out in accordance with the United Kingdom Animals 
(Scientific Procedures) act of 1986. Prior to imaging, all mice were secured in a cradle 
under anaesthesia with 1-2% isoflurane in 100% oxygen using a custom-built head 
holder, which was designed and 3D printed in collaboration with Simon Richardson at 
the UCL Centre for Advanced Biomedical Imaging (Figure 3.1). Body temperature was 
maintained at 36 – 37.5oC using a water-heating system and warm air fan. Core body 
temperature and respiratory rate were monitored using an MR-compatible temperature 
probe and pressure pad (SA Instruments, NY).  
 
Figure 3.1 Custom-built mouse brain head holder. (A) It is compatible with the RAPID 4 channel split 
array mouse head coil, and clips onto the nose cone. (B) The mouse head is stabilized by pressure from the 
protruding arms. (C) Additional support can be provided using a cable tie which fits into the grooves without 
applying pressure on the mouse’s respiratory tract. (D) Optional ear bars provide further stability.  
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3.3.2 Image acquisition  
All images were acquired using a 9.4T Agilent MRI scanner. A 120 mm diameter 
imaging gradient set (SGRAD 205/120/HD/S, Agilent Technologies UK Ltd., 
Berkshire, UK) was used. A 72 mm birdcage RF coil was employed for RF transmission 
and a quadrature mouse brain surface coil (RAPID, Germany) was used for signal 
detection. Tuning and matching of the coil was performed manually. Shimming was 
performed across the mouse brain prior to image acquisition. 
3.3.3 Measurement of tissue parameters  
To provide tissue information for the optimisation of the high resolution structural 
imaging sequence, T2 maps were acquired with a SE sequence with the following 
parameters: FOV = 16 × 16 mm; matrix size = 128 × 128; 1 mm slice thickness; TE = 
6.3, 10, 15, 20, 25, 30, 35, 40, 50, 60 ms; TR = 2000 ms; number of signal averages 
(NSA) = 1. A total of 4 slices were obtained. 
T2 relaxation times were calculated by manually selecting and drawing regions of interest 
(ROIs) on the images using custom software written in MATLAB (The Mathworks 
Inc., Natick, MA, USA). Measurements were taken and averaged for 3 wildtype mice. 
 
Figure 3.2 Example SE images of a wildtype mouse at increasing TEs for calculating T2 relaxation times of 
the corpus callosum, cortex, hippocampus and thalamus. 
 
The MATLAB Curve Fitting Toolbox was used to fit T2 curves to Equation 2.5, which 
describes the decay of magnetization in the xy plane following a 900 excitation pulse. 
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T2 relaxation times were calculated for the following ROIs: corpus callosum, cortex, 
hippocampus, and thalamus. Table 3.1 shows the T2 relaxation fitting results, with 95% 
confidence bounds for the fitted coefficients. 
Table 3.1 T2 relaxation times (with 95% confidence bounds) for mouse brain ROIs: the corpus callosum, 
cortex, hippocampus and thalamus. 
Structure T2 relaxation time (ms) 
Corpus callosum 31.99 (30.36, 33.62) 
Cortex 39.75 (37.86, 41.66) 
Hippocampus 38.93 (37.9, 39.93) 
Thalamus 34.99 (30.36, 33.62) 
 
T2 relaxation times were highly consistent with literature values (158, 159).  
Due to time restrictions, it was not possible to also acquire T1 maps. Instead, T1 
relaxation times for the scan parameter optimisation were taken from previous work by 
van de Ven et al. at 9.4T (160). As the T1 relaxation time for the thalamus was not 
reported in this work, the relaxation time for the periaqueductal gray was presumed to 
be representative of the thalamus as they are both centrally locate grey matter structures.  
Table 3.2 T1 relaxation times taken from the literature for mouse brain ROIs: the corpus callosum, cortex, 
hippocampus and thalamus 
Structure T1 relaxation time  (ms) 
Corpus callosum 1750 
Cortex 1890 
Hippocampus 1820 
Thalamus 1700 
3.3.4 Contrast optimisation by computer simulation  
To determine optimum scan parameters, the SE signal equation (Equation 2.6) was 
used to calculate signal intensity for a SE sequence using a 90o excitation pulse and 180o 
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refocusing pulse (161): Signal intensity was simulated for a range of TEs (1 – 100ms) 
and TRs (1 – 2500ms). TR was limited to 2500 ms which corresponded to an in vivo 
imaging time of 1 hour 30 minutes with the previously determined resolution (150μm) 
and whole brain FOV (19.2 mm × 16.8 mm × 12.0 mm). This imaging time was chosen 
as a compromise between resolution and signal-to-noise ratio (SNR), and permits the 
acquisition of complementary functional data for the remaining duration of the scan. 
The SE signal equation was used first to calculate optimum scan parameters for 
maximum contrast between the hippocampus and thalamus; this was defined as the 
greatest signal difference between the two tissues occurring over a range of scan 
parameters (162). 
 
𝐶𝑜𝑛𝑡𝑟𝑎𝑠𝑡 =  𝑆𝑖𝑔𝑛𝑎𝑙ℎ𝑖𝑝𝑝𝑜𝑐𝑎𝑚𝑝𝑢𝑠  −  𝑆𝑖𝑔𝑛𝑎𝑙𝑡ℎ𝑎𝑙𝑎𝑚𝑢𝑠 (3.1) 
 
In the rTg4510 mouse, atrophy is most pronounced in the forebrain regions, with high 
NFT deposition previously observed in the hippocampus and frontal regions of the 
cortex (114). It was therefore crucial that that these two structures could be readily 
delineated from their neighbouring grey and white matter structures. The corpus 
callosum lies between the cortex and the hippocampus within the forebrain regions, 
providing an inherent white matter barrier between these two ROIs. However, there is 
no dividing white matter structure between the hippocampus and thalamus. Therefore a 
two-tier simulation was performed to investigate sequence parameters for optimal 
contrast between i) the hippocampus and the thalamus and ii) the cortex and the corpus 
callosum.   
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Figure 3.3 Results from the scan parameter optimisation for maximum contrast between the hippocampus and 
the thalamus. The simulation identified scan parameters where optimal contrast could be achieved: TR 2050 – 
2500 ms; TE 30 – 65 ms. 
 
The results from the simulation revealed that a T2-weighted sequence employing a 90
o 
excitation pulse would offer the maximum contrast between the hippocampus and 
thalamus (Figure 3.3), since long TRs and TEs were found to produce maximal 
contrast. The simulation identified a range of scan parameters that would produce high 
contrast (contrast > 2) between the hippocampus and thalamus (Table 3.3) which were 
then used as constraints in part ii) of the optimisation (optimising contrast between the 
cortex and corpus callosum).  
Table 3.3 Range of optimum scan parameters identified from the SE signal equation for high contrast between 
the hippocampus and thalamus. 
TR (ms) TE (ms) 
Minimum Maximum Minimum Maximum 
2050 2500 30 65 
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In order to enhance contrast between the grey and white matter structures, the SE 
signal equation was used to calculate optimum scan parameters for maximum CNR 
between the corpus callosum and cortex using the range of TEs and TRs previously 
identified in part i) of the simulation (Figure 3.4). 
 
 
Figure 3.4 Results from the scan parameter optimisation for maximum contrast between the cortex and the 
corpus callosum, constrained by the range of parameters for high contrast between the hippocampus and the 
thalamus.  
 
The result from this second SE optimisation revealed that maximum contrast between 
the cortex and corpus callosum would be achieved at a TR of 2500 ms and a TE of 43 
ms.  
3.3.5 Implementation of optimum scan parameters: single time-point study of 
neurodegeneration in the rTg4510 mouse model 
Female rTg4510 mice (n = 9) and wildtype controls (n = 17) were imaged in vivo using a 
3D FSE sequence with the following parameters: FOV = 19.2 mm × 16.8 mm × 12.0 
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mm; resolution = 150 μm × 150 μm × 150 μm; TR = 2500 ms, effective echo time 
(TEeff) = 43 ms, ETL = 4, NSA = 1. Total imaging time was approx. 1 h and 30 mins. 
3.3.6 Perfuse fixation 
Following in vivo imaging, animals were terminally anaesthetised with Euthanol (1 mL) 
administered via intraperitoneal (i.p.) injection. The thoracic cavities were opened and 
the animals perfused through the left ventricle with 15–20 mL of saline (0.9%) followed 
by 50 mL of buffered formal saline (10%) at a flow rate of 3 mL per minute. Following 
perfusion, the animal was decapitated, defleshed, and the lower jaw removed. All brains 
were stored in-skull in buffered formal saline (10%) at 4 °C before being dispatched for 
histology. 
3.3.7 Histology and immunohistochemistry 
Histology was performed by my collaborators at Eli Lilly. Brain samples were processed 
using the Tissue TEK® VIP processor (GMI Inc, MN USA) before being embedded in 
paraffin wax for coronal brain sectioning. Serial sections (6m) were taken using HM 
200 and HM 355 (Thermo Scientific Microm, Germany) rotary microtomes. 
Immunohistochemistry (IHC) was performed using a primary antibody for tau 
phosphorylated at serine 409 (PG-5; 1:500 from Peter Davies, Albert Einstein College 
of Medicine, NY, USA) as previously described (163).  Stained sections were digitised 
using the Scanscope XT slide scanner (Aperio, CA, USA) at 20× magnification. 
Imagescope software (version 11.1.2.760; Aperio, CA, USA) was used to view the 
digitised tissue sections and delineate the regions of interest (cortex, hippocampus and 
thalamus). The number of PG-5 positive neurons was manually counted within a 
delineated region and expressed as a density (mm2). Both sides of the brain were 
analysed and averaged before statistical analysis. 
3.3.8 Image analysis 
In vivo MR images were reconstructed using custom software written in MATLAB by 
Nick Powell.  
Manual segmentation of the hippocampus was performed using open source software 
(ITK-SNAP) (164) with visual reference to a mouse brain atlas. A previously published 
calibration protocol (165) was used to adjust volume estimates to  correct for scaling 
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errors caused by the imaging gradients.  Briefly, a 3D grid phantom was imaged in both 
gradient sets and CT data was used as a ground truth to generate absolute scaling 
factors that were then applied to the data. This protocol was developed by my 
collaborator at the UCL Centre for Advanced Biomedical Imaging. The computer-aided 
design (CAD) drawings for the 3D grid phantom are available online:  
http://www.ucl.ac.uk/cabi/publications/open_source 
3.3.9 Tensor-based morphometry 
For TBM analysis, in vivo structural images were automatically oriented to a standard 
atlas space (Right Antero-Superior), corrected for intensity non-uniformity using the N3 
algorithm (166), and skull stripped using a STAPLE algorithm (167) to combine masks 
from several prior atlases registered to the data. Intensities were normalised and a multi-
iteration group-wise registration, implemented in the open-source NiftyReg software 
(168), was performed as follows to align equivalent voxels between subjects. First, all 
subjects were rigidly aligned to a randomly-chosen target member of the group. This 
was followed by four iterations of affine registration (12 degrees of freedom), using a 
block-matching algorithm based upon normalised mutual information, and 20 iterations 
of non-rigid registration (NRR), based upon symmetric free-form deformation. After 
each iteration, the intensity average image was found and used as the target for the 
subsequent registration. Deformation fields were transformed by taking the log of the 
determinant of the Jacobian matrix calculated at each voxel, to give that voxel's relative 
expansion or contraction in the final average image compared to each original. These 
values were smoothed with a 0.2 mm FWHM Gaussian kernel to account for 
registration error and to render the values closer to a normal distribution, and mass-
univariate statistics (two-tailed t-tests) were performed on each voxel, fitting a General 
Linear model controlling for total brain volume (TBV) based upon the brain masks. 
The resulting statistical parametric map was corrected for multiple tests using the False 
Discovery Rate (FDR (169), q = 0.05).  
3.3.10 Signal-to-noise and contrast-to-noise ratio calculations 
SNR was calculated for all brain regions under investigation. Contrast-to-noise ratio 
(CNR) was calculated for grey and white matter regions; I chose to investigate CNR 
between the cortex and corpus callosum, following the protocols from previous CNR 
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measurements in the literature (140). SNR and CNR were calculated using the following 
formulae: 
 
𝑆𝑁𝑅 =  
𝑀𝑒𝑎𝑛 𝑠𝑖𝑔𝑛𝑎𝑙 
𝑁𝑜𝑖𝑠𝑒
 (3.2) 
 
 
𝐶𝑁𝑅 =  
𝑀𝑒𝑎𝑛 𝑠𝑖𝑔𝑛𝑎𝑙𝐴 –  𝑀𝑒𝑎𝑛 𝑠𝑖𝑔𝑛𝑎𝑙𝐵
𝑁𝑜𝑖𝑠𝑒
 (3.3) 
 
Signal was taken from ROIs including: corpus callosum, cortex, hippocampus, and 
thalamus. The noise ROI was placed in a “ghost-free” region of background signal. 
Noise was defined as the standard deviation (SD) of the background signal. CNR was 
calculated between the grey matter (cortex) and white matter (corpus callosum). 
3.4 Results 
3.4.1 Visual inspection of the data 
Figure 3.5 shows coronal and axial slices of a representative wildtype mouse. Visual 
inspection of the data revealed sufficient contrast to identify many ROIs, including the 
hippocampus and cortex. These structures are frequently compromised in 
neurodegenerative disease models, so it was crucial they could be easily identified. 
Appreciable contrast between the grey and white matter regions enabled the corpus 
callosum to be readily delineated. The grey-white matter folds of the cerebellum were 
also noted. Adequate contrast between adjacent grey matter regions, as well as grey-
white matter contrast is crucial for the optimal implementation of automated analysis 
techniques; these require high contrast boundaries between neighbouring structures for 
the application of pre-existing mouse brain atlases. 
Figure 3.6 shows coronal and axial slices of a representative rTg4510 mouse. Shrinkage 
of the hippocampus and thinning of the cortex was readily observed, in additional to 
expansion of the ventricles containing CSF which appear hyperintense in the T2-
weighted MRI images. 
We observed some artefacts in the coronal FOV which may be due to the spontaneous 
respiration of the animals in the scanner. However, I do not anticipate this being a  
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Figure 3.5 Coronal and axial slices taken from a representative wildtype mouse. Contrast was sufficient to 
enable visualization of many ROIs. 
 
 
Figure 3.6 Coronal and axial slices taken from a representative rTg4510 mouse. Visual inspection of the 
data revealed known morphological changes in this model, including gross hippocampal atrophy, cortical thinning 
and expansion of the ventricles. 
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dramatic confounder in the automated image analysis, which relies on registration 
algorithms to produce a groupwise average image. 
3.4.2 SNR measurements 
SNR measurements were taken from all ROIs under investigation in a single, 
representative, animal in order to quantify image quality (Table 3.4). CNR was 
calculated between the cortex and corpus callosum, and served as a measure of how 
well grey and white matter features can be distinguished in the images (170). 
Table 3.4 SNR and CNR measurements taken from a representative wildtype mouse in vivo. ROIs were 
drawn within the corpus callosum, cortex, hippocampus and thalamus. CNR was defined as the absolute 
difference in SNR between the corpus callosum and the cortex. 
Structure SNR 
Corpus callosum 8.7 
Cortex 12.4 
Hippocampus 11.8 
Thalamus 7.8 
CNR (grey-white matter) 3.7 
 
Given the limitations on scan time imposed by in vivo imaging, the optimised structural 
sequence permitted the acquisition of whole brain images at 150μm3 resolution. CNR of 
3.7 proved sufficient to unveil detailed anatomical structures (identified in Figure 3.5), 
and is in agreement with previously published measurements in the mouse brain (170). 
3.4.3 Manual segmentation 
In this work, the scan parameters were optimised for high contrast between the 
hippocampus and its neighbouring structures. In order to assess the sensitivity of the 
structural sequence to neuropathological changes occurring in the hippocampus and to 
investigate correlations to histological quantification of tau burden, this structure was 
manually delineated in the wildtype (n=17) and the rTg4510 (n=9) mice at 8.5 months 
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(Figure 3.7). An entirely female cohort was investigated in order to reduce any gender-
related variance in the animals. 
 
 
Figure 3.7 Manual segmentation results from the 9 rTg4510 and 17 wildtype control mice at 8.5 months. A 
t-test was performed to identify significant differences between the groups. **** = p ≤ 0.001. 
 
Complete discrimination was observed between the rTg4510 mice and wildtype 
controls (p<0.0001), with 59.3% difference in hippocampal volume in the rTg4510 
mice compared to wildtype controls. Mean hippocampal volume in the rTg4510 mice 
was 9.268 mm3 (±1.5 mm3) compared to 22.78 mm3 (± 2.3 mm3) in the wildtype 
controls. Due to the highly laborious and time consuming nature of manual 
segmentation, only the hippocampus was delineated in both the rTg4510 mice and 
wildtype controls in order to make this comparison.  
3.4.4 Histology and immunohistochemistry 
It order to investigate possible correlations between the structural MRI findings with 
alterations occurring at the cellular level, immunohistochemistry was performed on each 
of the individual rTg4510 (n = 9) and wildtype (n = 17) mice (Figure 3.9) to estimate 
the density of NFTs.  
The PG-5 antibody was used, which exhibits immunoreactivity with 
hyperphosphorylated tau.  The rTg4510 mice exhibited high PG-5 staining in regions 
known to be affected in this model: the cortex (mean PG-5 density = 229.3 ± 29.51 
mm2) and hippocampus (mean PG-5 density = 82.92 ± 15.3 mm2) (Figure 3.9C, D). 
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Conversely, low levels of PG-5 staining were observed within the thalamus (mean PG-5 
density = 2.267 ± 0.81 mm2) (Figure 3.9D). No PG-5 positive cells were observed in 
the wildtype controls in any of the regions under investigation (Figure 3.9C-E). 
3.4.5 Structural correlations with histology 
To further explore the relationship between the hippocampal volumetric estimates and 
tau pathology, the density of PG-5 positive neurons taken from a single slice in the 
hippocampus was plotted against the manual segmentation results of the rTg4510 mice.  
 
Figure 3.8 A significant negative correlation was observed between the density of PG-5 positive neurons in the 
hippocampus, and hippocampal volume (p ≤ 0.01). 
 
A significant negative correlation between hippocampal volume and PG-5 positive 
neurons was observed (p≤0.01) (Figure 3.8), suggesting that this optimised structural 
sequence produces accurate hippocampal volume estimates that correlate to NFT 
deposition in this model. 
I performed additional manual segmentation in the cortex of the rTg4510 mice in order 
to investigate structural correlations in this structure, which also suffers high NFT 
deposition. However, no significant correlations were observed between cortical 
volume and PG-5 positive neurons (Figure 3.10). 
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Figure 3.9 Immunohistochemistry to estimate regional 
PG-5 positive NFT density. (A) Single slice from a 
representative rTg4510 mouse with staining for PG-5 
positive NFTs. (B) Marked regional dependence of NFT 
density is observable, with high PG-5 staining in the 
cortex and hippocampus, and low levels in the thalamus. 
Quantitative regional estimates of NFT density for each of 
the 17 wildtype and 9 rTg4510 mice within (C) the 
cortex, (D) the hippocampus and (E) the thalamus. A t-
test was performed to identify significant differences between 
the groups. **** = p ≤ 0.0001. 
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Figure 3.10 No significant correlations were observed between the density of PG-5 positive neurons in the 
cortex, and cortical volume. 
 
3.4.6 Tensor-based morphometry 
The manual segmentation of the hippocampus revealed volume loss within this region 
in the rTg4510 mice compared to wildtype controls. In order to explore morphological 
changes across the entire brain, TBM was employed. 
Figure 3.11A-F shows the group-wise average with TBM statistics overlaid. Extensive 
bilateral changes throughout the rTg4510 brains relative to the average were observed, 
including atrophy in the cortex, caudate putamen, hippocampus and olfactory bulbs. 
Hippocampal atrophy could be localised to the CA1 subfield. TBM also detected 
expansion of the lateral, third and fourth ventricles. Negligible significant voxels were 
observed within the thalamus. 
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Figure 3.11 Structural analysis results, showing TBM statistical results through representative (A – C) coronal and (D – F) axial slices of the final average image of all subjects after 20 
iterations of NRR (locations indicated on schematic diagram above). Red: regions where the rTg4510 brains are significantly smaller than the average; blue: regions where the rTg4510 brains 
are significantly larger than the average. Based upon FDR-corrected t-statistics (q = 0.05), controlling for total intracranial volume. Clusters smaller than 20 voxels were removed. 
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3.5 Discussion 
In this chapter, a structural sequence for in vivo mouse brain imaging has been 
developed. The sequence permits the acquisition of high resolution, isotropic voxels 
within a feasible in vivo imaging time of 1.5 hours. Scan parameters (TR, TE) were 
optimised for maximum contrast between the hippocampus and thalamus, as well as the 
cortex and corpus callosum. The first application of TBM to the rTg4510 mouse model 
of tauopathy is also presented, where marked morphological changes have been 
identified in this model. This work presents a platform for my subsequent investigations 
of longitudinal structural changes in the rTg4510 mouse that is presented in this thesis. 
Previous in vivo structural characterisation of AD mouse models has largely employed 
2D sequences, with a range of spatial resolutions: 94 μm × 140 μm × 400 μm (171); 
62.5 μm  × 125 μm  × 500 μm (172); 78 μm  × 78 μm  × 500 μm (173); 120 μm  × 120 
μm  × 500 μm   (174). In all these studies, the researchers have favoured high in-plane 
resolution over slice thickness. Analysis of these data sets has largely been restricted to 
manual segmentation of ROIs, in order to determine volumetric alterations. However, 
the thickness of the imaging slice may have introduced partial volume artefacts which 
would have led to inaccuracies in the volumetric results. When optimising the sequence 
for high resolution in vivo imaging, I selected a 3D sequence in order to minimise this 
effect. 
All of the studies detailed above have employed a SE (T2-weighted) rather than GE 
(T2*-weighted) sequence; this is likely to be due to the susceptibility artefacts which are 
frequently observed in in vivo mouse brain data, and can corrupt GE imaging data. Very 
few of these papers have reported SNR measurements for their imaging data; however, 
Natt et al. have previously reported that SNR of 15 – 20 was sufficient to unveil 
anatomical details in the mouse brain (175). In this work, my sequence returned an SNR 
of between 8 and 12 which appeared suitable for manual delineation of ROIs as well as 
voxel-wise analysis techniques. 
Previously published work in the rTg4510 mouse has reported structural changes in the 
hippocampus and cerebral cortex, as well as enlargement of the ventricles using manual 
segmentation of in vivo MRI data sets (157). Using TBM, we were able to extend these 
observations and additionally detect local volume reductions in the cortex, 
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hippocampus, caudate putamen and olfactory bulbs as well as ventricular expansion. At 
this time point, the transgenic brains have undergone gross atrophy which is noticeable 
by eye in the in vivo structural images. I therefore anticipate that TBM will be most 
valuable in the detection of subtle structural abnormalities that occur at earlier stages 
of tauopathy that I investigate in the longitudinal study of the rTg4510 described in 
Chapter 4.  
The hippocampal atrophy observed using TBM was validated by manual delineation of 
this region, where complete discrimination of the rTg4510 animals and wildtype 
controls was observed. However, this marked loss in hippocampal volume was not 
entirely encapsulated in the TBM findings, which only showed a handful of significant 
voxels in the caudal slices of the hippocampus. According to Lerch et al., image 
registration works best when the data to be matched is comparable (176); that is, when 
the phenotype to be explored is reasonably subtle. In this work, the transgenic animals 
had undergone gross atrophy of the forebrain regions, which may have introduced 
some difficulties when registering these data sets to the wildtype controls. This may 
have resulted in an underestimation of the hippocampal atrophy in the TBM findings. 
The negative correlation that we measured between hippocampal volume and NFT 
density provides evidence of a direct relationship between NFT pathology and atrophy, 
whilst highlighting the sensitivity of in vivo MRI to subtle volume changes. This 
correlation was not present in the cortex, despite higher NFT density. This may be 
because the hippocampus has a more rapid progression of tangle formation and thus 
the subsequent neurodegeneration is more advanced at 8–9 months of age. 
Structural MRI has already established itself as a reliable biomarker in the clinical 
diagnosis of Alzheimer's disease (93) , where characteristic grey matter reduction and 
ventricular enlargement can be readily visualised using standard structural MRI 
sequences. Structural MRI has found additional clinical relevance in the differential 
diagnosis of AD over other forms of dementia (e.g. dementia with Lewy bodies) where 
neuropsychological testing alone may be insufficient (177, 178). Crucially, structural 
MRI may enable detection of AD prior to the onset of clinical symptoms, making it a 
valuable biomarker of the disease (98). It is currently employed within the ADNI study 
– a worldwide collaboration between research institutes, with the aim of understanding 
the physical brain changes that accompany the descent into dementia (179).  
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Advanced image processing techniques are routinely applied to large clinical AD cohort 
studies (179), to identify morphological differences in AD subjects. These techniques 
include voxel-wise analysis methods e.g. TBM, in addition to atlas-based segmentation 
techniques (180-182). The utility of these techniques has expedited high throughput 
analysis of large clinical data sets, such as those generated within the ADNI study, 
enabling automated and unbiased detection of morphometric changes occurring within 
AD subjects. These methods are being increasingly applied to structural data sets of the 
AD mouse brain.  
Quantification of volumetric alterations in mouse models of AD has traditionally been 
performed using manual segmentation, which requires a trained user to delineate 
regions of a target structure in each image slice in order to generate a 3D volume (183, 
184). Manual analysis methods suffer a number of disadvantages; they are prone to 
user-bias, are time-consuming, and require a priori hypotheses to inform the regional 
analysis. In order to overcome these limitations, the preclinical MRI community are 
rapidly adopting advanced image processing techniques to analyse mouse brain MRI 
data. In particular, atlas-based segmentation techniques have established themselves as 
robust alternatives to manual segmentation for regional analysis of AD mouse brains 
(157, 185). A number of published pipelines for automatic structural parcellation are 
now available (186, 187), enabling the automatic delineation of mouse brain regions. 
The application of these pipelines to mouse brain data sets has been facilitated by 
increasing availability of in vivo (188) and ex vivo (189-192) mouse brain atlases, to 
support atlas-based segmentation techniques.  
Despite the growth of automated segmentation techniques to characterise structural 
mouse brain data sets, the translation of voxel-wise analysis methods has been 
somewhat slower to progress; however, they are gaining popularity due to their ability to 
detect discrete morphological changes which may be undetected by regional analysis. A 
number of rodent studies have employed voxel-wise analysis techniques to investigate a 
range of neurological disorders including: Huntington’s disease (154, 193, 194), AD 
(155, 195-197), Prader-Willi syndrome (198) and neurodevelopmental abnormalities 
(199-203). These techniques have demonstrated enhanced sensitivity to morphological 
disturbances over manual segmentation in mice, making them an attractive alternative 
for characterising a mouse model (204). However, the vast majority of these studies 
were performed using ex vivo mouse brain data, which involves perfuse-fixation of the 
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tissues before they are imaged at near-microscopic resolution (205). A contrast agent is 
frequently employed as a tissue-active stain, to highlight detailed anatomical structures 
(140). Although this produces high quality imaging data with exquisite soft tissue 
contrast, it sacrifices the ability to image the same animal longitudinally.  
Only a handful of studies have successfully employed voxel-wise analysis techniques to 
study in vivo AD mouse brains (155, 197). This is surprising, given the significance of 
longitudinal data in characterising neurodegeneration and its modulation by emerging 
therapeutics. This may be due to inadequacies in the imaging data, as most in vivo 
imaging protocols employ multi-slice 2D sequences with high in-plane resolution at the 
expense of poor section thickness (175). This may render the data unsuitable for TBM 
analysis, where high resolution isotropic voxels are a requirement. Indeed, previous 
work by Teipel et al. employed structural MRI in conjunction with voxel-wise analysis 
techniques to characterise a mouse model of AD (206). In this work, no grey matter 
alterations were observed, despite histological observations of cerebral amyloidosis at 
this timepoint (207). Closer inspection of the imaging parameters employed by Teipel et 
al. revealed that a 2D sequence was employed; with high in-plane resolution (31.25μm) 
at the expense of poor slice thickness (600μm). This choice of parameters is likely to be 
non-optimal for voxel-wise analysis methods, and may have prohibited the detection of 
morphological changes. 
In this work, I have optimised the sequence for high resolution in vivo mouse brain 
imaging, which fulfils the specific requirements for TBM analysis. The application of 
the optimised sequence to the rTg4510 mouse demonstrated its suitability to detect 
AD-related changes in this mouse. 
3.6 Conclusion 
In conclusion, in this chapter I developed a structural MRI sequence designed with 
consideration of the following factors: i) spatial resolution ii) isotropic imaging voxels 
iii) contrast between the hippocampus and surrounding tissue iii) SNR iv) spatial 
distortion due to magnetic field inhomogenities v) imaging time.  
Whilst I did not perform an exhaustive exploration all these parameters, I developed a 
sequence with spatial resolution and SNR aligned with literature values with isotropic 
voxel size and optimised contrast to delineate the hippocampus (using a T2-weighted 
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FSE 3D sequence). Using this sequence, I observed marked atrophy of cortical and 
hippocampal regions in the rTg4510 mouse model of AD using both manual 
segmentation and TBM. Importantly, I observed a correlation between hippocampal 
volume and NFT density in agreement with clinical findings. As such this observation 
supports the clinical relevance of this model to explore the interaction of tau pathology 
and tissue atrophy in AD.  
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Chapter 4: Imaging the accumulation and 
suppression of tau pathology using multi-parametric 
MRI 
4.1 Aims 
In the preceding chapter, a sequence for high resolution in vivo structural has been 
developed. The sensitivity of this sequence to morphological changes in the rTg4510 
mouse was assessed in a single time-point study of neurodegeneration, at an age when 
the mice experience gross atrophy within the forebrain regions. 
In this chapter, this sequence has been applied in a longitudinal study of 
neurodegeneration in the rTg4510 mouse, a subset of which were treated with 
doxycycline at different timepoints to suppress the tau transgene. Using this paradigm, I 
investigated the sensitivity of MRI biomarkers to both a) progressive tau-driven 
neurodegeneration in the rTg4510 mice, and b) the suppression of pathological tau in 
the doxycycline-treated rTg4510 mice. High resolution structural MRI was employed 
alongside other MR biomarkers which offer sensitivity to other pathological 
mechanisms which have been implicated in AD: arterial spin labelling (ASL) to quantify 
cerebral blood flow (CBF), diffusion tensor imaging (DTI) to explore microstructural 
changes and chemical exchange saturation transfer (CEST) which is sensitive to the 
chemical exchange of mobile protons. 
In this work, I have been involved in the experimental set-up, acquisition of the imaging 
data and post-processing of the results. Following in vivo scanning, I perfuse-fixed all of 
the mice before dispatching the tissues to my collaborators for histology.  I also 
investigated and interpreted all MR findings, and performed cross-correlations between 
the imaging parameters, as well as against histology. 
I would like to acknowledge my colleagues and collaborators: Jack Wells and James O’Callaghan at the 
UCL Centre for Advanced Biomedical Imaging for development of the ASL and DTI sequences 
respectively; Patxi Torrealdea and Marilena Rega at the UCL Institute for Neurology for development 
of the CEST sequence; and Ma Da and Nick Powell for developing the image processing software. 
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4.2 Introduction 
It has been over a century since Alois Alzheimer first described the symptoms of the 
presenile dementia which would come to bear his name (208), but to date there is still 
no disease-modifying or preventative treatment for this devastating disease. As the 
incidence of Alzheimer’s disease (AD) continues to rise to epidemic proportions (209), 
effective therapies are urgently required to ease both the economic and emotional 
burdens of this devastating disease. 
The two key neuropathological hallmarks of AD are plaques composed of amyloid-β 
and NFTs of hyperphosphorylated tau. Emerging therapies targeting the production or 
clearance of these protein aggregates require robust biomarkers to evaluate and quantify 
therapeutic efficacy. The development of reliable biomarkers in humans, however, is 
complicated by the length of clinical studies required to follow the evolution of 
pathology; this is currently believed to occur as much as 30-40 years prior to cognitive 
deficits (98). One approach is to establish and validate biomarkers using mouse models 
of AD as a surrogate for patient populations.  
Tau pathology, not amyloid-β burden, independently predicts cognitive status in 
patients with AD (210). This suggests the potential value of tau-targeted therapies in 
AD and the requirement for non-invasive biomarkers that are sensitive to the severity 
of tau pathology. To investigate tau specific biomarkers of pathology I have used the 
rTg4510 mouse (153), which was previously characterised in a single timepoint study 
using structural MRI in the preceding chapter. This mouse expresses a mutant form of 
the hMAPT human gene under the control of a tetracycline-responsive (tetO) CaMKII-α 
promoter. One advantage of the model is that the expression of mutant tau can be 
suppressed by the administration of the tetracycline derivative doxycycline (Figure 4.1) 
(114). Longitudinal assessment of this model enables the investigation of biomarkers 
sensitive to the accumulation of tau pathology and provides a framework to evaluate the 
efficacy of therapeutic strategies targeted at the suppression or removal of pathological 
tau. 
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Figure 4.1 Schematic showing the suppression of the transgene in the presence of doxycycline. Adapted from 
SantaCruz et al. (114) 
 
In this work, I have sought to identify specific elements of the pathological cascade, as 
well as the advancement and inhibition of tau pathology, using multi-parametric MRI 
measures in the rTg4510 mouse. I explored morphological changes using high 
resolution structural MRI, the breakdown in chemical exchange of mobile proteins 
using CEST, microstructural changes in the cytoarchitecture through DTI and 
alterations in CBF using ASL, over time. To coincide with the development of NFTs 
from 4 months, I conducted two longitudinal studies: one group received doxycycline 
from 3.5 months, representing an “early” therapeutic intervention. The second cohort 
received doxycycline from 4.5 months, representing “late” therapeutic intervention. 
Utilising these multi-parametric MRI techniques, I demonstrate sensitivity to tau-driven 
pathological changes as well as tau suppression in the rTg4510 in mice treated at two 
distinct time points.  
4.3 Materials and Methods 
4.3.1 Mice 
The rTg4510 animal model used in this study was previously described in Chapter 4. 
For this study, Female rTg4510 mice and litter-matched wildtype controls were bred on 
a mixed FVB/NCrl + 129S6/SvEvTa background for Eli Lilly and Company by 
Taconic (Germantown, USA) and received on site 2 weeks prior to the initiation of the 
studies.  
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Two doxycycline intervention cohorts are reported in this study and summarized in 
Figure 4.2: ‘early’ (3.5 months) and ‘late’ (4.5 months) intervention. The early 
intervention cohort consisted of 20 rTg4510 mice with 10 wildtype controls, and the 
late intervention cohort consisted of 19 rTg4510 mice with 11 wildtype controls. 
Subsequent to their initial scan, the rTg4510 mice were divided into two subgroups: the 
treated rTg4510 mice received two boluses of 10mg/kg doxycyline hyclate (Sigma 
Aldrich; 10mg per kg of body weight) via oral gavage and were maintained on 
doxycycline-mixed chow diet (Harlan Teklad Rodent Diet; 200mg doxycycline per kg of 
dietary chow) until the end of the study (Harlan Teklad Rodent Diet); the untreated 
rTg4510 animals and the wildtype controls received two boluses of a 5% glucose vehicle 
via oral gavage and were maintained on standard chow. The dietary content of the 
doxycycline-mixed and standard chow was consistent for each group.   
For further evaluation of the rTg4510 mouse’s response to increasing concentrations of 
isoflurane, a separate cohort of female rTg4510 mice and wildtype controls were imaged 
at 9 months. 
All mice were kept in standard size mouse cages (29 × 18 × 13 cm; up to 5 per same sex 
groups) at 20oC to 26oC on a daily 12 hour light-dark cycle with ad libitum access to food 
and water.  All studies were carried out in accordance with the United Kingdom Mice 
(Scientific Procedures) act of 1986 and subject to approval by UCL’s internal ethical 
review panel. 
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Figure 4.2 Schematic describing the early and late doxycycline intervention studies. High resolution structural MRI, CEST, DTI and ASL was acquired at all timepoints. Doxycycline was 
administered to a subset of rTg4510 mice following the baseline scan; all treated rTg4510 mice were maintained on a doxycycline mixed chow diet until the end of each respective study. 
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4.3.2 Magnetic resonance imaging  
Mice were placed in an induction box before anaesthesia was induced using 2% 
isoflurane at 1 l/min in 100% O2, Mice were subsequently positioned in a MRI-
compatible head holder to minimise motion artefacts. Anaesthesia was maintained 
throughout imaging using 1.5% isoflurane at 1 l/min in 100% O2 delivered via a nose 
cone g, which permitted spontaneous breathing of the mice. Core temperature and 
respiratory rate were monitored using a rectal probe and pressure pad respectively (SA 
instruments). Mice were maintained at ~37oC using heated water tubing and a warm air 
blower with a feedback system (SA instruments). Scans were performed in the following 
order: CEST, ASL, DTI and structural imaging. Prior to imaging, shimming was first 
performed across the CEST imaging slice (3mm slice thickness). Following CEST 
acquisition, shimming was performed across the whole mouse brain for the structural, 
ASL and DTI sequences.   
I employed high resolution structural MRI, CEST, DTI and ASL at each timepoint to 
characterise the treated and untreated rTg4510 mice and wildtype controls. The imaging 
protocol is detailed in Figure 4.2. The mice from the early intervention cohort were 
perfuse-fixed following the final imaging timepoint before being dispatched for 
histology. The mice from the late intervention cohort were similarly perfuse-fixed 
following the final imaging timepoint; however, their brains were retained for high 
resolution ex vivo structural scanning in order to compare the sensitivity of the in vivo 
and ex vivo structural sequences. This study is summarised in Chapter 5. Once these 
extra scans were complete, the brains were dispatched for histology.  
4.3.3 High resolution in vivo structural MRI 
High resolution structural scans were acquired using the sequence parameters previously 
optimised in Chapter 3. Briefly, a 3D T2-weighted FSE sequence was employed with the 
following parameters: FOV = 19.2 mm × 16.8 mm × 12.0mm; resolution = 150 μm × 
150 μm × 150 μm; TR = 2500 ms, TE = 43 ms, ETL = 4, NSA = 1. Total imaging 
time was approx. 1 h and 30 mins. 
4.3.4 Tensor-based morphometry 
TBM was performed by my collaborators at the UCL Centre for Medical Image 
Computing, using the methods previously detailed in Chapter 3.3.9. Briefly, the in vivo 
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structural images were automatically oriented to a standard atlas space, non-uniformity 
corrected, skull-stripped and intensity-standardised at each imaging timepoint. This was 
followed by 1 iteration of rigid registration, 4 iterations of affine registration and 15 
iterations of non-rigid registration, to align equivalent voxels between subjects. The 
determinant of the Jacobian matrix was calculated at each voxel of the resulting 
deformation fields which was subsequently smoothed, before statistics were performed 
at each voxel in order to compare groups. The resulting statistical parametric maps were 
corrected for multiple tests using the FDR (169); q=0.05). 
4.3.5 Automatic structural parcellation 
Automatic structural parcellation was performed by my collaborators at the UCL Centre 
for Medical Image Computing. Using a multi-atlas-based structural parcellation 
framework (211), three structures of interest were extracted: the cortex, hippocampus 
and thalamus for each animal at each timepoint. The brain images were oriented, non-
uniformity corrected and skull-stripped as above. Following orientation, non-uniformity 
correction and skull-stripping as above, my collaborators adopted the publicly available 
in vivo mouse brain MRI atlas previously published by Ma et al. (188) for the framework. 
First, the atlas images were registered affinely to the original MRI image data using a 
block-matching algorithm (212). Once complete, the STAPLE algorithm [17] was 
applied to fuse the resampled atlas masks together to create a consensus brain mask for 
each animal’s scans. A further non-rigid registration based on fast free-form 
deformation was then performed to correct any remaining local mis-alignment of the 
affinely registered atlas to the brain volumes (168). The structural labels from the atlas 
were then resampled to match the resolution of the brain scans and fused using the 
STEPS algorithm (167) to create the final parcellated structures of interest: the cortex, 
hippocampus and thalamus.  
As described in Chapter 3.3.8, a previously published calibration protocol was used to 
correct gradient scaling errors in the data (165).   
4.3.6 Chemical exchange saturation transfer  
The CEST sequence was independently developed for in vivo imaging of the rTg4510 
mouse by my collaborator at the UCL Centre for Advanced Biomedical Imaging (213). 
The CEST sequence was acquired using a single slice GE imaging sequence positioned 
axial using the splenium of the corpus callosum as a landmark for consistency of slice 
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positioning between subjects (TR = 6.1 ms, TE = 2ms, flip=5°, FOV = 20 mm × 20 
mm, slice thickness 3 mm, matrix size = 64 × 64). Saturation pulses were applied at 79 
frequency offsets covering ± 6 ppm to encompass APT saturation peaks approximately 
3.5 ppm downfield from the water; this corresponds to the 8.25 ppm in the proton 
resonance spectrum. A reference offset at 200 ppm was also acquired for normalisation. 
Shimming was performed across the entire imaging slice (3 mm thickness). The APT 
signal was calculated as the area under the MTRasym curves between 3.3 and 3.7 ppm 
on a pixel-by-pixel basis by fitting a polynomial function to Z spectra, correcting for 
off-resonance effects by cubic spline interpolation and subtracting the signal intensities 
at either side of the direct water saturation peak (214). Total imaging time was 5 
minutes. 
4.3.7 Diffusion tensor imaging 
The DTI sequence was independently developed for in vivo imaging of the rTg4510 
mouse by my collaborators at the UCL Centre for Advanced Biomedical Imaging (213). 
A four shot SE echo planar imaging (EPI) sequence was used to acquire sixteen slices.  
The fissure between the olfactory bulbs and the cortex was used as an anatomical 
landmark to maintain consistency in slice positioning between mice.  The FOV was 20 
× 20mm with a matrix size of 100 × 100 and a slice thickness of 0.5 mm.  Diffusion 
gradients were applied in twenty directions with the following parameters G = 0.25 
T/m, Δ = 9.3ms, δ = 5.5 ms, and b = 1050 s/mm2 to generate diffusion weighted 
images in addition to a single unweighted B0 image.  Acquisition of 5 averages with a TR 
of 2000ms gave a total imaging time of 25 minutes.  Software written in Matlab was 
used to construct tensors at each voxel through a least squares solution approach (215). 
The FA, MD and RD were calculated from the tensors following standard methods 
(216, 217). The total imaging time was 25 minutes. 
4.3.8 Arterial spin labelling  
The ASL sequence was independently developed for in vivo imaging of the rTg4510 
mouse by my collaborator at the UCL Centre for Advanced Biomedical Imaging (213). 
A flow-sensitive alternating inversion recovery (FAIR) sequence (218, 219) with a 4-
shot segmented SE EPI readout was impemented with the following parameters:  5 
slices, slice thickness = 1 mm, FOV = 20 × 20 mm, matrix size = 64 × 64, slice 
selective inversion pulse width = 12 mm,  inversion time = 1500 ms, TE = 11 ms, TR 
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= 3500 ms, 20 averages.  A hyperbolic secant adiabatic inversion pulse was used with a 
bandwidth of 20 kHz for the FAIR labelling pulses (220). The splenium of the corpus 
callosum was used as a landmark for consistency of slice positioning between subjects. 
Total imaging time was 20 minutes. CBF maps were generated using the model 
described by Buxton et al. (221). 
The total time dedicated to image acquisition was 2 hours 10 minutes. The animal set-
up, positioning and shimming took no longer than 30 minutes, which ensured the total 
time the animal was under isoflurane did not exceed the three hour anaesthesia 
tolerance, as defined by Lerch et al. (222). 
4.3.9 Perfuse fixation 
The perfusion fixation protocol for preparation of the post-mortem brain samples for 
histological evaluation was fully described in Chapter 3.3.6. Briefly, mice were terminally 
anaesthetised before being perfused through the left ventricle with 15 – 20 mL of saline 
(0.9%) followed by 50 mL of buffered formal saline (10%) at a flow rate of 3 mL per 
minute. Following perfusion, the animal was decapitated, defleshed, and the lower jaw 
removed. All brains were stored in-skull at 4 oC before being dispatched for histology. 
4.3.10 Histology and immunohistochemistry 
Brain samples were processed using the Tissue TEK® VIP processor (GMI Inc, MN 
USA) before being embedded in paraffin wax for coronal brain sectioning. Serial 
sections (6m) were taken using HM 200 and HM 355 (Thermo Scientific Microm, 
Germany) rotary microtomes. Immunohistochemistry (IHC) was performed using a 
primary antibody for tau phosphorylated at serine 409 (PG-5; 1:500 from Peter Davies, 
Albert Einstein College of Medicine, NY, USA) as previously described (163).  Stained 
sections were digitised using the Scanscope XT slide scanner (Aperio, CA, USA) at 20× 
magnification. Imagescope software (version 11.1.2.760; Aperio, CA, USA) was used to 
view the digitised tissue sections and delineate the regions of interest (cortex, 
hippocampus and thalamus). The number of PG-5 positive neurons was manually 
counted within a delineated region and expressed as a density (mm2). Both sides of the 
brain were analysed and averaged before statistical analysis. 
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4.3.11 Statistical analysis 
Quantitative data were analysed using a one-way ANOVA to determine whether there 
were any significant differences between the immunohistochemistry results for the 4 
mice cohorts (wildtype controls, early treatment rTg4510 mice, late treatment rTg4510 
mice and untreated rTg4510 mice). A two-way ANOVA with a post-hoc Sidak multiple 
comparison was performed to investigate group differences in the longitudinal imaging 
studies. GraphPad Prism 5 (version 5.04; GraphPad software Inc., CA, USA) was used 
to perform statistical tests and to produce graphs, which display mean values ± standard 
error of the mean (SEM). Statistical significance was set at p ≤ 0.05. 
For the CEST, DTI and ASL analysis, measurements were taken from ROIs drawn in a 
single slice positioned approximately Bregma -2.3; this was to align our MRI 
measurements with the histology. ROIs were manually drawn in the cortex, 
hippocampus, thalamus and corpus callosum (DTI only), as illustrated in Figure 4.2. 
The results within the hippocampus and cortex were averaged in order to calculate 
parameters within regions suffering from gross tau pathology. 
The structural images were analysed using the automated methods as described in 
Section 4.3.4 and 4.3.5. 
 
Figure 4.3 Slice section taken from The Mouse Brain Library’s Mouse Brain Atlas showing location of 
hippocampal (yellow), cortical (red), thalamic (blue) and white matter (green) ROIs for quantitative multi-
parametric MRI analysis. The cortical and hippocampal results were averaged to extract parameters within the 
“high ranked” tau pathology regions. 
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4.4 Results 
In this work, I have explored the sensitivity of multi-parametric MRI to the 
accumulation and suppression of pathological tau. A detailed description of the imaging 
protocol is provided in Figure 4.2, including the “early” and “late” doxycycline 
intervention strategy. 
4.4.1 Histology and immunohistochemistry 
To quantify the severity of tau pathology in the treated and untreated rTg4510 groups, 
all mice (21 wildtype controls; 23 untreated rTg4510 mice, 10 early treatment rTg4510 
mice and 6 late treatment rTg4510 mice) were sacrificed following the final imaging 
timepoint (7.5 months) and prepared for neuropathological assessment. Histology was 
performed by my collaborators at Eli Lilly. Immunohistochemistry using PG-5 (pS409), 
a marker of tau hyperphosphorylation, was used to quantify the density of tau-positive 
neurons in the cortex, hippocampus and thalamus (Figure 4.4).  
Consistent with literature data and my previous findings in this model (114), untreated 
rTg4510 mice contained a high density of PG-5 positive neurons in the cortex and 
hippocampus (mean = 345.2 ± 10.05  and 103.3 ± 7.64 (SEM), respectively; Figure 1A-
C).  In contrast, the thalamus had a significantly lower density (mean = 5.369 ± 0.64 
(SEM); Figure 4.4A, D).  For this reason, I classified the cortex and hippocampus as 
‘high tau burden’ regions and the thalamus as a ‘low tau burden’ region. There was no 
PG-5 positive staining observed in the wildtype mice. (Figure 4.4B- D).  
Following administration of doxycycline to rTg4510 mice, I observed a significant 
reduction in the number of PG-5 positive neurons in the cortex, hippocampus and 
thalamus of early (p<0.0001) and late (p<0.001, p<0.05 and p<0.01 respectively) 
treated mice when compared to the untreated group (Figure 4.4A–D).  The group 
treated with doxycycline early (3.5 months) showed the greatest reduction in PG-5 
positive neuron density, especially in the hippocampus and thalamus regions, illustrating 
the effectiveness of early intervention in this model. However, it is worth noting that 
the thalamus suffers markedly less PG-5 positive neurons in comparison to the 
hippocampus and cortex, hence its classification as a ‘low tau burden’ region, as 
described above. 
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Figure 4.4 Immunohistochemistry to estimate regional density of tau (PG-5) positive neurons. (A) Representative coronal slice illustrating the distribution of PG-5 positive neurons in the untreated 
rTg4510. Quantitative estimates of PG-5 neuron density in cortical (B), hippocampal (C) and thalamic (D) regions for wildtype (n=21), untreated rTg4510 mice (n=20), late treated Tg4510s 
mice (n=6) and early treated rTg4510 mice (n=10) at 7.5 months of age. A one-way ANOVA was performed to identify significant differences between the groups. Statistically significant groups 
have been identified and highlighted. Error bars represent the SEM. *=p<0.05; ** = p≤0.01; ***=p<0.001; **** = p≤0.0001. 
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4.4.2 High resolution structural MRI 
To investigate morphometric changes in the rTg4510 mice, I acquired high resolution in 
vivo structural images for the two longitudinal cohorts, using the sequence I optimised in 
Chapter 3. In both cases, doxycycline was administered to a subset of rTg4510 mice 
following the baseline scan: at 3.5 months for the early intervention study, and 4.5 
months for the late intervention study. 
My collaborators at the UCL Centre for Medical Image Computing used TBM to 
identify local areas of significant brain atrophy or expansion in the rTg4510 mice; the 
results at 7.5 months are shown in Figure 4.5. For each set of comparisons, three 
coronal slices with TBM statistics overlaid are presented. Extensive bilateral 
morphometric changes were detected in the untreated rTg4510 mice compared to 
wildtype controls, including significant atrophy in the forebrain, cortex, lateral striata 
and hippocampus as well as expansion of the lateral, third and fourth ventricles (Figure 
4.5A). Reductions were also observed in the thalamus; in the absence tau pathology, this 
is likely to reflect global differences in brain volume of the rTg4510 mice compared to 
wildtype controls. 
To investigate the morphological changes within the doxycycline-treated rTg4510 mice, 
two comparisons have been made: first, wildtype vs. doxycycline-treated rTg4510 mice 
(Figure 4.5B, C) and second, untreated rTg4510 vs. the treated rTg4510 mice (Figure 
4.5D, E). In mice treated with doxycycline from 3.5 months, TBM detected small 
discrete structural changes within the caudate putamen and the hippocampus compared 
to wildtype controls (Figure 4.5B), indicating preservation of cortical regions and 
ventricular spaces which presented with markedly fewer significant voxels. Figure 4.5D 
compares early doxycycline-treated rTg4510 mice with untreated rTg4510 mice. Here, 
TBM detected gross relative expansion of the ventricles and a bilateral pattern of 
cortical atrophy, highlighting regions preserved due to suppression of the tau transgene. 
Following administration of doxycycline from 4.5 months (late intervention), a similar 
yet more marked pattern of changes was observed in comparison to wildtype controls 
(Figure 4.5C). The comparison between late doxycycline-treated rTg4510 mice and 
untreated rTg4510 mice revealed a small number of significant voxels within the 
hippocampus, indicating small differences between the two cohorts (Figure 4.5E); early 
intervention appeared more successful at limiting atrophy and ventricular expansion.
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Figure 4.5 Results from structural analysis at 7.5 months, showing TBM statistical results overlaid on representative coronal slices of the final group average images after 15 iterations of 
NRR. Red: regions where the rTg4510 brains are relatively locally smaller than the average; blue: rTg4510 brains are locally larger. Based upon FDR-corrected t-statistics (q=0.05). 
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At 5.5 months (Figure 4.6), TBM detected comparable yet less widespread differences 
between the wildtype and early doxycycline-treated rTg4510 mice in the same regions 
implicated in Figure 4.5. In the comparison between the untreated rTg4510 mice and 
early doxycycline-treated rTg4510 mice (Figure 4.6C), no significant voxels survived 
FDR correction.  TBM results at the baseline scan revealed negligible significant local 
differences between the rTg4510 mice and wildtype controls (data not shown). 
 
 
Figure 4.6 Results from structural analysis at 5.5 months, showing TBM statistical results overlaid on 
representative coronal slices of the final group average image after 15 iterations of NRR. Red: regions where the 
rTg4510 brains are relatively locally smaller than the average; blue: rTg4510 brains are locally larger. Based 
upon FDR-corrected t-statistics (q=0.05). 
 
In order to quantify longitudinal volume differences between the transgenic mice and 
wildtype controls in the regions selectively vulnerable to high tau accumulation, my 
collaborators at the UCL Centre for Medical Image Computing also employed a fully 
automated atlas-based brain segmentation pipeline to measure absolute and normalised 
volume changes in the high ranked pathology regions across all timepoints. A sample 
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parcellated wildtype mouse brain can see seen in Figure 4.7. As well as investigating 
absolute volume alterations, normalized volume changes were explored by dividing the 
regional volume changes divided by the change in the whole brain volume (to account 
for gross differences in whole brain volume) (Figure 4.9). 
 
 
Figure 4.7 Representative wildtype mouse with atlas-based parcellation results overlaid. The methodology 
segments the mouse brain into 40 different regions of interest (187).  
 
A significant reduction in absolute volume of the high ranked pathology regions within 
the untreated rTg4510 mice from 3.5 months of age compared to the wildtype controls 
was detected (p<0.001) (Figure 4.8A). The absolute volume of the high ranked 
pathology regions within the untreated rTg4510 mice continued to decline by a further 
16.2% until the final imaging timepoint at 7.5 month (Figure 4.8A). The early treated 
rTg4510 mice suffered less atrophy compared to the untreated rTg4510 mice; the 
decline in volume was reduced to 6.3% owing to the suppression of the transgene 
(Figure 4.8A). Meanwhile, the absolute volume of the wildtype controls remained 
consistent from 3.5 months (82.1 mm3) to 7.5 months (83.8 mm3) indicating the 
volume changes were specific to the rTg4510 mice (Figure 4.8A). A similar trend was 
observed within the untreated rTg4510 mice in the late treatment study (Figure 4.8C). 
The volume of the thalamus, a region of low tau burden, was reduced in the rTg4510 
mice compared to wildtype controls at 3.5 months. This echoed the result in the high 
tau burden regions, possibly indicating the effect of the transgene of brain morphology 
(Figure 4.10). 
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Figure 4.8 Longitudinal volumetric changes in the high ranked pathology regions, extracted from the high 
resolution structural images. Early intervention: wildtype (n=10), untreated rTg4510 (n=10) and treated 
rTg4510 animals (n=10). Late intervention: wildtype (n=11), untreated rTg4510 (n=13) and treated 
rTg4510 animals (n=6). Hippocampal and cortical volumes were averaged in order to extract absolute and 
normalised volume changes in the high ranked pathology regions. The absolute volume changes within the high 
ranked pathology regions following (A) early and (C) late intervention are presented. In addition, the absolute 
volume changes were normalized to the TBV in order to extract the proportional volume changes following (B) 
early and (D) late intervention. A two-way ANOVA with a post-hoc Sidak multiple comparison was 
performed to identify significant differences between the groups. Statistically significant groups have been identified 
and highlighted. Error bars represent the SEM. Wildtype vs. untreated rTg4510s: ** = p≤0.01; *** = 
p<0.001; **** = p≤0.0001. Wildtype vs. treated rTg4510s: + = p≤0.05; ++++ = p≤0.0001. Treated 
rTg4510s vs. untreated rTg4510s: -- = p≤0.01; ---- = p≤0.0001. 
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Figure 4.9 TBVs for wildtype, rTg4510 and doxycycline-treated rTg4510 mice across all imaging timepoints. 
In order to account for the marked differences in brain volume between the mice cohorts, absolute volumes from the 
atlas-based parcellation were normalized to TBV in order to explore volumetric changes occurring 
disproportionately to alterations in brain volume. A two-way ANOVA with a post-hoc Sidak multiple 
comparison was performed to identify significant differences between the groups. Statistically significant groups 
have been identified and highlighted. Error bars represent the SEM. Wildtype vs. untreated rTg4510s: *** = 
p<0.001; **** = p≤0.0001. Wildtype vs. treated rTg4510s: ++ = p≤0.01; +++ = p≤0.001; ++++ 
= p≤0.0001. Treated rTg4510s vs. untreated rTg4510s: - = p≤0.05
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Figure 4.10 Longitudinal volume changes in the thalamus, extracted from the high resolution structural 
images, following (A, B) early and (C, D) late doxycycline treatment. Results are shown for (A, C) absolute 
volume and (B, D) normalised volume. A two-way ANOVA with a post-hoc Sidak multiple comparison was 
performed to identify significant differences between the groups. Statistically significant groups have been identified 
and highlighted. Error bars represent the SEM. Wildtype vs. untreated rTg4510s: * = p≤0.05; ** = 
p≤0.01; **** = p≤0.0001. Wildtype vs. treated rTg4510s: + = p≤ 0.05; ++ = p≤ 0.01 +++ = 
p≤0.001. Treated rTg4510s vs. untreated rTg4510s: -- = p≤0.01; ---- = p≤0.0001. 
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In order to uncover tau-specific volume changes, I also explored the normalised volume 
changes.  Following normalisation of the absolute volumes to TBV at each timepoint, a 
significant volume loss was detected in the high ranked pathology regions of the 
untreated rTg4510 mice compared to wildtype controls at 7.5 months (p<0.0001) 
(Figure 4.8B, D). Atrophy was detectable from 5.5 months within these mice (p<0.001) 
illustrating the sensitivity of high resolution structural MRI to tau-specific 
morphological changes occurring in the rTg4510 mice (Figure 4.8B). 
Following treatment with doxycycline, I observed significantly less atrophy in the 
treated rTg4510 mice when compared to the untreated rTg4510 mice at 7.5 months 
(p<0.0001), following both early and late therapeutic intervention (Figure 4.8B, D). 
Interestingly, the atrophy within the mice treated from 3.5 months was significantly less 
than rTg4510 mice treated from 4.5 months: 7.0% and 12.4% volume loss respectively. 
These results suggest that earlier intervention was able to reduce atrophy to a greater 
extent. 
Normalisation of the thalamus to TBV resulted in an expected (as this region suffers 
little tau pathology) increase in normalised thalamic volume within the rTg4510 mice 
compared to the wildtype controls (Figure 4.10B, D). This is due to normalisation with 
the decreasing TBV, leading to an apparent increase in thalamic volume over time. 
4.4.3 Chemical exchange saturation transfer 
Figure 4.11A shows the CEST results within the high ranked pathology regions of the 
rTg4510 mice following early intervention. A decrease in the APT signal was identified 
in the untreated rTg4510 mice relative to the wildtype controls at 7.5 months (p<0.01).  
Administration of doxycycline, following both early and late intervention, resulted in an 
increase in the APT signal towards wildtype values by 7.5 months (Figure 4.11). At this 
timepoint, the APT signal in the treated rTg4510 mice was not significantly different 
from the wildtype controls (Figure 4.11A, B). The early treated rTg4510 mice showed 
greater conservation: at this timepoint, both the treated rTg4510 mice and the wildtype 
controls were significantly different from the untreated rTg4510 mice (p<0.01) (Figure 
4.11A). This indicates that the APT signal may be sensitive to the suppression of 
pathological conformations of tau. 
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Figure 4.11 Longitudinal CEST results from the high ranked pathology regions following (A) early and (B) 
late doxycycline treatment. A two-way ANOVA with a post-hoc Sidak multiple comparison was performed to 
identify significant differences between the groups. Statistically significant groups have been identified and 
highlighted. Error bars represent the SEM. Wildtype vs. untreated rTg4510s: * = p≤ 0.05; ** = 
p≤0.01.Treated rTg4510s vs. untreated rTg4510s: -- = p≤0.01. 
 
 
Within the thalamus, in the presence of low tau burden, the APT signal was not 
significantly different between the rTg4510 mice and wildtype controls (Figure 4.12). 
These results provide evidence in support of APT’s sensitivity to tau-related pathology 
at later time points. 
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Figure 4.12 Longitudinal CEST results from the thalamus – a region of low tau burden - following (A) early 
and (B) late doxycycline treatment. A two-way ANOVA with a post-hoc Sidak multiple comparison was 
performed to identify significant differences between the groups. No significant differences were identified between 
groups at any of the timepoints under investigation. 
 
4.4.4 Diffusion tensor imaging 
DTI was employed to longitudinally investigate the microstructural changes in the grey 
and white matter of the rTg4510 mice. The results within the high ranked pathological 
grey matter tissues are shown in Figure 4.13.  
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Figure 4.13 Longitudinal (A, C) FA and (B, D) MD in the high ranked pathology regions following (A, 
B) early and (C, D) late doxycycline treatment. A two-way ANOVA with a post-hoc Sidak multiple 
comparison was performed to identify significant differences between the groups. Statistically significant groups 
have been identified and highlighted. Error bars represent the SEM. Wildtype vs. untreated rTg4510s: ** = 
p≤0.01; *** = p≤0.001; **** = p≤0.0001. Wildtype vs. treated rTg4510s: + = p≤0.05. Treated 
rTg4510s vs. untreated rTg4510s: --- = p≤0.001; ---- = p≤0.0001. 
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At 7.5 months, the untreated rTg4510 mice exhibited increased FA and MD, with both 
parameters able to discriminate between the untreated rTg4510 mice and wildtype 
controls (Figure 4.13A-D). Interestingly, at earlier timepoints neither FA (Figure 4.13A, 
B) nor MD (Figure 4.13C, D) were able to distinguish between the rTg4510 mice and 
wildtype controls, suggesting that detectable changes in these DTI parameters occur 
downstream from the formation of tau lesions from 4 months. 
Following early treatment with doxycycline, I observed no significant differences with 
control values of MD in the treated rTg4510 mice (Figure 4.13C, D). In this instance, 
MD readily discriminates between the treated and untreated rTg4510 mice (p<0.0001) 
as well as the untreated rTg4510 mice and wildtype controls (P<0.0001) at 7.5 months. 
Following late treatment, I saw a similar pattern of results (Figure 4.13C, D: 7.5 
months). In particular, I observed good discrimination in FA between treated and 
untreated rTg4510 mice (p<0.001). In contrast the thalamus presented with 
comparatively few significant differences in DTI parameters between the cohorts in 
both longitudinal studies (Figure 4.14). 
The RD results for the white matter region in the corpus callosum are shown in Figure 
4.15. The findings of increased RD in the rTg4510 mice are consistent with previous 
findings in this model (223). The mean RD in the treated group was less than the 
untreated group at 7.5 months in both longitudinal studies and showed a trend towards 
wildtype values, however these differences were non-significant (Figure 4.15). Similarly 
to FA and MD (Figure 4.13, Figure 4.14), RD is not able to distinguish between the 
rTg4510 mice and wildtype controls at earlier timepoints, further reinforcing the 
observations that the DTI parameters may not be sensitive to early neuropathology in 
this model. Taken together, the pattern of FA, MD and RD results suggest that these 
DTI parameters are sensitive to more downstream events following suppression of the 
tau transgene.  
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Figure 4.14 Longitudinal (A, C) FA and (B,D) MD in the thalamus following (A, B) early and (C, D) 
late doxycycline treatment. A two-way ANOVA with a post-hoc Sidak multiple comparison was performed to 
identify significant differences between the groups. Statistically significant groups have been identified and 
highlighted. Error bars represent the SEM. Treated rTg4510s vs. untreated rTg4510s: - = p≤0.05. 
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Figure 4.15 Longitudinal RD in the corpus callosum following (A) early and (B) late doxycycline treatment. 
A two-way ANOVA with a post-hoc Sidak multiple comparison was performed to identify significant 
differences between the groups. Statistically significant groups have been identified and highlighted. Error bars 
represent the SEM. Wildtype vs. untreated rTg4510s: * = p≤ 0.05; ** = p≤0.01. 
 
4.4.5 Arterial spin labelling 
ASL was employed to measure CBF in the rTg4510 mice. The results within the high 
ranked pathology regions, following early and late therapeutic intervention, are shown 
in Figure 4.16.  
In the late treatment group, I detected significant elevation in CBF in the rTg4510 mice 
compared to the wildtype controls (p<0.0001) (Figure 4.16B: 4.5 and 7.5 months). 
Unexpectedly, this observation was not replicated in the early treatment group (Figure 
4.16A). This discrepancy may be due to subtle differences in the concentration of 
isoflurane, a vasodilator, between the two animal cohorts (1.5%) (224, 225).  
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Figure 4.16 Longitudinal CBF results from the high ranked pathology regions following (A) early and (B) 
late doxycycline treatment. A two-way ANOVA with a post-hoc Sidak multiple comparison was performed to 
identify significant differences between the groups. Statistically significant groups have been identified and 
highlighted. Error bars represent the SEM. Wildtype vs. untreated rTg4510s: * = p≤0.05; **** = 
p≤0.0001. Wildtype vs. treated rTg4510s: ++++ = p≤0.0001. Treated rTg4510s vs. untreated rTg4510s: 
-- = p≤0.01. 
 
I endeavoured to maintain consistency in the experimental set-up between imaging 
timepoints; this included executing the ASL sequence within the first 30 minutes of the 
imaging protocol, in order to reduce complications due to prolonged anaesthesia. 
Despite my best efforts, I believe that mis-calibration of the isoflurane vaporiser may 
have resulted in differences in the depth of anaesthesia. In order to investigate this 
hypothesis further, my collaborator at the UCL Centre for Advanced Biomedical 
Imaging acquired CBF measurements at increasing concentrations of isoflurane in a 
separate cohort of aged rTg4510 mice (9 months) and wildtype controls.  
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Figure 4.17 CBF results within the (A) cortex and (B) thalamus at different concentrations of isoflurane. A 
two-way ANOVA with a post-hoc Sidak multiple comparison was performed to identify significant differences 
between the groups. Statistically significant groups have been identified and highlighted. Error bars represent the 
SEM. Wildtype vs. untreated rTg4510s: *** = p≤0.001.  
 
A marked increase in cortical CBF (high tau region) was observed when the isoflurane 
concentration was increased from 1.5 to 2% in the rTg4510 mice. This increase was not 
observed in the thalamus (low tau region) (Figure 4.17). These results support the 
hypothesis that CBF in the rTg4510 mice is dependent on the concentration of 
administered isoflurane, and may indicate that high ranked tau pathology regions are 
more vulnerable to isoflurane-driven hyperperfusion, as no significant increases in CBF 
were observed in the thalamus.  
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4.5 Discussion 
As the incidence of Alzheimer’s disease continues to rise to epidemic proportions, it is 
crucial that biomarkers of neurodegeneration are developed, to aid early diagnosis of the 
disease and facilitate drug development. The recent failure of several Phase III clinical 
trials targeting amyloid-β production or aggregation(33) has resulted in a surge of 
interest for tau-mediating therapies.(226) Tau plays an undeniable role in 
neurodegeneration; the spreading of tau pathology throughout the AD brain follows a 
hierarchical pattern which reflects the degree of cognitive impairment.(227, 228) In 
order to evaluate the efficacy of tau-targeting therapies, robust biomarkers which are 
sensitive to tau pathology are required. In this work, I report the first application of 
imaging biomarkers, including structural MRI, ASL, DTI and APT, in a longitudinal 
study of neurodegeneration in the rTg4510 mouse model of tauopathy. The rTg4510 
mouse exhibits key cognitive and neuropathological features of the human condition, 
including early tau burden in the forebrain from 4 months, neuronal loss and marked 
atrophy within the forebrain (114). In addition, the rTg4510 mice provide an excellent 
platform to assess the sensitivity of the different MRI techniques, as the expression of 
tau can be effectively regulated with doxycycline. 
In this work, I report the first application of multi-parametric MRI biomarkers, 
including structural MRI, ASL, DTI and APT, in a longitudinal study of 
neurodegeneration in the rTg4510 mouse model of tauopathy.  
Histological evaluation of pathological tau revealed a distinct pattern of regional 
severity, with high deposition within the cortex and hippocampus, and milder affliction 
of the thalamus as previously observed in Chapter 3. Treatment with doxycycline 
dramatically reduced the amount of PG-5 positive neurons in all the regions analysed, 
through deactivation of the promoter within the transgene which drives tau expression 
and subsequent NFT formation (114).  Although observed in both treatment groups the 
effect of doxycycline were more marked in the hippocampus and thalamus of the early 
(3.5 month) treatment group, suggesting that the transgene was repressed before the 
accumulation of significant tau pathology. These histological results illustrate the 
efficacy of the doxycycline intervention for reducing tau accumulation. I sought to 
exploit the dynamic range in tau accumulation, between early- and late- doxycycline 
treated and vehicle treated rTg4510 mice, and assess the sensitivity of MRI biomarkers 
to the development and suppression of pathological tau. 
138 
 
Structural MRI is now routinely employed in large-scale longitudinal studies of AD 
patients such as ADNI, which aims to identify early biomarkers and evaluate emerging 
AD intervention (179). It has been hypothesised that MR-detectable structural changes 
may precede cognitive impairment in AD, supporting the clinical utility of this 
technique for early diagnosis. In this work, I applied the previously optimised structural 
sequence in order to evaluate neurodegeneration in the rTg4510 mice. TBM was 
employed to detect morphological changes, in addition to atlas-based parcellation to 
explore regional volume differences. Both of these image processing techniques offers 
an unbiased estimation of brain atrophy, and eliminates the need for time-consuming 
manual methods for structural data analysis (211). 
The TBM results identified gross structural changes within the rTg4510 brains, 
including extensive atrophy within the cortex. Gross morphometric changes in the late 
stage of the disease were previously described in Chapter 3, and substantiate my current 
imaging and histological findings (157, 229). These changes are markedly reduced 
following treatment with doxycycline, suggesting that structural MRI is sensitive to the 
suppression of pathological tau in this model. The atlas-based parcellation results 
provided quantitative regional volume estimates, with detectable atrophy occurring 
within the high ranked pathology regions of the rTg4510 mice from 3.5 months. 
However, this volume difference was also seen in the thalamus (low ranked pathology), 
indicating that this difference could be due to either neurodevelopmental effects of 
transgene expression during prenatal development, or brain alterations and 
compensation in response to the forebrain atrophy. Normalising the absolute volumes 
to TBV revealed a pattern of atrophy that is specific to tau pathology, and accounts for 
the early global changes in brain volume. The normalised volume data revealed 
deterioration of the high ranked pathology regions detectable at 5.5 months, proceeding 
the development of NFTs within the cortex from 4 months (114). I also observed a 
reduction in atrophy within rTg4510 mice treated with doxycycline; this was more 
apparent when treatment began at the earlier timepoint of 3.5 months. Normalising the 
absolute volumes to total intracranial volume instead of TBV may mitigate the 
proportional increases observed within tissues unaffected by tau pathology. 
These results suggest that the presence of pathological tau underpins the key structural 
changes seen in this model. In addition to detectable volume losses within areas 
expressing high tau burden, the suppression of the tau transgene resulted in markedly 
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reduced atrophy, which correlates with the reduction of PG-5 positive cells in the high 
ranked pathology regions. 
My findings support the application of structural MRI as a close correlate of tau 
pathology, where it has already garnered clinical acceptance (230). In addition, I believe 
that structural MRI may serve as a valuable biomarker for assessing therapies targeting 
the production or clearance of pathological tau and the associated neurodegeneration 
and volume loss.  
CEST is a comparatively new technique for measuring the exchange water protons in 
bound and free states  (231). The amide proton pool can be selectively saturated using 
an off-resonance RF pulse, permitting the APT signal to be calculated. APT imaging is 
more commonly used for imaging brain tumours (232, 233) owing to its sensitivity to 
changes in protein expression in malignant tissues (234). In this work, a reduction in the 
APT signal in high ranked pathology regions within the rTg4510 mice compared to 
wildtype controls was observed at 7.5 months. These changes may be caused by the 
presence of neuronal tau pathology, impairing the chemical exchange between the 
amide protons and water protons (229). No significant differences were observed within 
the thalamus, where tau pathology was notably mild, further supporting this 
interpretation.  
While CEST aims to provide a direct measure of proton exchange, it is highly sensitive 
to changes in tissue pH. Acidification of the brain of AD patients has already been 
observed (235) and attributed to the accumulation of acidic metabolites and a 
breakdown in the brain’s ability to maintain a constant internal pH. The decreased APT 
signal within the rTg4510 mice may therefore also reflect changes in tissue pH within 
the high ranked pathology regions. A separate study employing 31P magnetic resonance 
spectroscopy would determine whether there was a pH change in the rTg4510 animals 
(236).  
Isoflurane anaesthesia is not believed to alter tissue pH (237, 238), although the 
implications following prolonged anaesthesia have yet to be explored. In order to 
mediate any isoflurane-related changes in tissue pH, the CEST acquisition was 
performed at the beginning of the imaging protocol. 
In addition to pH, the APT signal can also be influenced by the cellular water content, 
and the T1 relaxation time of the bulk tissue water (239). It is also worth noting that 
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APT imaging is highly sensitive to B0 and B1 field in homogeneities, especially when 
applied to in vivo imaging data at high magnetic field strengths (240).  
It is difficult to elucidate one underlying factor which is causing the APT signal changes 
in this model; regardless, these results illustrate the sensitivity of measures of APT to 
tau-related pathology in this model and may reflect neurodegenerative processes. In 
particular, it may serve as an important biomarker when assessing the efficacy of novel 
therapeutics targeting pH-sensitive pathways, such as neuronal transmitters (44). 
DTI is increasingly being employed in longitudinal studies of AD (241, 242). It can 
offer heightened sensitivity to changes in grey and white matter integrity, which are not 
so readily detectable using structural MRI. It is believed that DTI changes may precede 
volume changes in AD, and therefore may represent an important early biomarker of 
the disease with enhanced sensitivity to early microstructural changes. (243)  
RD is a valuable DTI parameter which reflects diffusion perpendicular to the primary 
direction in a voxel, which may reflect fibre orientation in the white matter. My 
observation of increased RD in the corpus callosum mimics the clinical picture (244) 
and has been previously observed in the rTg4510 mouse (229). Demyelination has been 
cited as a possible mechanism underpinning this change (223, 245). This is supported by 
previous work in the rTg4510 mouse, where electron microscopy revealed swollen 
unmyelinated processes in the corpus callosum from 4 months (223). No axial 
diffusivity changes have been observed in this model, suggesting that demyelination is 
occurring in the absence of axonal injury (217). Alterations in RD were not significantly 
different until the final imaging timepoint at 7.5 months; my observations therefore 
suggest that RD may be sensitive to downstream events proceeding the accumulation of 
pathological tau and unmyelinated processes from 4 months (114). Treatment with 
doxycycline marginally reduced the RD changes; however, there was no marked 
improvement in this parameter when treatment was commenced earlier.  
Whilst DTI is traditionally used to characterise white matter structures, it can also be 
applied to fibre-rich grey matter structures such as the hippocampus.(246) FA and MD 
were extracted to investigate the high ranked pathology regions of the cortex and 
hippocampus. The observation of increased FA within the rTg4510 mice was 
unexpected, as this traditionally implies more intact axons. However, the phenomenon 
of increased FA in brain regions undergoing gross degenerative processes has 
141 
 
previously been observed (247), and may suggest increased disruption and loss of 
isotropic cells (247). Meanwhile, the observation of increased MD in the rTg4510 mice 
mimics the clinical condition (248, 249); this change is believed to indicate enlargement 
of the extracellular space, suggesting neurodegeneration is occurring (249, 250).  
Similarly to the RD results, FA and MD in the high ranked pathology regions were only 
able to discriminate between the rTg4510 mice and wildtype controls at the final 
imaging timepoint.  However, these parameters offered heightened sensitivity to the 
doxycycline treatment. Following early- and late-stage treatment, recovery of both FA 
and MD was observed, suggesting that the presence of pathological tau is underpinning 
these DTI changes. I observed greater recovery of MD following early treatment with 
doxycycline, suggesting that MD may be more sensitive to suppression of pathological 
tau. 
While it has been claimed that microstructural changes detectable using DTI may 
precede structural changes,(251) my results do not support this hypothesis for this 
model. Increased FA, MD and RD in the rTg4510 mouse were only detectable at 7.5 
months, in the presence of significant atrophy and tau burden at this timepoint. I 
therefore propose that the strength of DTI may not lie in its ability to discriminate 
between rTg4510 mice and wildtype controls; rather, it offers valuable information that 
may compliment the structural MRI results. This may be particularly beneficial when 
assessing therapeutic efficacy of treatments which target pathways for which DTI offers 
heightened sensitivity. 
There is growing evidence supporting the role of CBF as a biomarker of AD (252). The 
vascular hypothesis for AD stipulates that underlying vascular factors such as 
hypertension, diabetes and obesity may substantially contribute to the development of 
AD pathogenesis (253, 254). Measurements of CBF therefore may represent an 
important biomarker in the early diagnosis of AD, and for evaluation of therapies which 
may produce a vascular response (255). CBF differences have already been observed in 
AD patients using ASL, with decreased perfusion in cortical regions affected by the 
disease.(252)  
Previous observations in the rTg4510 mouse identified a distinct pattern of 
hyperperfusion in the cortical and hippocampal regions in an advanced stage of the 
pathology (229). In the late intervention group, I noted distinct hyperperfusion, 
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consistent with this previous work although this was not replicated in the early 
treatment group.  To understand this further, the effects of the anaesthetic isoflurane in 
the rTg4510 mouse were investigated. I hypothesized that these discrepancies may be 
due to differences in the concentration of administered isoflurane, a volatile anaesthetic 
which causes a dose-dependent increase in CBF (225). This theory was supported by 
evidence of hyperperfusion at high concentrations of isoflurane.(224)  Interestingly, 
when the mice were challenged with a higher concentration of isoflurane, the regions of 
high tau pathology responded with a marked increase in CBF; this was much less 
evident in the wildtype controls. Although it is unclear why this is the case, a recent 
work demonstrates that the rTg4510 mouse has increased cerebrovascular response 
(CVR) (256), which could suggest that elevated levels of blood CO2, due to the reduced 
respiration rate that accompanies increased delivery of isoflurane, may result in the 
increased CBF. Similar results have recently been observed in a bigenic mouse model of 
AD, where increased CVR in response to hypoventilation was reported (257). 
Furthermore, the sensitivity of the rTg450 mouse to increased isoflurane concentration 
may be due to a breakdown in autoregulation (258), a mechanism which may be 
affected as a result of tau pathology, leading to vascular compensation and the increase 
in CBF, although the precise mechanism is still unknown (256). 
A number of additional rodent studies have reported cortical hypoperfusion using ASL 
in conjunction with isoflurane anaesthesia at varying concentrations: 1-1.5% (259), 1.5-
2% (260) and 2% (261). However, these studies all focus on models exhibiting amyloid 
pathology. In this study, the observation of hyperperfusion at high concentrations of 
isoflurane may be unique to the rTg4510 mouse, and reflect a tau-related effect. Despite 
the complexity surrounding CBF measurements, at higher concentrations of isoflurane 
complete discrimination of the rTg4510 mice from wildtype controls was observed. 
However, careful calibration of administered anaesthetic gases may be required in future 
studies in order to extract meaningful longitudinal CBF measurements in the rTg4510 
mouse. 
Previous work in the rTg4510 mouse at 8.5 months indicated that hyperperfusion and 
increased MD was detectable in regions of low tau pathology (the thalamus of the 
rTg4510 [mean NFT density = 2.3 cells/mm2]). Thus these biomarkers were considered 
to be strong candidates for relatively early detection of tau-driven abnormalities in the 
cortex and hippocampus of the rTg4510. However, no differences in MD between the 
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wildtype and rTg4510 cohorts were detected in the high rank regions at 3.5, 4.5 or 5.5 
months. Increased CBF at 4.5 months was observed in the late intervention study but 
this finding was not reproduced at 5.5 months in the early intervention study, likely 
owing to discrepancies in anaesthetic delivery between the two longitudinal studies. 
4.6 Conclusion 
This study demonstrates the value of non-invasive multi-parametric quantitative MRI 
for longitudinal assessment of tau pathology in the rTg4510 model, and monitoring 
distinct properties that reflect the biological responses to therapy in AD.  The imaging 
protocol permits the acquisition of structural, ASL, DTI and CEST data in a 
longitudinal framework within the three hour anaesthesia tolerance of mice (222). Each 
of these techniques can be readily translatable to clinical studies, aided by ongoing 
efforts to standardise the sequences, enabling meaningful comparisons between sites 
(262). These diverse scans all offer complimentary information, and provide insight into 
different pathological mechanisms occurring within the disease process. The structural 
scans and analysis proved to be the earliest biomarker, in addition to offering the 
highest degree of sensitivity to the doxycycline treatment; however, over half of the 
imaging time is dedicated to the acquisition of the structural data, which should be 
considered upon interpretation. This data represents a platform for future longitudinal 
and therapeutic efficacy studies of novel therapeutic strategies that target varying 
aspects of the pathology time course in this model.  
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Chapter 5: Is alive better than dead when 
investigating structural changes in transgenic mice 
using magnetic resonance imaging? 
5.1 Aims 
The preceding chapters have demonstrated the application of structural MRI for in vivo 
characterisation of the rTg4510 mouse and litter matched wildtype controls. Despite the 
growth of in vivo structural imaging to characterise mouse models of neuropathology, it 
is still not known whether it is best to scan a mouse alive or dead in order to maximise 
sensitivity to structural defects associated with disease models. 
In this chapter, I have explored the trade-offs between in vivo and ex vivo imaging for 
morphometric characterisation of the rTg4510 mouse. I acquired structural images of 
the rTg4510 mice and wildtype controls in vivo before perfuse-fixing and scanning the 
same brains ex vivo. I also investigated cross-correlations between the TBM data and the 
histology. 
I would like to acknowledge my collaborator Nick Powell at the UCL Centre for Medical Image 
Computing for developing the image processing software. 
5.2 Introduction 
Since Nature published the initial sequence of the mouse genome in 2002 (263), there 
has been an exponential rise in the number of transgenic and targeted mice that have 
been engineered to deepen our understanding of the function of genes in human 
biology . An astonishing 99% of mouse genes have a homologue in humans, with great 
tracts of code appearing in the same order in the two genomes (264). In fact, the 
laboratory mouse has now been hailed as the "experimental key to the human genome”, 
partly because of the exquisite refinement with which it is possible to engineer human 
mutations and so model human disease. (265) Mice also breed well,  do not appear to 
suffer from stress in captivity, and have a lifespan of approximately two – three years, 
making them a good model organism for phenotyping. Expanding our knowledge of 
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the operation and function of genes could ultimately lead to the development of 
improved and more selective therapies for the treatment of genetic diseases.  
It has been estimated that to create a knock-out mouse for each of the 20,000 genes in 
the mouse genome, over 7 million animals will be needed to generate and characterize 
each of the knockout lines (266). This figure does not include knock-in and transgenic 
mice, all of which will also require characterisation in order to fully comprehend gene 
function.  
In order to analyse increasingly complex phenotypes, robust and reproducible methods 
for phenotyping are required (267). Biochemical, behavioural, anatomical, physiological 
and pathological assays all contribute to understanding the true function of a gene (268).  
Phenotyping at the macroscopic and microscopic level is traditionally carried out using 
histological methods. These techniques are useful for validating hypotheses and 
uncovering unexpected biochemical changes that accompany altered gene function. 
However, these techniques are terminal, invasive and limited by low throughput. 
Recently techniques for structural phenotyping have moved beyond the use of histology 
to embrace whole-body, high resolution methods of imaging. In recent years however, 
MRI has increasingly been employed for phenotyping transgenic mice, largely due to 
advances in MRI hardware and computer power, enabling sophisticated image 
processing techniques (269). Through a combination of high resolution MRI and 
automated computational analysis, the throughput and efficiency of the structural 
phenotyping of transgenic mice will significantly improve. 
One of the key experimental decisions in the structural MRI of mouse neuroanatomy is    
whether to scan the mouse brain in vivo or ex vivo to maximise sensitivity to 
morphological changes with respect to wild-type controls. Imaging the animal post-
mortem enables longer scan times, the use of contrast agents in high concentrations and 
limits motion. All of these factors can boost resolution, SNR and CNR, to support 
advanced computation approaches such as TBM. In addition, multiple brains can be 
imaged simultaneously using standard MRI hardware, thereby improving the 
throughput of data acquisition. Conversely, live animals do not suffer distortions and 
dehydration from fixation, which may disrupt the integrity of the tissues. Crucially, in 
vivo imaging permits longitudinal studies, where the same animal can be serially assessed 
to observe morphological and functional changes over time. This has been shown to 
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improve the statistical power of the results (222) as well as reducing the number of 
animals dedicated to imaging studies, compared to cross-sectional studies. In vivo 
imaging has particular relevance in preclinical drug studies, which are required before a 
candidate therapy can enter clinical trials.  
In this chapter I have explored the sensitivity of in vivo and ex vivo structural imaging for 
detecting regions of structural changes in the rTg4510 mouse model of tauopathy (114). 
This mouse has been extensively characterized using in vivo structural MRI in the 
preceding chapters as well as within the literature, where gross atrophy of the forebrain 
regions has been observed (157, 229). In this chapter, I sought to investigate the 
morphological differences that can be detected in either in vivo or ex vivo structural MRI 
using an automated TBM pipeline for high throughput analysis of neuroanatomy in the 
mouse brain. TBM has previously been applied to a number of clinical disorders, 
including epilepsy (270) and Alzheimer’s disease (180, 271, 272), and has recently been 
applied to both in vivo and ex vivo structural mouse brain data sets, as detailed in Chapter 
3 (154, 155, 194-202).  
As described in Chapter 4, the rTg4510 mouse offers a novel paradigm to support our 
investigation as the overexpression of tau can be inactivated by the administration of 
doxycycline. Therefore in addition to characterising the gross morphological differences 
between the transgenic and wildtype animals, I also sought to identify the structural 
changes occurring in a subset of doxycycline-treated rTg4510 mice using both in vivo 
and ex vivo structural MRI. 
5.3 Methods 
5.3.1 Transgenic animals 
Generation of homozygous rTg4510 transgenic mice has been reported previously 
(114). rTg4510 mice were licensed from the Mayo Clinic (Jacksonville Florida, USA) 
and bred for Eli Lilly by Taconic (Germantown, USA).  Mice were imported to the UK 
for imaging at the Centre for Advanced Biomedical Imaging, UCL, London.  All studies 
were carried out in accordance with the United Kingdom Animals (Scientific 
Procedures) Act of 1986 and subject to review by the UCL internal ethics committee.  
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In this study, 11 female wildtype and 19 female rTg4510 litter-matched control mice 
were imaged both in vivo and ex vivo at 7.5 months of age. Of the 19 rTg4510 animals, 6 
were fed with Doxycycline mixed chow from 4.5 months to suppress the 
overexpression of tau. These mice formed the ‘late’ intervention cohort, as described in 
Chapter 4. 
5.3.2 Magnetic resonance imaging 
All imaging was performed using a 9.4T VNMRS horizontal bore scanner (Agilent Inc.). 
The key differences between the in vivo and ex vivo are outlined in Table 5.1.  
Table 5.1 Summary of the key differences between in vivo and ex vivo imaging protocols. 
 In vivo Ex vivo 
Sequence Fast spin echo Gradient echo 
Weighting T2-weighted T2*-weighted 
Resolution 150 μm 40 μm 
Imaging coil 
Volume coil transmit/4 
channel surface coil receive 
Volume coil 
Imaging time 1 h 30 mins 11 h 24 mins 
No. of subjects imaged 
per acquisition 
1 3 
Averages 1 6 
Contrast agent? N Magnevist 
 
For in vivo imaging, mice were placed in an induction box before anaesthesia was 
induced using 2% isoflurane at 1 l/min in 100% O2, Mice were subsequently positioned 
in a MRI-compatible head holder to minimise motion artefacts. Anaesthesia was 
maintained throughout imaging using 1.5% isoflurane at 1 l/min in 100% O2 delivered 
via a nose cone g, which permitted spontaneous breathing of the mice. Core 
temperature and respiratory rate were monitored using a rectal probe and pressure pad 
respectively (SA instruments). Mice were maintained at ~37oC using heated water 
tubing and a warm air blower with a feedback system (SA instruments). 
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5.3.3 In vivo structural imaging 
A 120 mm diameter imaging gradient set (SGRAD 205/120/HD/S, Agilent 
Technologies UK Ltd., Berkshire, UK) was used. A 72 mm birdcage RF coil was 
employed for RF transmission and a quadrature mouse brain surface coil (RAPID, 
Germany) was used for signal detection. Tuning and matching of the coil was 
performed manually. Shimming was performed across the mouse brain prior to image 
acquisition. 
High resolution structural scans were acquired using the sequence optimised in Chapter 
3. Briefly, a T2-weighted, 3D FSE sequence was implemented with the following 
parameters: FOV = 19.2 mm × 16.8 mm × 12.0 mm; resolution = 150 μm × 150 μm × 
150 μm; TR = 2500 ms, TEeff = 43 ms, ETL = 4; NSA = 1. Total imaging time was 
approx. 1 h and 30 mins. 
5.3.4 Perfusion fixation 
The perfusion fixation protocol for the preparation of tissues for histological evaluation 
was previously described in Chapter 3.3.6. In this work, the protocol was adapted in 
order to prepare the brains for high resolution contrast-enhanced ex vivo scanning. 
Briefly, animals were terminally anaesthetised following in vivo scanning before being 
intracardially perfused through the left ventricle of the heart: first with 15 – 20 mL of 
saline (0.9%) and heparin; second with 50 mL of buffered formal saline (10%) doped 
with 8 mM Magnevist, at a flow rate of 3 mL per minute. Following perfusion, the 
animal was decapitated, defleshed, and the lower jaw removed. All brains were stored 
in-skull at 4 oC and soaked in buffered formal saline (10%) doped with 8 mM Magnevist 
for 9 weeks prior to ex vivo scanning (140).  
5.3.5 Ex vivo structural imaging 
An imaging gradient set with a 60 mm inner diameter (SGRAD 115/60/HD/S, Agilent 
Technologies UK Ltd., Berkshire, UK) was used. A 35L mm birdcage RF coil was 
employed for RF transmission and signal detection. Tuning and matching of the coil 
was performed manually. 
A custom-build three brain holder was used to acquire high resolution ex vivo images of 
multiple brains simultaneously. A 3D GE sequence was implemented for structural 
imaging with the following parameters: FOV = 32 mm × 25 mm × 25 mm; resolution 
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= 40 μm × 40 μm × 40 μm; TR = 17 ms; TE = 4.54 ms; flip angle = 51o; NSA= 6. 
Total imaging time was 11 h 36 minutes (140). 
Following ex vivo scanning, all brains were dispatched for histology. 
 
 
Figure 5.1 (A) Custom 3D-printed three brain holder, which was engineered to fit inside a 50 mL syringe. 
(B) Representative MRI image, showing three brains scanned simultaneously. The hyperintense spheres are 
markers which aid identification of the brains in post-processing. 
 
5.3.6 Image processing 
In vivo and ex vivo MR images were reconstructed using custom software written in 
MATLAB. As described in Chapter 3.3.8, a previously published calibration protocol 
(165) was used to adjust volume estimates to correct for scaling errors caused by the 
imaging gradients.  
5.3.7 Tensor-based morphometry 
TBM was performed by my collaborators at the UCL Centre for Medical Image 
Computing, using the methods previously detailed in Chapter 3.3.9. Briefly, the in vivo 
structural images were automatically oriented to a standard atlas space, non-uniformity 
corrected, skull-stripped and intensity-standardised. This was followed by 1 iteration of 
rigid registration, 4 iterations of affine registration and 15 iterations of non-rigid 
registration, to align equivalent voxels between subjects. The determinant of the 
Jacobian matrix was calculated at each voxel of the resulting deformation fields which 
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was subsequently smoothed, before statistics were performed at each voxel in order to 
compare groups. The resulting statistical parametric maps were corrected for multiple 
tests using the FDR (169); q=0.05). 
5.3.8 Deformation maps 
To measure the degree of local variability between ex vivo and in vivo images, my 
collaborators at the UCL Centre for Medical Image Computing registered each ex vivo 
brain to its corresponding in vivo counterpart, and calculated the mean positional 
distance (MPD) at each voxel, after resampling the resulting deformation fields into the 
in vivo brains’ average space. The magnitude of the 3D vectors was calculated and the 
mean found over all 𝑁 deformation fields, 𝑖: 
𝑀𝑃𝐷 (𝑣𝑜𝑥𝑒𝑙) =
1
𝑁
∑ √𝑥𝑖
2 + 𝑦𝑖
2 + 𝑧𝑖
2
𝑁
𝑖=1
 
where 𝑥, 𝑦, 𝑧 are the vector components from the non-rigid registration only (excluding 
rigid and affine). 
5.3.9 Signal-to-noise and contrast-to-noise ratio calculations 
SNR and CNR were calculated as described previously, using Equation 3.2 and 3.3.  
Signal was taken from ROIs including: caudate putamen, cerebellum, corpus callosum, 
cortex, hippocampus, hypothalamus, olfactory bulb, midbrain and thalamus. The noise 
ROI was placed in a ghost-free region of background signal. Noise was defined as the 
SD of the background signal. 
5.3.10 Histology and immunohistochemistry 
Histology was performed by my collaborators at Eli Lilly. Brain samples were processed 
using a Tissue TEK® VIP processor (GMI Inc, MN USA). After processing, sections 
were embedded in paraffin wax to allow coronal brain sections to be cut. Serial sections 
(6 - 8μm) were taken using HM 200 and HM 355 (Thermo Scientific Microm, 
Germany) rotary microtomes. 
Immunohistochemistry (IHC) was performed using a primary antibody for tau 
phosphorylated at serine 409 (PG-5; 1:500 from Peter Davies, Albert Einstein College 
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of Medicine, NY, USA) and the neuronal marker NeuN (1:500 from Millipore; 
MAB377).  Following de-paraffinisation and rehydration of the tissue sections, antigen 
retrieval was performed using the Lab Vision PT module system (Thermo Scientific), 
where sections were heated to 100oC for 20 min in citrate buffer (TA-250-PM1X; 
Thermo Scientific).  Slides were transferred to a Lab Vision Autostainer (Thermo 
Scientific) where the following incubations were performed: 10 min in H2O2 (0.3%); 30 
min in normal goat serum (1:20; Vector Laboratories); 60 min in primary antibody; 30 
min in biotinylated goat anti-mouse IgG (1:200, BA9200; Vector Laboratories); 30 min 
avidin-biotin complex solution (PK-7100; Vector Laboratories); 5 min in 3,3′-
diaminobenzidine (SK-4105; Vector Laboratories).  Apart from the last two steps, PBS 
with 0.05% Tween-20 (PBS-T) was used for diluting reagents and washes between 
steps. Sections were then counterstained with haematoxylin before dehydration and 
cover-slipping.  
To quantify the density of PG-5 and NeuN positive neurons, stained sections were 
digitised using the Scanscope AT slide scanner (Aperio) at 20× magnification. 
Imagescope software (version 11.1.2.780; Aperio) was used to view the digitised tissue 
sections and delineate the boundaries of the cortex. PG-5 positive cells were manually 
counted within the delineated region and NeuN positive cells were quantified using a 
nuclear detection algorithm (Imagescope, version 11.1.2.780; Aperio); both were 
expressed as a percentage of the total area.   These analyses were performed in a blinded 
fashion.    
5.4 Results 
5.4.1 Signal-to-noise and contrast-to-noise measurements 
In order to explore quantitative differences in image quality between the in vivo and ex 
vivo images, SNR and CNR measurements were taken and averaged for 3 representative 
wildtype animals. Table 5.2 shows the mean SNR values for in vivo and ex vivo mouse 
brains.  
I observed a significant increase in SNR of the in vivo images compared to the ex vivo 
images in 7 of the 9 regions under investigation, including: caudate putamen (p ≤ 
0.001), corpus callosum (p ≤ 0.0001), cortex (p ≤ 0.01), hippocampus (p ≤ 0.0001), 
olfactory bulb (p ≤ 0.05), midbrain (p ≤ 0.01) and thalamus (p ≤ 0.01). Meanwhile, the 
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SNR ex vivo was significantly increased in the cerebellum (p ≤ 0.05). However it is 
important to note that SNR is highly dependent on spatial resolution, so the increased 
SNR in the in vivo data is likely to be due to the greater voxel sizes of the in vivo data. 
Conversely, I observed a three-fold increase in CNR between the grey (cortex) and 
white matter (corpus callosum) structures in the ex vivo images compared to CNR 
measured in vivo (p ≤ 0.01).  
Table 5.2 Mean (± SD) SNR and CNR for in vivo and ex vivo wildtype mouse brains. 
Region 
SNR 
P value 
In vivo (n=3) Ex vivo (n=3) 
Caudate putamen 14.4 ± 1.7 9.3 ± 1.1 ≤0.001 
Cerebellum 7.6 ± 0.9 11.4 ± 0.6 ≤0.05 
Corpus callosum 15.6 ± 0.6 4.2 ± 0.7 ≤0.0001 
Cortex 14.2 ± 1.4 10.0 ± 0.8 ≤0.01 
Hippocampus 19.3 ± 1.2 10.8 ± 0.8 ≤0.0001 
Hypothalamus 11.2 ± 1.2 11.5 ± 0.7 ns 
Olfactory bulb 14.8 ± 1.9 10.9 ± 1.1 ≤0.05 
Midbrain 11.1 ± 1.2 6.9 ± 0.6 ≤0.01 
Thalamus 12.4 ± 1.5 7.8 ± 1.0 ≤0.01 
CNR 1.5 5.8 ≤0.01 
 
5.4.2 Total brain volumes 
It has previously been reported that formalin fixation causes tissue shrinkage (154, 222, 
273) which may be a confounder in our ex vivo MRI analysis, particularly if this 
shrinkage is inhomogeneous across structures. In order to investigate the changes in 
brain morphometry occurring due to formalin fixation, my collaborators at the UCL 
Centre for Medical Image Computing extracted TBVs for the in vivo and ex vivo mouse 
brain specimens using a previously published segmentation protocol (211). 
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Figure 5.2 In vivo and ex vivo TBVs for wildtype, rTg4510 and rTg4510(+DOX) animals. In vivo vs. ex 
vivo comparisons: **** = p ≤ 0.0001. In vivo TBV comparisons: ++ = p ≤ 0.01; ++++ = p ≤  0.0001. 
Ex vivo TBV comparisons: - - = p ≤ 0.01; - - - - = p ≤ 0.0001. 
 
A significant reduction in ex vivo TBV in comparison to the corresponding in vivo TBV 
was observed (p ≤ 0.0001) (Figure 5.2). Tissue shrinkage in post-mortem specimens has 
been previously been observed and attributed to dehydration of the tissues (274). In this 
work, I stored the ex vivo brains in gadolinium-doped formalin for 9 weeks, to enable 
the contrast agent sufficient time to diffuse uniformly across the tissues (140). Despite 
this discrepancy in the ex vivo TBVs, I observed that the degree of shrinkage was 
consistent across the wildtype controls (10.3%), rTg4510 mice (10.4%) and doxycycline-
treated rTg4510 mice (10.1%). I therefore do not anticipate tissue shrinkage to 
confound group comparisons of ex-vivo structural MRI data. 
In addition to identifying significant shrinkage of the tissues during the fixation process, 
the TBV results identified gross differences in TBV of the wildtype mice when 
compared to the rTg4510 mice (p ≤ 0.0001) and the doxycycline-treated rTg4510 mice 
(p ≤ 0.01) (Figure 5.2). The differences were consistent between the in vivo and ex vivo 
TBV measurements: 21.3% volume loss within the rTg4510 cohort compared to 
wildtype controls, and 16.2% volume loss within the rTg4510 cohort compared to the 
doxycycline-treated rTg4510 cohort.  
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5.4.3 Deformation maps to estimate tissue shrinkage uniformity  
The TBV results revealed a significant volume reduction in ex vivo TBV compared to 
the corresponding in vivo TBV (p ≤ 0.0001) (Figure 5.2). In order to further investigate 
the morphological differences between in vivo and ex vivo brain tissues at a voxel-wise 
level, my collaborators at the UCL Centre for Medical Image Computing registered the 
ex vivo mouse brains to their corresponding in vivo mouse brain template.  
Figure 5.3 shows the mean distance moved by each voxel when aligning ex vivo images 
to in situ, in vivo images, from all three mouse cohorts. The greatest deformations were 
identified within structures located frontally and caudally in the mouse brain, including 
the brainstem and olfactory bulb. In these regions, displacements greater than 0.25 mm 
can be readily visualised. The brainstem was particularly vulnerable to disturbance; in 
this structure, displacements of 0.5 mm can be observed.  
I observed deformations within the rostral aspect of the olfactory bulb; however, the 
displacements are markedly less than previous findings within this structure (188). By 
scanning the ex vivo specimens in the skull, I have minimised disturbances to this 
structure. The remaining brain structures, including the midbrain, hippocampus, 
thalamus and cortex, were relatively unaffected ex vivo; I attribute this preservation to 
keeping the brains in the skull for scanning, to prevent damage. It is notable that the 
cortical surface shows very few signs of systematic perturbation, suggesting high validity 
of ex vivo morphometric results in these structures. 
Another possible cause of the apparent displacements seen in Figure 5.2 is the different 
sequences used for in vivo (FSE) and ex vivo (GE) acquisition. The latter may have 
induced some geometric distortion away from the bore isocentre, giving a similar 
pattern. However, the ex vivo brains were always aligned in the scanner bore so that their 
centres were aligned with the isocentre. Previous work by O’Callaghan et al. found 
gradient warp distortion was below 0.1 mm within ± 20 mm of the isocentre (35); the 
mouse skulls easily fit within this 40 mm window. Additionally, the displacements seen 
caudally appear predominately in the brainstem (rather than equally in the cerebellum), 
so it is more likely that physical distortion caused the dominant appearance here. 
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Figure 5.3 Deformation maps showing local distortions of the ex vivo mouse brains in comparison to their in 
vivo mouse brain template.  Deformations were calculated at a voxel-wise level. The colour bar illustrates the 
distance travelled by a voxel during registration of the ex vivo mouse brains to the in vivo atlas. 
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5.4.4 Tensor-based morphometry 
5.4.4.1 Unnormalized TBM results for the comparison between wildtype and 
rTg4510 mice 
Figure 5.4 shows representative in vivo (Figure 5.4A, B) and ex vivo (Figure 5.4C, D) axial 
and coronal slices through the group average images after group-wise registration, with 
statistically significant voxels overlaid (FDR, q=0.05). Regions highlighted in red 
represent a significant local decrease in volume of rTg4510 group compared to the 
wildtype group, while regions highlighted in blue represent a significant increase in 
volume. I present un-normalized in vivo and ex vivo results (Figure 5.4A, C), in addition 
to results which have been normalized to TBV (Figure 5.4B, D) in order to account for 
global differences in TBV between the transgenic and wildtype mice (Figure 5.2). The in 
vivo TBM results have also been presented in Chapter 4; here, more slices are displayed 
in order to further explore the morphological changes detected in the in vivo and ex vivo 
data sets. 
As discussed in Chapter 4, TBM applied to the unnormalized in vivo data identified 
extensive atrophy within the forebrain regions, including the cortex, caudate putamen, 
hippocampus and hypothalamus, as well as expansion of the lateral, third and fourth 
ventricles (Figure 5.4A). 
The unnormalized ex vivo TBM results are shown in in Figure 5.4C. Good consistency 
was observed between the TBM results for the in vivo and ex vivo images for identifying 
morphological changes in this model, with a similar pattern of atrophy detected in both 
data sets. Interestingly, expansion of the lateral and third ventricles was visibly reduced 
in the ex vivo results (Figure 5.4Cii-iii). This may be due to collapse of the ventricular 
space during specimen preparation; a phenomenon which has previously been observed 
in ex vivo mouse brains (188).  
5.4.4.2 Normalized TBM results for the comparison between wildtype and 
rTg4510 mice 
The TBV results in Figure 5.2 highlighted the gross differences in brain volume 
between the rTg4510 mice and wildtype controls. In order to account for these 
differences and reveal local morphological changes which are disproportionately more 
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severe that the overall reduction in TBV, the TBM statistics were normalized to TBV. 
Figure 5.4 additionally shows the normalized in vivo (Figure 5.4B) and ex vivo (Figure 
5.4D) TBM results. 
Markedly fewer regions of expansion and contraction were observed in the normalized 
TBM results, in contrast to the corresponding unnormalized TBM results. The 
normalized in vivo TBM results identified atrophy within the rTg4510 mice which could 
be localised to the retrosplenial region of the cortex and thalamus (Figure 5.4Bii) as well 
as the caudate putamen (Figure 5.4Biii). These regions were implicated in the 
unnormalized in vivo TBM results (Figure 5.4A); these findings suggest volume loss 
occurring disproportionately to global TBV reduction within these regions. 
The normalized ex vivo TBM results detected significant atrophy within the rTg4510 
mice that could be localised to the somatosensory region of the cortex (Figure 5.4Dii). 
The CA1 region of the hippocampus was also identified (Figure 5.4Div). Interestingly, 
more voxels retained their significance in the normalized in vivo TBM results in 
comparison to the normalized ex vivo TBM results; this is likely to be due to the 
expansion and contraction correlating better with the TBV differences in the ex vivo 
mouse brains. 
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Figure 5.4 TBM results for the morphological comparison between rTg4510 mice and wildtype controls. 
Results from in vivo (A, B) and ex vivo (C, D) structural analysis, showing TBM statistical results overlaid on 
representative axial and coronal slices of the final group average image after 20 iterations of NRR. I present 
unnormalized in vivo (A) and unnormalized ex vivo (C) TBM results in addition to normalized in vivo (B) and 
ex vivo (D) TBM results. Normalized TBM results were calculated by normalizing the TBM statistical results 
to TBV. Red: regions where the rTg4510 brains are relatively locally smaller than the wildtype controls; blue: 
rTg4510 brains are locally larger. Based upon FDR-corrected t-statistics (q=0.05). 
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5.4.4.3 Unnormalized TBM results for the comparison between rTg4510 mice 
and doxycycline-treated rTg4510 mice 
In order to investigate the sensitivity of in vivo and ex vivo imaging to more subtle 
structural changes, I sought to identify morphological differences between the 
doxycycline-treated and untreated rTg4510 mice. Figure 5.4 shows the unnormalized in 
vivo (Figure 5.4A) and ex vivo (Figure 5.4C) TBM results for the comparison between 
rTg4510 mice and doxycycline-treated rTg4510 mice. Regions highlighted in red 
represent a volume decrease in the rTg4510 mice compared to the doxycycline-treated 
rTg4510 mice; regions highlighted in blue represent a volume increase in the rTg4510 
mice compared to the doxycycline-treated rTg4510 mice. 
In contrast to the unnormalized results detailed in Figure 5.4A and C, I observed 
markedly reduced regions of expansion and contraction in the unnormalized in vivo and 
ex vivo TBM results (Figure 5.5A, C) due to the smaller morphological differences 
previously observed between the doxycycline-treated and untreated rTg4510 mice at 
this timepoint (previously described in Chapter 4.4.2). 
The unnormalized in vivo TBM results identified small discrete clusters of significant 
voxels within the piriform area of the cortex (Figure 5.5Aii) and caudal slices of the 
hippocampus (Figure 5.5Aiv). I observed good correspondence between the 
unnormalized TBM results observed in vivo and those identified ex vivo (Figure 5.5B), 
with significant voxels identified in many of the same regions ex vivo. However, the ex 
vivo TBM results were significantly more widespread, with atrophy detected extensively 
throughout the cortex, caudate putamen and caudal hippocampal regions (Figure 5.5C). 
This may be due to the increased CNR of the ex vivo images (Table 5.2) which permits 
improved localisation of discrete morphological changes occurring between the 
rTg4510 and doxycycline-treated rTg4510 mice. 
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5.4.4.4 Normalized TBM results for the comparison between rTg4510 mice and 
doxycycline-treated rTg4510 mice 
The TBV results identified significant differences in brain volume between the rTg4510 
mice and the doxycycline-treated rTg4510 mice (p ≤ 0.01) (Figure 5.2). As detailed 
previously, the TBM statistics were normalized to TBV in order to reveal changes 
occurring disproportionality to the differences in brain volume. 
Figure 5.5 shows the normalized in vivo (Figure 5.5B) and ex vivo (Figure 5.5D) TBM 
results for the comparison between rTg4510 mice and doxycycline-treated rTg4510 
mice. In comparison to the unnormalized ex vivo TBM results (Figure 5.5B), many 
voxels retained their significance when normalized to TBV, suggesting the changes 
observed are occurring disproportionately to TBV differences. The observable 
alterations can therefore be attributed to the effects of doxycycline. Atrophy was 
detected in the CA1 region of the hippocampus (Figure 5.5Ci) and the somatosensory 
region of the hippocampus (Figure 5.5Cii).  
Following normalization of the in vivo TBM results to TBV, all statistically significant 
voxels disappeared (Figure 5.5B). This finding suggests that the in vivo MRI study may 
have been underpowered to detect changes occurring disproportional to brain volume 
differences. 
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Figure 5.5 TBM results for the morphological comparison between rTg4510 mice and doxycycline-treated 
rTg4510 mice. Results from in vivo (A, B) and ex vivo (C, D) structural analysis, showing TBM statistical 
results overlaid on representative axial and coronal slices of the final group average image after 20 iterations of 
NRR. I present unnormalized in vivo and ex vivo TBM results (A, B) and normalized ex vivo TBM results 
(C). Normalized TBM results were calculated by normalizing the TBM statistical results to TBV. Red: regions 
where the rTg4510 brains are relatively locally smaller than the treated rTg4510 brains; blue: rTg4510 brains 
are locally larger. Based upon FDR-corrected t-statistics (q=0.05). 
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5.4.5 Immunohistochemistry to estimate cortical PG-5 and NeuN density 
In order to corroborate the TBM findings with alterations occurring at the cellular level, 
quantitative immunohistochemistry was performed on each of the individual wildtype 
(n=11), untreated rTg4510 (n=13) and treated rTg4510 (n=6) mice following ex vivo 
imaging. My collaborators at Eli Lilly employed two stains: 1) NeuN, a neuronal marker, 
and B) PG-5, a marker for phosphorylated tau. Both neuronal loss and tau 
accumulation have previously been shown to correlate with structural MRI findings (93, 
97, 230); in this work, I have used the histology results as a ground truth and identified 
regions where morphological changes identifiable using MRI were likely to be observed. 
Figure 5.6A shows the regional distribution of NeuN positive neurons in a 
representative untreated rTg4510 mouse. The untreated rTg4510 mice showed a 
significant decrease in the density of NeuN positive cells in the cortex (mean NeuN 
density = 1099 ± 107.3 cell/mm2) compared to wildtype mice (mean NeuN density = 
1253 ± 131.3 cell/mm2) (p ≤ 0.05) (Figure 5.6B). These results are consistent with 
previous findings, and indicate severe neurodegeneration in this model (114, 229). 
Following treatment with doxycycline, I observed a significant increase in NeuN density 
in the treated rTg4510 mice (mean NeuN density = 1301 ± 44.89 cell/mm2) compared 
to the untreated rTg4510 mice (p ≤ 0.01) (Figure 5.6B).  No significant differences were 
observed between NeuN cell densities in the treated rTg4510 mice compared to 
wildtype mice. 
Figure 5.6C shows the regional distribution of PG-5 positive cells in a representative 
untreated rTg4510 mouse. Visual inspection of the slice section revealed high levels of 
PG-5 staining in the cortex and hippocampus. In agreement with previous findings in 
this model, I observed high levels of PG-5 positive cells in the cortex of the untreated 
rTg4510 mice (mean PG-5 density = 369.1 ± 39.11 cell/mm2) (Figure 5.6C, D). No 
PG-5 positive cells were observed in the wildtype mice mean (Figure 5.6D). Following 
treatment with doxycycline, I observed a significant decrease in PG-5 positive cell 
density in the treated rTg4510 mice (mean PG-5 density = 268.6 ± 39.11 cell/mm2) 
compared to untreated rTg4510 mice (p ≤ 0.001) (Figure 5.6D). 
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Figure 5.6 Immunohistochemistry to estimate NeuN and PG-5 positive cell density in the cortex. 
Representative coronal slices illustrating the distribution of (A) NeuN and (C) PG-5 positive neurons in the 
cortex of an untreated rTg4510 mouse. Quantitative estimates of (B) NeuN and (D) PG-5 positive cell density 
in the cortex for each of the 7 wildtype, 10 untreated rTg4510 and 6 treated rTg4510 mice at 7.5 months of 
age. * = p ≤ 0.05; ** = p ≤ 0.01;  *** = p ≤ 0.001; **** = p≤0.0001. 
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5.4.6 Histological ranking to explore changes in NeuN staining 
To further investigate whether the discrete volume changes detected using ex vivo TBM 
normalized to TBV reflected alterations at the cellular level, I explored whether the 
localized changes within the somatosensory region of the cortex (shown as statistically 
significant voxels in the TBM maps in Figure 5.4D) were mirrored in the NeuN 
staining. 
Each NeuN slice section was manually delineated to identify the parietal (region 1), 
somatosensory (region 2) and auditory (region 3) regions of the cortex (Figure 5.7A). 
The degree and severity of NeuN disruption was assessed by semi-quantitative ranking 
by five independent and blinded raters (1, highly disrupted, to 5, no disruption). 
 
Figure 5.7 Immunohistochemistry to estimate extent of NeuN disruption. Representative coronal slice 
illustrating the distribution of  NeuN  within the (1) parietal, (2) somatosensory and (C) auditory regions of the 
cortex. Modal ranking scores for each of the 7 wildtype, 10 rTg4510 and 6 rTg4510 (+DOX) animals at 7.5 
months of age. *** = p≤0.001; **** = p≤0.0001. 
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Significant disruption in NeuN staining in the rTg4510 mice compared to wildtype 
controls was observed in all regions under investigation: the parital (p ≤ 0.001), 
somatosensory (p ≤ 0.001) and auditory (p ≤ 0.0001) regions of the cortex (Figure 
5.7B-D). A similar pattern of disruption was also observed between the rTg4510 and 
doxycycline-treated rTg4510 (Figure 5.7B-D). No significant differences in NeuN 
staining were observed between the treated rTg4510 mice and wildtype controls (Figure 
5.7B-D). 
These findings suggest that alterations in cell density may be underpinning the 
widespread cortical changes detected using TBM (Figure 5.4 and Figure 5.5). However, 
the somatosensory region of the cortex did not show increased NeuN disruption. These 
results therefore suggest there is no link between discrete (sub-cortical) disruption in 
NeuN staining, and the proportional volume changes observed in the normalized ex vivo 
TBM results. 
5.5 Discussion 
With increasing numbers of rodent neuroimaging studies employing automated analysis 
techniques to identify regions of structural change, it is important that the compromises 
between in vivo and ex vivo MRI are fully understood in order to maximise sensitivity to 
morphological differences. A number of studies have previously addressed the trade-
offs associated with imaging in vivo and ex vivo mouse brains (186, 188, 222); in this 
chapter, I present the first application of TBM to both in vivo and ex vivo structural MRI 
for investigating morphological changes in the rTg4510 mouse model of tauopathy. In 
addition to characterising the gross morphological differences in the rTg4510 mice 
compared to wildtype controls, the ability to modulate the expression of the tau 
transgene with doxycycline introduced more subtle group differences in brain 
morphology to explore using in vivo and ex vivo MRI. 
The T2-weighted in vivo MRI images enabled visual identification of many structures of 
interest, including the hippocampus, caudate putamen and cortex. This was achieved in 
the absence of exogenous contrast agents such as manganese, which is frequently 
employed in in vivo studies of mouse neuroanatomy (275, 276). However, high doses of 
manganese are believed to produce neurotoxic effects (277, 278), which could confound 
longitudinal analysis by interfering with both normal healthy aging and disease 
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progression. In this chapter, I instead exploited the inherent differences in the T1 and T2 
relaxation times to achieve adequate in vivo image contrast, as described in Chapter 3. 
Conversely, high resolution ex vivo MR images were acquired using a previously 
optimised protocol which employed the gadolinium-containing contrast agent 
Magnevist (140); the T1-shortening effects of gadolinium enabled the acquisition of high 
resolution data sets within a feasible scan time (typically overnight to maximise the 
efficiency of scanner usage). The protocol was adapted to permit the acquisition of 3 ex 
vivo mouse brains simultaneously, which markedly improved throughput. 
SNR and CNR measurements of the in vivo and ex vivo data sets allowed a quantitative 
assessment of image quality to support my investigation. Despite limits on scan time, 
the increasing availability of specialist hardware to support in vivo imaging studies 
permits the acquisition of in vivo data with sufficient SNR and CNR to perform voxel 
wise analyses. In the protocols applied here, SNR was significantly greater in vivo than ex 
vivo for 7 out of the 9 regions under investigation.  The larger voxel size (150 μm3 in vivo 
in contrast to 40 μm3 ex vivo) of the in vivo acquisition and use of a surface coil will have 
been key contributors to the increased signal in ROIs. 
Fixation of the ex vivo brain specimens results in dehydration and subsequent reduction 
of the relative proton density of tissues (279). This can cause a reduction in SNR in ex 
vivo images, although increasing the number of signal averages helped to mitigate this 
effect. Despite the lower SNR, ex vivo MRI experienced an increase in grey-white matter 
contrast compared to the in vivo images; this enhancement in CNR can be largely 
explained by the use of Magnevist. Despite the differences in the two protocols, in vivo 
and ex vivo imaging present different challenges and each protocol was optimised to 
mediate the unique demands of each. 
In addition to comparison of the image signal quality, the main aim of this investigation 
was to explore the sensitivity of in vivo and ex vivo MRI to the morphometric changes 
occurring in the rTg4510 mouse. When investigating differences between the rTg4510 
and wildtype mice, a similar bilateral pattern of atrophy in vivo and ex vivo was observed 
using TBM. Many of the same regions were identified as suffering volume loss, 
including the frontal cortical regions and caudal slices of the hippocampus. These 
regions are selectively vulnerable to NFT pathology and neuronal loss in this model, as 
depicted by the immunohistochemistry results. Conversely, expansion of the ventricles 
was underestimated in the ex vivo images, owing to collapse of the ventricular space 
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during formalin fixation. Whilst this doesn’t appear to interfere with the findings in the 
rTg4510 mouse, if the model under investigation has a ventricular abnormality, this may 
not be observed so readily ex vivo. 
When TBM was used to investigate more subtle structural changes, the benefits of ex 
vivo MRI became more apparent. A more extensive bilateral pattern of atrophy in the 
untreated vs. treated rTg4510 mice was detected in the ex vivo data sets, which could be 
localised to sub-regional structures: the anterior cingulate, somatosensory and piriform 
regions of the cortex, as well as the CA1 hippocampal subfield. The increased CNR of 
the ex vivo data sets is likely to enable the voxel-wise tests to highlight more extensive 
regions of difference between groups. In addition, the higher resolution afforded by ex 
vivo MRI permitted improved localisation of volume changes to sub-regional structures. 
Although not as spatially extensive, the in vivo TBM results produced significant voxels 
which implicated the same sub-regional structures as the ex vivo results. It is possible 
that increasing the sample size in vivo would enable the detection of a more extensive 
pattern of atrophy. However the in vivo results were adequate to guide further 
histological evaluation into the underlying cellular changes underpinning these MR 
findings. 
Within the normalized ex vivo TBM results, detection of significant atrophy was 
maintained in the somatosensory region of the cortex, in addition to the CA1 
hippocampal subfield. This finding suggests that volume loss within these regions was 
occurring disproportionate to the global brain volume changes. No significant voxels 
were detected in the normalized in vivo TBM results. Despite this negative finding, in 
Chapter 3 I reported in vivo TBM findings in the rTg4510 mouse which had been 
normalized to TBV at 8.5 months. This earlier study consisted of 17 wildtype and 9 
rTg4510 mice. I therefore hypothesise that the lack of sensitivity to discrete changes 
occurring disproportionately to the TBV differences is due to low animal numbers in 
each group. Increasing the sample size may increase the significance of the findings. A 
power calculation would confirm this hypothesis, and identify the minimum number of 
animals required to identify these changes for future studies. 
I revisited the histology data to try and corroborate the TBM findings with alterations 
occurring at the cellular level. The somatosensory region of the cortex has been 
implicated in all of the TBM results as a region suffering from significant volume loss; I 
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sought to uncover whether this may reflect disruption in NeuN staining. The results 
from the user ranking did not reveal further NeuN disruption within the somatosensory 
region of the cortex when compared to its neighbouring cortical structures. This may be 
due instead to nearby deformations within the TBM results manifesting within that 
region.  
I observed that the formalin fixation process causes an overall reduction in TBV of 
around 10%. Tissue shrinkage associated with formalin fixation is a widely accepted 
occurrence, yet the extent to which the tissues suffer differential distortion is still not 
fully known. A previous study identified 4.37% shrinkage in post-mortem wildtype 
mouse brains prepared for ex vivo MRI (154), markedly less than my observation of 
10.3%. This discrepancy may be due to differences in the fixation protocol, such as time 
spent in fixative and the use of contrast agents. The authors also did not specify 
whether a calibration protocol was in place to estimate gradient scaling errors of the 
different imaging systems used for the acquisition of the in vivo and ex vivo data. An 
additional study reported no significant difference in in vivo and ex vivo TBVs in a cohort 
of Wistar rats (280); in this work, the post-mortem rat brains were scanned using 
different scanners located at different sites. This work was also published in the absence 
of a calibration protocol, and the authors did not provide details of the fixation 
protocol. In both cases, if discrepancies between the respective gradient sets were not 
accounted for, this may cause inaccuracies in the estimation of ex vivo tissue shrinkage. 
In this work, I adopted a previously published gradient calibration protocol (165) to 
calculate scaling errors which then used to correct the in vivo and ex vivo data, thus 
improving the brain volume estimates.   
My observations of consistent whole brain shrinkage across the groups of wildtype, 
rTg4510 and doxycycline-treated rTg4510 mice suggest that this should not interfere 
with the TBM results, which rely on rigid and non-rigid registration algorithms to 
identify regions of expansion and contraction. In addition, the deformation maps 
identified minimum disruption to the cortical and central structures of the ex vivo mouse 
brains, which were of particular relevance in this work. The brain stem suffered the 
greatest deformations, as it is not protected from disturbance by the skull. A previous 
study identified similar disruption to the brain stem using a voxel-wise analysis (188); 
however, the authors reported additional disturbances in the dorsal cortical regions. 
These brains were removed from the skull prior to ex vivo imaging (189) which is likely 
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to have caused damage to the surface structures  and subsequent local deformations. 
The olfactory bulb,  cortex and cerebellum are particularly vulnerable to damage when 
extracting brains from the skull (186).  
5.6 Conclusion 
In this chapter, I have explored the compromises and trade-offs between in vivo and ex 
vivo MRI in conjunction with TBM for detecting regions of morphometry in transgenic 
mouse models. My findings support the utility of in vivo MRI, where atrophy was 
detected in regions known to be affected in this model. As demonstrated in Chapter 4, 
in vivo imaging permits longitudinal studies of neurodegeneration or neurodevelopment, 
which can offer novel insight into the mouse model under investigation. In addition, the 
data does not suffer from dehydration or distortion artefacts which can confound ex vivo 
studies. Furthermore I strongly advocate the use of a gradient calibration protocol in 
order to correct for gradient scaling errors and ensure accurate volume measurements 
(165). 
I hope that this work will help support research groups working in the field of 
preclinical MRI, and shape their decision about the best way to image their transgenic 
mice.  
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Chapter 6: Application of in vivo MRI biomarkers 
to the J20 mouse model of Alzheimer’s disease and 
the Tc1 mouse model of Down’s syndrome: a single 
timepoint study 
6.1 Aims 
The preceding chapters have focused on the sensitivity of MRI biomarkers to tau 
pathology in the rTg4510 mouse model. This chapter aims to explore the relationship 
between genetics and neurodegeneration by applying clinically relevant biomarkers to 
novel mouse models of AD and DS. 
In this work, I have been involved in the experimental set-up, acquisition of the imaging 
data and post-processing of the results. Following in vivo characterisation, I perfuse-
fixed all of the mice in order to perform high resolution ex vivo structural imaging, 
before dispatching the tissues for histology. Furthermore, I investigated cross-
correlations between the imaging parameters, as well as against histology. 
I would like to acknowledge my colleagues and collaborators: Frances Wiseman and Susan Noy at the 
UCL Institute of Neurology who provided the animals used and performed histological sectioning and 
staining; and Nick Powell and Ma Da at the UCL Centre for Medical Image Computing for 
developing the image processing software. 
6.2 Introduction 
Down’s syndrome (DS), or trisomy 21, is a genetic disorder caused by the presence of 
an extra copy of chromosome 21. Individuals with DS have a greater predisposition to 
early onset AD (26), widely believed to be due to the extra dosage of the APP gene. 
APP is an established risk factor gene for AD, with a number of mutations associated 
with familial forms of the disease (281). Crucially in the context of DS, the APP gene 
lies on chromosome 21, so individuals with DS have an additional copy of this gene. It 
is believed that the increased APP  mRNA and protein expression, in conjunction with 
increased levels of amyloid-β results in early onset AD (28). However, is it likely that 
other disease-modulating genes lie on chromosome 21 which contribute to the 
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increased incidence of AD observed in DS individuals (282). Furthering our 
understanding of AD in individuals with DS may provide useful insights into the 
disease within the wider population. 
Mouse models of DS are valuable tools for furthering our understanding of the 
significance of trisomy 21 and its relationship with AD. There are several mouse models 
of DS to choose from, each carrying various segments of chromosome 21. The 
transchromic 1 (Tc1) mouse is an established model of DS which carries an almost-
complete copy of human chromosome 21 but is not functionally trisomic for APP  
(283). The unique genetics of the Tc1 strain allow the study of the DS phenotype 
without the effects of APP trisomy. Several of the key features seen in the human DS 
condition are recapitulated in this mouse model, including altered heart development 
and behavioural changes (283). While initial characterisation of the Tc1 showed 
abnormalities in cerebellar neuronal density and skull morphology (283), there has since 
been no further investigation into additional cerebral defects in this mouse model.   
In order to introduce AD pathology to the Tc1 DS mouse, my collaborators at the UCL 
Institute of Neurology bred the Tc1 DS mouse to the J20 mouse - an established model 
of AD (104). The J20 AD mouse overexpresses human APP, with two mutations which 
have been linked to familial forms of AD: the Swedish (APP KM670) and Indiana (APP 
V717F) mutations. The J20 AD mouse exhibits many key features of the human 
condition, including cognitive decline, neuronal loss and the build-up of amyloid 
plaques (104). By breeding the Tc1 DS mouse to the J20 AD mouse, progeny have been 
generated that carry chromosome 21 genes with mutant APP. This new DS-AD mouse, 
termed the Tc1*J20 mouse, permits the study of the DS phenotype in the presence of 
AD pathology, compared to AD pathology alone, to see if chromosome 21 genes 
modulate pathology when present in three copies to echo the early-onset AD seen in 
DS. 
In this work, I have used multi-parametric MRI to characterise a cohort of Tc1, J20, 
Tc1*J20 and wildtype controls at 16 months, with the aim of investigating the 
relationship between genetics and the manifestation of AD neuropathology. The MRI 
biomarkers described in this study were chosen for their sensitivity to pathological 
mechanisms that have been implicated in neurodegenerative diseases. The use of 
identical MRI measurements across the different mouse strains permitted meaningful 
comparisons to be deduced. I used ASL to quantify CBF (252), MRA to evaluate 
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cerebral vasculature (284) and high resolution structural MRI (93) to evaluate 
morphological differences in these mice.  
6.3 Methods 
6.3.1 Animals 
Generation of the Tc1 and J20 mice used in this study have been reported previously (2, 
3). Tc1*J20 mice were generated by my collaborators at the UCL Institute of 
Neurology, by crossing Tc1 females with J20 males (Figure 6.1). In this study, two 
cohorts of animals were imaged. For initial characterisation, female Tc1 (n = 16), J20 (n 
= 14), Tc1*J20 (n = 9) and wildtype litter-matched controls (n = 22) were scanned aged 
16 months. For further CBF characterisation, a separate cohort of male Tc1 (n= 5) and 
wildtype controls (n = 6) were scanned aged 6 months. 
 
 
Figure 6.1 Schematic showing generation of Tc1*J20 mice by crossing the Tc1 and J20 mice. 
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All animals were bred at the Medical Research Council (MRC) Prion Unit (London, 
UK) and received on site 2 weeks prior to experimentation. All mice were kept in 
standard size mouse cages (29 × 18 × 13 cm; up to 5 per same sex groups) at 20oC to 
26oC on a daily 12 hour light-dark cycle with ad libitum access to food and water.   
All studies were carried out in accordance with the United Kingdom Animals (Scientific 
Procedures) act of 1986 and subject to approval by UCL’s internal ethical review panel. 
6.3.2 Magnetic resonance imaging  
All imaging was performed with a 9.4T VNMRS horizontal bore scanner (Agilent Inc.).   
For in vivo imaging, a 120 mm diameter imaging gradient set (SGRAD 205/120/HD/S, 
Agilent Technologies UK Ltd., Berkshire, UK) was used. A 72 mm birdcage RF coil 
was employed for RF transmission and a quadrature mouse brain surface coil (RAPID, 
Germany) was used for signal detection. Tuning and matching of the coil was 
performed manually. Shimming was performed across the mouse brain prior to image 
acquisition. 
Mice were placed in an induction box before anaesthesia was induced using 2% 
isoflurane at 1 l/min in 100% O2, Mice were subsequently positioned in a MRI-
compatible head holder to minimise motion artefacts. Anaesthesia was maintained 
throughout imaging using 1.5% isoflurane at 1 l/min in 100% O2 delivered via a nose 
cone g, which permitted spontaneous breathing of the mice. Core temperature and 
respiratory rate were monitored using a rectal probe and pressure pad respectively (SA 
instruments). Mice were maintained at ~37oC using heated water tubing and a warm air 
blower with a feedback system (SA instruments).  
For ex vivo imaging, an imaging gradient set with a 60 mm inner diameter (SGRAD 
115/60/HD/S, Agilent Technologies UK Ltd., Berkshire, UK) was used. A 35L mm 
birdcage RF coil was employed for RF transmission and signal detection. Tuning and 
matching of the coil was performed manually. A custom-build three brain holder was 
used to acquire high resolution ex vivo images of multiple brains simultaneously. 
6.3.3 Arterial spin labelling 
ASL was performed using the sequence previously described in Chapter 4.3.8. Briefly, a 
FAIR sequence (218, 219) with a 4-shot segmented SE EPI readout was implimented 
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with the following parameters:  5 slices, slice thickness = 1 mm, FOV = 20 × 20 mm, 
matrix size = 64  64, slice selective inversion pulse width = 12 mm,  inversion time = 
1500 ms, TE = 11 ms, TR = 3500 ms, 20 averages.  A hyperbolic secant adiabatic 
inversion pulse was used with a bandwidth of 20 kHz for the FAIR labelling pulses 
(220). The splenium of the corpus callosum was used as a landmark for consistency of 
slice positioning between subjects. CBF maps were generated using the model described 
by Buxton et al. (221). In this work, T1 maps were also acquired using an inversion 
recovery SE-EPI sequence for CBF quantification. CBF maps were generated by fitting 
the ASL images and T1 maps to the model described by Buxton et al. (221). ROIs were 
manually drawn in the cortex, hippocampus and thalamus across two 1 mm thick slices 
and averaged, matching the regions that underwent histological analysis of amyloid-β 
burden.  
6.3.4 Magnetic resonance angiography 
High-resolution angiograms of the whole brain were acquired using a TOF MRA 
sequence. A 3D GE sequence was employed with the following parameters: TR = 40 
ms; TE = 2.5 ms; FA = 40°; NSA = 2; matrix = 128 × 128 × 128; FOV = 15 mm × 15 
mm × 20 mm; resolution = 117 μm × 117 μm × 156 μm.  
6.3.5 Perfuse fixation 
The perfusion fixation protocol was previously described in Chapter 3.3.6, in order to 
prepare the brains for histological evaluation. Following in vivo imaging, a subset of 
wildtype (n = 13), Tc1 (n = 15), J20 (n = 14) and Tc1*J20 (n = 8) were perfuse-fixed 
for high resolution ex vivo scanning and histological evaluation. The perfuse-fixation 
protocol for prepare post-mortem brain samples for contrast-enhanced ex vivo scanning 
was previously described in Chapter 5.3.4. Briefly, mice were terminally anaesthetised 
before being perfused through the left ventricle with 15 – 20 mL of saline (0.9%) 
followed by 50 mL of buffered formal saline (10%) doped with Magnevist (8 mM) at a 
flow rate of 3 mL per minute. Following perfusion, the animal was decapitated, 
defleshed, and the lower jaw removed. All brains were stored in-skull in buffered formal 
saline (10%) doped with Magnevist (8 mM) at 4oC for 9 weeks prior to ex vivo imaging. 
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6.3.6 High resolution ex vivo structural imaging  
A 3D GE sequence was implemented for structural imaging with the following 
parameters: FOV = 32 mm × 25 mm × 25 mm; resolution = 40 μm × 40 μm × 40 μm; 
TR = 17 ms; TE = 4.54 ms; flip angle = 51o; NSA= 6. Total imaging time was 11 h 36 
minutes (140). 
Following ex vivo imaging, post-mortem brain samples were dispatched for histology. 
6.3.7 Histology and immunohistochemistry 
Histology was performed by my collaborators at the UCL Institute of Neurology. The 
brains were removed from the skulls and dissected down the midline with a scalpel to 
separate the left and right hemispheres.  The blocks were placed in plastic cassettes and 
processed to wax overnight in a Leica ASP300S tissue processor.  The processing was 
performed under vacuum, which involved dehydration through a graded series of 
alcohols, clearing in xylene followed by infiltration with paraffin wax.  The blocks were 
sagitally orientated and embedded in fresh wax using a Leica embedding centre 
(EG1150H) and cold plate.  The blocks of tissue were trimmed laterally from the 
midline by approx. 0.9-1.4mm to give a sagittal section of the hippocampal formation.  
4𝜇m thick sections were cut using a Leica RM2135 rotary microtome, dried overnight at 
40°C before immunostaining for amyloid-β. 
The sections were dewaxed in xylene, rehydrated through an alcohol series and washed 
in distilled water.  The sections were then transferred to 98% formic acid for 8mins, 
followed by washing in distilled water.  The sections were then loaded onto a Ventana 
XT automated stainer where they underwent a further 30min antigen retrieval 
procedure using Tris Boric acid EDTA buffer (pH9.0).  The sections were incubated in 
a blocking solution prior to being stained for amyloid-β using a directly biotinylated 
mouse monoclonal IgG2b antibody from Sigma (SIG-39240).  The antibody was raised 
to amino acid residues 17-24 of amyloid-β with the epitope between aa18-22 (VFFAE). 
This antibody has been reported to bind to abnormally processed isoforms, as well as 
precursor forms of amyloid-β.  The sections were incubated with primary antibody at a 
concentration of 2μg/ml for 12hrs, followed by development of the staining using the 
Ventana DabMap kit.  The sections were counterstained with haematoxylin, washed in 
distilled water, dehydrated, cleared and mounted in DPX prior to being microscopically 
assessed.   
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4G8 burden was quantified using ImageJ (285). 
6.3.8 High resolution ex vivo structural image processing 
Ex vivo MR images were reconstructed using custom software written in MATLAB. As 
described in Chapter 3.3.8, a previously published calibration protocol (165) was used to 
adjust volume estimates to correct for scaling errors caused by the imaging gradients.   
6.3.9  Automatic structural parcellation 
Atlas-based structural parcellation was performed by my collaborators at the UCL 
Centre for Medical Image Computing, using the methods previously described in 
Chapter 4.3.5. Briefly, images were automatically oriented to a standard atlas space, non-
uniformity corrected, skull-stripped and intensity-standardised. The publicly available ex 
vivo mouse brain MRI atlas previously published by Ma et al. (189) was adopted for the 
framework. The atlas images were registered affinely to the imaging data, before the 
atlas masks were fused together to create a consensus brain mask for each animal’s scan. 
This was followed by non-rigid registration of the atlas to the imaging data, before 
resampling of the structural labels to create the final parcellated images.  
6.3.10 Tensor-based morphometry 
TBM was performed by my collaborators at the UCL Centre for Medical Image 
Computing, using the methods previously detailed in Chapter 3.3.9. Briefly, the in vivo 
structural images were automatically oriented to a standard atlas space, non-uniformity 
corrected, skull-stripped and intensity-standardised. This was followed by 1 iteration of 
rigid registration, 4 iterations of affine registration and 15 iterations of non-rigid 
registration, to align equivalent voxels between subjects. The determinant of the 
Jacobian matrix was calculated at each voxel of the resulting deformation fields which 
was subsequently smoothed, before statistics were performed at each voxel in order to 
compare groups. The resulting statistical parametric maps were corrected for multiple 
tests using the FDR (169); q=0.05). 
6.3.11 Magnetic resonance angiography image processing 
Images were reconstructed using custom software written in MATLAB. A groupwise 
average angiography image was produced by registering the wildtype (n = 17), Tc1 (n = 
14), J20 (n = 18) and Tc1*J20 (n = 8) angiography images together, using the TBM 
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protocol detailed in Chapter 3.3.9. This protocol was adapted for analysis of the 
angiography data: a mask was generated for the vasculature by thresholding the average 
image, and TBM stats were performed within this mask in order to constrain the region 
of interest and reduce the multiple testing problem. 
6.4 Results 
In this chapter, the influence of chromosome 21 genes on the AD phenotype has been 
investigated. By imaging the progeny of the Tc1 DS mouse and the J20 AD mouse, I 
explored whether deficits or alterations in the J20 mouse were exaggerated with the 
introduction of chromosome 21 genes compared to the J20 AD phenotype without the 
presence of chromosome 21 genes.  
The highest levels of APP expression in the J20 AD mouse have been reported in the 
cortex and hippocampus; this is due to the PDGF-β promoter, which drives expression 
of APP within these regions (104). To align our MR measures with regions vulnerable 
to amyloid-β deposition, I took ROIs within the cortex and hippocampus. The 
thalamus, a region of low APP expression and low amyloid-β deposition, was selected 
as a control region.  
6.4.1 Arterial spin labelling 
ASL was employed to quantify CBF in the wildtype, J20, Tc1 and Tc1*J20 mice. Figure 
6.2 shows the raw CBF maps for representative wildtype (Figure 6.2A), J20 (Figure 
6.2B), Tc1 (Figure 6.2C) and Tc1*J20 (Figure 6.2D) mice.  
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Figure 6.2 CBF maps for representative (A) wildtype, (B) J20, (C) Tc1 and (D) Tc1*J20 mice. 
 
CBF was subsequently measured within ROIs within the cortex (Figure 6.3), 
hippocampus (Figure 6.4) and thalamus (Figure 6.5).  
Figure 6.3 shows the CBF results within the cortex. I measured CBF within an ROI 
taken from the caudal and rostral cortex (Figure 6.3D); these measurements were 
subsequently averaged to investigate mean cortical perfusion.  
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Figure 6.3 CBF results from the 14 wildtype, 16 J20, 12 Tc1 and 7 J20*Tc1 animals 16 months in the 
(A) rostral cortex, (B) caudal cortex, and (C) the average of the two ROIs. (D) Cortical ROIs illustrated on 
slice sections taken from The Mouse Brain Library’s Mouse Brain Atlas. A one-way ANOVA with a post-
hoc Tukey multiple comparison was performed to identify significant differences between the groups. * = p≤0.05; 
** = p ≤0.01; *** = p ≤0.001. 
 
The mean CBF within the rostral region of the cortex was significantly decreased in the 
Tc1*J20 mice compared to wildtype controls (p≤0.01) (Figure 6.3A). Within the caudal 
region of the cortex, I observed a similar decrease in CBF within the Tc1*J20 mice 
compared to wildtype controls (p≤0.001) (Figure 6.3B).  Within this region, I also 
observed hypoperfusion within the Tc1 DS mice compared to wildtype controls 
(p≤0.05) (Figure 6.3B). When the caudal and rostral cortical measurements were 
combined, the CBF deficits within the Tc1 and Tc1*J20 mice retained significance 
compared to wildtype controls (p≤0.05 and p≤0.001 respectively).  
Previously published CBF measurements taken from the J20 AD mice using ASL 
detected significant hypoperfusion in this model (197). Despite observing a significant 
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decrease in CBF within the caudal cortex of the J20 AD mice compared to wildtype 
controls (p ≤ 0.05), this significance did not survive Tukey multiple comparison 
correction (Figure 6.3B). 
Mean cortical perfusion was found to be significantly lower in the Tc1*J20 mice (209.8 
± 38.67 ml/100g/min) compared to the J20 AD mice (253.9 ± 35.34 ml/100g/min) (p 
≤0.05), however this alteration did not survive Tukey multiple comparison correction 
(Figure 6.3B). 
 
 
Figure 6.4 CBF results from the 14 wildtype, 16 J20, 12 Tc1 and 7 J20*Tc1 animals 16 months in the 
(A) rostral hippocampus, (B) caudal hippocampus, and (C) the average of the two ROIs. (D) Cortical ROIs 
illustrated on slice sections taken from The Mouse Brain Library’s Mouse Brain Atlas. A one-way ANOVA 
with a post-hoc Tukey multiple comparison was performed to identify significant differences between the groups. * 
= p≤0.05.  
 
Within the caudal region of the hippocampus, a significant decrease in CBF was 
detected in the Tc1 DS mice compared to wildtype controls (p≤0.05) (Figure 6.4B). 
CBF in the Tc1 DS mice was also significantly reduced in comparison to the J20 AD 
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mice (p<0.05). These alterations did not retain significance when combined with the 
measurements from the rostral region of the hippocampus (Figure 6.4C). 
 
 
Figure 6.5 CBF results from the 14 wildtype, 16 J20, 12 Tc1 and 7 J20*Tc1 animals 16 months in the 
(A) thalamus. (B) Thalamic ROI illustrated on slice sections taken from The Mouse Brain Library’s Mouse 
Brain Atlas. A one-way ANOVA with a post-hoc Tukey multiple comparison was performed to identify 
significant differences between the groups. * = p≤0.05. 
 
Within the thalamus, a region of low APP expression (104), I observed hypoperfusion 
in the Tc1 DS mice compared to wildtype controls (p≤0.05) (Figure 6.5A). I also 
observed a significant decrease in CBF within the Tc1*J20 mice compared to wildtype 
controls (p ≤ 0.01), however this finding did not survive Tukey multiple comparison 
correction. 
In order to elucidate whether the CBF deficits that I observed within the Tc1 mice were 
a neurodevelopmental or neurodegenerative abnormality, I imaged a separate cohort of 
young (6 month) Tc1 DS mice (n=5) and wildtype controls (n=6). Figure 6.6 shows the 
CBF maps for representative wildtype (Figure 6.6A) and Tc1 DS mice (Figure 6.6B). 
CBF measurements were taken from the same regions as detailed before. 
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Figure 6.6 CBF maps for a representative (A-E) wildtype and (F-J) Tc1 mice.  
 
 
Figure 6.7 CBF results from the 6 Tc1 and 6 wildtype animals at 6 months in the (A) rostral cortex, (B) 
caudal cortex, and (C) the average of the two ROIs. (D) Cortical ROIs illustrated on slice sections taken from 
The Mouse Brain Library’s Mouse Brain Atlas. A t-test was performed to identify significant differences 
between the groups. No significant differences were found. 
 
183 
 
 
Figure 6.8 CBF results from the 6 Tc1 and 6 wildtype animals at 6 months in the in the (A) rostral 
hippocampus, (B) caudal hippocampus, and (C) the average of the two ROIs. (D) Cortical ROIs illustrated on 
slice sections taken from The Mouse Brain Library’s Mouse Brain Atlas. A t-test was performed to identify 
significant differences between the groups. No significant differences were found. No significant differences were 
found. 
 
 
 
Figure 6.9 (A) CBF results from the 5 Tc1 and 6 wildtype animals at 5-7 months in the thalamus. (B) 
Thalamic ROIs illustrated on slice sections taken from The Mouse Brain Library’s Mouse Brain Atlas. A t-
test was performed to identify significant differences between the groups. No significant differences were found. 
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No differences in CBF were detected in any of the cortical regions (Figure 6.7), 
hippocampal regions (Figure 6.8), or the thalamus (Figure 6.9) at 5-7 months. These 
findings suggest that the CBF deficits I observed within the aged (16 month) cohort of 
Tc1 DS mice are due to an age-related decline in cerebral perfusion.  
In order to investigate this hypothesis further, the CBF measurements from the 6 
month and 16 month wildtype and Tc1 DS cohorts were combined to investigate age-
related changes in perfusion within the mice.  
 
Figure 6.10 Longitudinal CBF results from the cross-sectional wildtype and Tc1 animals at 6 months and 16 
months in the (A) mean cortex, (B) mean hippocampus and (C) thalamus. A 2-way ANOVA with post hoc 
Sidak multiple comparison was performed to identify significant differences between CBF measurements taken at 
the different timepoints. 6 month Tc1 vs. 16 month Tc1: * = p < 0.05.   
 
Figure 6.10 shows the serial CBF analysis within the mean cortex (Figure 6.10A), mean 
hippocampus (Figure 6.10B) and the thalamus (Figure 6.10C). I observed a significant 
decrease in CBF within the thalamus of the Tc1 mice from 6 months to 16 months 
(p≤0.05), suggesting an age-related decline in perfusion within this region. However, no 
changes in CBF were detected within the mean cortex or hippocampus of the Tc1 mice. 
6.4.2 Magnetic resonance angiography 
MR angiograms were acquired in order to investigate vascular alterations in the 
wildtype, J20, Tc1 and Tc1*J20 mice. My collaborators at the UCL Centre for Medical 
Image Computing employed TBM in order to explore differences in vascular 
morphometry between the different cohorts of mice. Figure 6.11 shows the MIP of the 
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averaged angiograms for wildtype (n=17), J20 (n=18), Tc1 (n= 14) and Tc1*J20 (n=8) 
following 15 iterations of non-rigid registration.  
Many of the major feeding vessels could be readily delineated and identified;  vessel 
labels were adapted from previously published MR angiograms of the mouse brain 
(286). In order to explore morphological changes within the vasculature, the individual 
angiography images were registered together to create a groupwise average. An intensity 
threshold was applied, and TBM statistics were performed on the vascular network to 
identify regions of expansion and contraction. 
The average groupwise MRA images are shown in Figure 6.12, with TBM statistics 
overlaid. TBM detected significant bilateral contraction of the ophthalmic artery, the 
azygus pericallosal artery and the anterior cerebral artery (Figure 6.12i-ii) in the Tc1 DS 
mice compared to wildtype controls. Unilateral vessel contraction was detected in the 
olfactory artery, with statistics localised to the left hemisphere (Figure 6.12i). Bilateral 
vessel expansion was detected in the posterior cerebral artery and the superior cerebral 
artery (Figure 6.12Aiii-iv), while unilateral changes were observed in the palatine portion 
of pterygopalatine. In addition, unilateral expansion of the olfactory artery of the J20 
AD mice compared to the Tc1*J20 mice (Figure 6.12Bi) and unilateral expansion within 
the palatine portion of pterygopalatine (Figure 6.12iv) were detected. TBM did not 
detect any significant differences between the J20 AD mice and wildtype controls. 
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Figure 6.11 Averaged time-of-flight MR angiograms for wildtype (n=17), J20 (n=18), Tc1 (n= 14) and Tc1*J20 (n=8) following 15 iterations of non-rigid registration. The MIPs are 
shown in (A) axial, (B) coronal and (C) sagittal orientations. AAzCA = Anterior azygos cerebral artery; AzPA = Azygos pericallosal artery; ACA = Anterior cerebral artery; BA = 
Basilar artery; CCA = Common carotid artery; CaCeA = Caudal cellebellar artery; CoCaA = common carotid artery; ICA = Internal carotid artery; MCA = Middle cerebral artery; 
OlA = Olfactory artery; OpA = Ophthalmic artery; PCA = Posterior cerebral artery; PPP = Palatine portion of pterygopalatine; SCA = Superior cerebellar artery; VA = vertebral 
artery. 
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Figure 6.12 MRA results showing statistically 
significant, FDR-corrected (q=0.05) t-statistics 
revealing local differences in vasculature. (A) Vessels in 
the Tc1 mice are significantly altered in comparison to 
the wildtype controls; (B) vessels in the J20 mice are 
significantly altered in comparison to the wildtype 
controls. Vessels highlighted in red represent a 
significant volume decrease, in the (A) Tc1 in 
comparison to wildtype controls and the (B) J20 in 
comparison to the Tc1*J20 mice. Vessels highlighted in 
blue represent a volume decrease. TBM results have 
been normalized to TBV to account for global volume 
differences between the groups. Arrows indicating 
regions of change have been coloured to correspond to 
expansion (blue) and contraction (red) of the vessel they 
are highlighting. OpA = ophthalmic artery; OlA = 
olfactory artery; AzPA = azygus pericallosal artery; 
ACA = anterior cerebral artery; PCA = posterior 
cerebral artery; PPP = Palatine portion of 
pterygopalatine; SCA = superior cerebral artery. 
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6.4.3 High resolution ex vivo structural MRI 
Following in vivo characterisation, a subset of wildtype (n = 13), J20 (n = 14), Tc1 (n = 
15) and Tc1*J20 mice (n = 8) were perfuse-fixed and prepared for high resolution ex 
vivo imaging. My collaborators at the UCL Centre for Medical Image Computing 
employed atlas-based parcellation to explore regional volume differences between the 
cohorts of mice, and TBM to examine local morphological alterations. 
TBVs were also extracted, to explore and control for overall differences in brain 
morphometry (Figure 6.13). The TBV results revealed a significant increase in brain 
volume of the Tc1 DS mice compared to wildtype controls (p≤0.001) (Figure 6.13). I 
also observed a significant increase in the brain volume of the Tc1 DS mice compared 
to the J20 AD mice (p≤0.05). Interestingly, I also noted that the mean TBV for the J20 
AD mice was larger than the wildtype control values (494.7 ±32.53 mm3 and 492.6 ± 
21.27 respectively); a finding which has previous been observed in the J20 AD mouse at 
6 months (287). However this observation was not significant. 
The Tc1 animals also revealed a surprisingly high variance in TBV compared to the 
other animal groups under investigation. This is likely to be due to the mosaicism which 
the Tc1 exhibits – that is, not all cells in the model carry human chromosome 21 (283). 
 
Figure 6.13 Mean ex vivo TBVs for wildtype (n=13), J20 (n=14), Tc1 (n=15) and Tc1*J20 (n=8) mice. 
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Figure 6.14 Absolute volume results extracted from the ex vivo structural mouse brain images. A 2-way 
ANOVA with post hoc Sidak multiple comparison was performed. The results for comparisons between the 
wildtype and Tc1 mice, wildtype and J20, and J20 and Tc1*J20 are shown. wildtype vs. Tc1: * = p≤0.05; ** 
= p ≤0.01; **** = p≤0.0001. J20 vs. Tc1*J20: + = p≤0.05; ++++= p≤0.0001.   
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Figure 6.15 Proportional volume results extracted from the ex vivo structural mouse brain images. The 
proportional volume changes were calculated by normalising the absolute regional volumes to the TBV (see Figure 
6.13. A 2-way ANOVA with post hoc Sidak multiple comparison was performed. The results for comparisons 
between the wildtype and Tc1 mice, wildtype and J20, and J20 and Tc1*J20 are shown. wildtype vs. Tc1: * = 
p≤0.05; **** = p≤0.0001. wildtype vs. J20: -- = p ≤0.01; ---= p≤0.001. J20 vs. Tc1*J20: ++ = p 
≤0.01; ++++= p≤0.0001.   
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The atlas-based parcellation results are shown in Figure 6.14 and Figure 6.15. I have 
chosen to present the absolute regional volumes (Figure 6.14) in addition to the 
proportional brain volume changes (Figure 6.15), which were calculated by normalising 
the absolute volumes (Figure 6.14) to TBV (Figure 6.13).  
The TBV results revealed a significant increase in brain volume of the Tc1 DS mice 
compared to wildtype controls (p≤0.001) (Figure 6.13). I also observed a significant 
increase in the brain volume of the Tc1 DS mice compared to the J20 AD mice 
(p≤0.05). Interestingly, I also noted that the mean TBV for the J20 AD mice was larger 
than the wildtype control values (494.7 ±32.53 mm3 and 492.6 ± 21.27 respectively); a 
finding which has previous been observed in the J20 AD mouse at 6 months (287). 
However this observation was not significant. In order to account for these differences, 
the absolute regional volumes (Figure 6.14) were normalized to TBV to calculate 
proportional volumes (Figure 6.15).  
I did not detect any significance differences in absolute volumes of any of the individual 
brain structures in the J20 AD mice compared to wildtype controls (Figure 6.14). 
However, following normalization to TBV, a significant decrease in the proportional 
volumes of the neocortex (p≤0.001) and external capsule (p≤0.01) was detected (Figure 
6.15). Atrophy within the cortex has previously been observed in AD patients and 
related to amyloid-β deposition (288); in addition, our findings are supported by 
previous work where cortical thinning has been observed in the J20 AD model (197). 
White matter alterations have previously been observed in AD patients, and may reflect 
demyelination and axonal loss in this model (289). 
Interestingly, a significant increase in the proportional volume of the brain stem of the 
J20 AD mice compared to wildtype controls was observed (Figure 6.15). Hypertrophy 
of brain structures has previously been observed in this model  and attributed to either 
an inflammatory response to the presence of amyloid-β, or a compensatory mechanism 
resulting in enlarged neurons (287). In the absence of APP overexpression, the 
observed enlargement of the brain stem may be due to disruption of these tissues 
during perfuse-fixation of the tissues. I took great care to reduce variability in the tissue 
preparation wherever possible, by perfuse-fixing all the brains myself using the same 
experimental protocol, and scanning the animal groups in a randomised way. However, 
the brain stem is particularly susceptible to disruption which may cause increased 
variability in the measurements (189). 
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A significant increase in the absolute volumes of the brainstem (p≤0.01), neocortex 
(p≤0.0001), caudate putamen (p≤0.05), and hippocampus (p≤0.01) was detected in the 
Tc1 DS mice compared to wildtype controls (Figure 6.14). Following normalization to 
TBV, these changes did not retain their significance, indicating that these observed 
regional increases were occurring proportionally to the increase in TBV in the Tc1 DS 
mice (Figure 6.13). The cerebellum and thalamus, however, were disproportionately 
smaller in the Tc1 DS mice compared to wildtype controls (p≤0.0001 and p≤0.05 
respectively) while the amygdala was disproportionately larger (p≤0.1) (Figure 6.15). 
The cerebellum has previously been implicated in the Tc1 DS mouse, where decreased 
granule neurons have been observed. 
Within the Tc1*J20 mice, no significant differences in absolute volumes were detected 
when compared to the J20 AD mice (Figure 6.14). However, following normalization to 
TBV, a significant decrease in the proportional volume of the olfactory bulb (p≤0.01) 
and cerebellum (p≤0.01) was observed (Figure 6.15); these regions presented as 
disproportionately smaller in the Tc1*J20 mice.  
In addition to atlas-based parcellation, TBM was employed to identify local small 
discrete local volume differences which may not be detected when investigating whole 
brain structures (287). The TBM images show statistically significant, FDR-corrected 
(q=0.05) t-statistics revealing local structural differences between the brains of each 
group, controlling for TBV (Figure 6.13). 
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Figure 6.16 Ex vivo TBM results showing statistically significant, FDR-corrected (q=0.05) t-statistics revealing local structural differences between the brains of the (A) J20 mice compared 
to wildtype controls, (B) Tc1 mice compared to wildtype controls, and (C) the J20 compared to Tc1*J20 mice. Regions highlighted in red represent a volume decrease, and regions highlighted in 
blue represent a volume increase. TBM results have been normalized to TBV to account for global volume differences between the groups (see Figure 6.13). 
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TBM detected extensive bilateral contraction in the J20 AD mice compared to wildtype 
controls in multiple cortical regions including: the auditory, cingulate, motor, 
retrosplenial, somatosensory and visual areas of the cortex (Figure 6.16A). This is in 
agreement with Herbert et al. who identified increased cortical thinning in the J20 AD 
mouse (197) and is also reflected in our normalized parcellation results (Figure 6.16B).  
Interestingly, the cortical changes appeared to be localised to the deeper layers, such as 
the internal granular and pyramidal layers, and multiform layer. The superficial layers 
appeared unaffected. Atrophy was also observed in the cingulum bundle and corpus 
callosum – regions which have previous been implicated using voxel-wise analysis 
techniques (197). Volume loss within the CA1 hippocampal subfield, in the absence of 
any alterations within the CA3 region, was additionally observed. This finding is in good 
agreement with previous work, where neuronal loss was reported in the CA1 but not 
the CA3 hippocampal subfield (290). It also supports clinical AD findings, as neuronal 
loss is greatest in this region (291). 
The Tc1 DS mice exhibited a marked pattern of expansion within the somatosensory 
and piriform regions of the cortex, with apparent preservation of all other cortical 
regions (Figure 6.16B). I observed additional expansion within the amygdala, midbrain 
and the CA1 hippocampal subfield. Atrophy was observed within the molecular and 
granular layers of the cerebellum, the olfactory bulb, thalamus and caudate putamen 
(Figure 6.16B). Decreased neuronal counts in the cerebellum have previously been 
observed in the Tc1 DS mouse and other mouse models of DS, which may be reflected 
in these structural changes (283, 292). Our atlas-based parcellation results also identified 
decreased cerebellar volume. The other regions implicated by TBM in Figure 6.16B 
have yet to be explored in the literature. 
Figure 6.16C shows the morphological differences between the Tc1*J20 mice compared 
to the J20 AD mice. A similar yet more extensive pattern of contraction and expansion 
was detected as observed in Figure 6.16B including atrophy within the cerebellum and 
olfactory bulb. These regions were also implicated in the atlas-based parcellation results 
(Figure 6.15). Expansion of the cingulate, motor, somatosensory and auditory regions 
of the cortex, as well as the midbrain and the CA3 hippocampal subfield, were also 
observed. 
In addition to atlas-based parcellation and TBM, I also scrutinised the unprocessed 
images for evidence of amyloid-β pathology. It has previously been reported that 
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amyloid-β plaques can be visualised using high resolution ex vivo MRI images in the 
form of discrete plaque-like hypointensities (293, 294). This has been attributed to the 
T2 relaxation effect of iron which is contained with the plaque (295). Careful 
examination of our ex vivo MRI images did not reveal any hypointensities which could 
be attributed to plaque pathology. Subsequent histology was performed using Perl’s 
Prussian blue, a stain used to detect the presence of iron within tissues. Perl staining was 
negative within the hippocampal and cortical tissues – regions vulnerable to plaque 
pathology in this mouse model – indicating that the plaque pathology in the J20 AD 
mice doesn’t contain iron, or the iron levels are too low to be detected using Perl 
staining. The absence of iron staining within these regions may account for the absence 
of hypointensities in our ex vivo MRI images. 
6.4.4 Histology and immunohistochemistry 
Following high resolution ex vivo structural imaging, my collaborators at the UCL 
Institute of Neurology performed histology on a subset of wildtype (n=5), J20 (n=5), 
Tc1 (n=5) and Tc1*J20 mice (n=5). Immunohistochemistry was performed using the 
monoclonal antibody 4G8, which stains for amyloid-β. 
Figure 6.17 shows sagittal slices stained using 4G8 for representative (A) wildtype, (B) 
J20, (C) Tc1 and (D) Tc1*J20. Consistent with the literature data, the J20 AD mice 
exhibited high 4G8 burden within the cortex and hippocampus (5.1 ± 2.8 % and 10.2 ± 
3.5 % respectively) (Figure 6.17E-F) (104, 296). Negligible 4G8 staining was detected 
within the thalamus (7.2 ± 6.8 × 10-3 %) (Figure 6.17G).  
Within the hippocampus, a significant increase in 4G8 burden of the J20 AD mice 
compared to the wildtype and Tc1 DS mice was observed (p≤0.0001) (Figure 6.17F). 
Despite observing a significant difference in 4G8 burden of the J20 AD mice compared 
to wildtype (p = 0.0049) and Tc1 DS mice (p = 0.0035) in the cortex, the significance 
did not survive Tukey multiple comparison correction (Figure 6.17E) 
Similar to the J20 AD mice, the Tc1*J20 mice exhibited high 4G8 burden within the 
cortex and hippocampus (7.2 ± 5.5 % and 12.77 ± 2.5 % respectively), and low 4G8 
burden within the thalamus (5.7 ± 4.3 x10-3 %). When compared with the J20 AD mice, 
a 40.0% increase in 4G8 burden within the cortex, and a 25.6% increase in 4G8 burden 
within the hippocampus were noted; however, this observation was not statistically 
significant.  
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Figure 6.17 Immunohistochemistry to estimate regional distribution of amyloid-β using the 4G8 antibody. 
Sagittal slices for representative (A) wildtype, (B) J20, (C) Tc1 and (D) Tc1*J20 mice,  illustrating the 
distribution of amyloid-β, with visible accumulation in the cortex and hippocampus of the J20 and Tc1*J20 
mice. Quantitative regional estimates of (E) cortical, (F) hippocampal and (G) thalamic 4G8 % burden for 
wildtype (n=5), Tc1 (n=5), J20 (n=5) and Tc1*J20 (n=5) mice. A one-way ANOVA with a post-hoc 
Tukey multiple comparison was performed to identify significant differences between the groups. * = p ≤ 0.05; 
**** = p ≤ 0.0001. 
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6.5 Discussion 
In spite of recent advances in our understanding of AD, the cause of the disease is yet 
to be fully understood.  People with DS carry an increased risk of developing early 
onset AD, with 50 – 70% of DS individuals exhibiting symptoms of dementia before 
the age of 60 (297). Studying individuals with DS, and the onset and development of 
AD within this population, can offer unique insights into the pathogenesis of AD 
within the wider population. Triplication of the APP gene, which lies on chromosome 
21, is believed to drive the development of AD by increasing the production of 
amyloid-β. Subsequent misfolding of amyloid-β results in the deposition of amyloid-β 
plaques – the classic neuropathological hallmark of AD, and believed by many to be the 
key causative agent in the disease (24). Indeed, DS individuals with partial trisomy of 
chromosome 21 resulting in APP disomy do not develop AD (298). However, it is 
believed that a number of other genes on chromosome 21 may contribute to the early 
onset of AD within DS (282). 
In this work, I have characterised the J20 AD mouse, a model of amyloid plaque 
deposition, and the Tc1 DS mouse using MRI. In addition, the effects of chromosome 
21 on AD pathogenesis have been introduced to the J20 AD mouse by breeding it with 
the Tc1 DS mouse – the progeny of which overexpress a mutant form of APP in the 
presence of chromosome 21 genes. The immunohistochemistry identified an increase in 
mean 4G8 staining within the cortex and hippocampus of the Tc1*J20 mice compared 
to the J20 AD mice; however this finding was not significant. I continued to probe for 
alterations in the MR parameters between these two mice cohorts, in addition to 
broader characterisation of the phenotypic differences in the J20 AD and Tc1 DS mice 
compared to wildtype controls.  
In my analysis of the CBF data, I focused on the hippocampus and cortex as regions 
selectively vulnerable to amyloid-β pathology in the J20 AD model. These have been 
both previously reported (104), and replicated in our immunohistochemistry using the 
4G8 stain for amyloid-β. The thalamus served as a control region without amyloid-β 
pathology. As the MRA and structural imaging sequences covered the whole brain, it 
was possible to implement automated atlas-based processing techniques, enabling the 
dissection of changes occurring globally. 
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ASL is an emerging MR biomarker of neurodegeneration, and is increasingly being 
applied to investigate regional CBF alterations in AD (299). A number of cortical 
regions have been reported to suffer hypoperfusion in AD, including the parietal and 
occipital lobes of the cortex, and the cingulate (300). The precise mechanisms 
underpinning these CBF alterations are not fully understood; however, they are believed 
to be associated with atrophy of neuronal tissues in regions vulnerable to AD 
neuropathology, as well as regions functionally connected to these degenerating tissues 
(301).  
Previous work by Hébert et al. characterised a cohort of 6 month J20 AD mice using 
ASL, and identified hypoperfusion in subcortical regions including the somatosensory, 
entorhinal and piriform regions of the cortex (197). I observed reduced perfusion in the 
J20 AD mice within an ROI placed caudally in the caudal cortex (p ≤; this ROI 
encompasses the somatosensory region of the cortex, supporting Hérbert et al.’s 
previous findings. However, our results lacked the significance to survive correction for 
multiple comparisons. Hérbert et al. noted that, when the whole cortical CBF was 
measured, no significant differences were observed, and emphasised the importance of 
examining sub-regional changes which may be obscured when extracting global 
measurements (197). In our analysis, I focused on a caudal and rostral ROI placed 
within the cortex, and averaged these measurements to explore mean cortical perfusion; 
however, these ROIs may have been too large to capture any sub-regional changes 
occurring. 
In contrast to the growing body of research into perfusion in AD, there are substantially 
fewer publications into CBF alterations in DS. To our knowledge, ASL has never been 
applied to a DS cohort – clinically or preclinically. A number of studies have employed 
single photon emission computed tomography (SPECT) to explore CBF in individuals 
with DS, and identified perfusion deficits similar to those seen in AD patients (302, 
303). However, it is still unclear whether these alterations are present in the absence of 
AD neuropathology. Gokcora et al. reported patterns of hypoperfusion in a study of 
young non-demented DS individuals, and suggested these findings may reflect higher 
cortical dysfunction (304). Conversely, Deb et al. reported no CBF alterations in 
younger, non-demented DS individuals (305), indicating that blood flow deficits may be 
due to an age-related decline and accompany the descent into dementia.  
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Hypoperfusion was observed in the Tc1 DS mouse in all regions under investigation – 
the cortex, hippocampus and thalamus. This suggests a global reduction in CBF, 
although additional ROIs placed within more posterior and anterior slices of the brain 
are required to confirm this. These findings, in the absence of amyloid-β, are in 
agreement with Gokcora et al. and may reflect mental abnormalities or dysfunction 
(304). A follow-up study in younger Tc1 DS mice identified no deficits in CBF, 
suggesting age-related decline in perfusion. In the absence of APP triplication, these 
findings suggest that hypoperfusion in DS individuals may be related to trisomy of 
other chromosome 21 genes.  
The Tc1 DS mouse exhibits a number of congenital heart defects which should also be 
considered when interpreting the CBF findings (306). These defects include 
perimembranous atrioventricular septal defect and ventricular septal defect which are 
also seen in the wider DS patient population.(307). Previous work exploring the 
relationship between cardiac output and CBF has found that cerebral autoregulation 
maintains CBF despite perturbations in systemic blood pressure associated with such 
cardiac abnormalities (308). Therefore, it is unlikely that our observations of 
hypoperfusion in the Tc1 DS mice relates to their cardiac defects.  
The Tc1*J20 mice exhibited marked hypoperfusion within the cortex, to a greater 
extent than the Tc1 DS mice. These findings suggest that trisomy of chromosome 21 
genes exacerbate the pathological processes, and may be related to the early-onset AD 
seen in the DS population. 
There is mounting evidence implicating vascular alterations in clinical cases of AD 
(309). This includes a number of risk factors for AD which carry a vascular component, 
including diabetes (310) and atherosclerosis (311). In addition, depositions of amyloid-β 
around vessel walls are frequently observed in post-mortem AD brains – a condition 
called cerebral amyloid angiopathy (309).  
MRA is a useful MRI technique for studying alterations within the artery vasculature, 
and permitted the study of differences in the morphology of large feeding arteries 
between the transgenic cohorts in this study. MRA is traditionally quantified manually, 
by visual inspection of whether the vessels appear altered within a transgenic cohort 
(312). However, it is possible to misinterpret flow artefacts as vascular alterations, 
including flow disturbances and signal voids (313). In this work, my collaborators at the 
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UCL Centre for Medical Image Computing registered the individual angiograms 
together to create an average atlas of the vasculature; this methodology provides a 
robust and unbiased framework for evaluating alterations in the cerebral vessels, and 
help mediate the confounding effects of flow artefacts as these are averaged out in the 
atlas (312). Visual inspection of the average vascular atlas revealed adequate contrast to 
detect many vessels previously identified by Kara et al. including branches of the 
cerebral and carotid arteries (286).  
Previous work in other AD mouse models overexpressing mutant APP have reported 
deficits in the middle cerebral artery (286, 314); alterations which have also presented in 
clinical cases of AD (315). However these models also carried PSEN1 mutations, which 
are known to accelerate the deposition of amyloid-β and exaggerate the AD phenotype 
(316). In this study, I did not detect any alterations in the vasculature of the J20 AD 
mouse. In the absence of any significant CBF alterations, this finding was not 
unexpected. The 4G8 staining revealed cerebral amyloid angiopathy around the 
meningeal and parenchymal vessels in the brain, indicating amyloid-β pathology within 
the vasculature; however, the vessels implicated by the MRA results have yet to be 
investigated. The absence of any significant findings in the J20 AD mice, therefore, may 
be a shortcoming of the MRA sequence itself, which lacks the sensitivity to detect 
smaller arteriole and venous alterations. The use of an endogenous contrast agent may 
have improved vessel delineation and highlighted smaller changes occurring within the 
finer vascular structures (317).  
The vascular alterations identifiable using MRA were markedly more extensive in the 
Tc1 DS model. Our observations of extensive vascular alterations within the olfactory, 
opthalamic, azygous pericallosal and anterior cerebral arteries may have arisen for a 
number of reasons, including narrowing or compression of the vessels, or reduced 
blood flow within these regions (286). Conversely, regions of artery expansion, 
including the posterior and superior cerebral arteries, suggest increasing flow or 
widening of the vessels.  
Contraction of the olfactory artery may be related to the local volume decreases 
observed within the olfactory bulb of the Tc1 DS mice, although further work at earlier 
timepoints is required to determine whether this vascular alteration pre or proceeds the 
changes identified using TBM. This vessel was also implicated in the Tc1*J20 mice, with 
corroborative structural alterations in the olfactory bulb, supporting the abnormal 
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function of the olfactory artery in DS. I was unable to corroborate any of the other 
observed angiography alterations against the structural results, indicating high resilience 
of the Tc1 DS mice to alterations in the vascular. 
Atrophy of the brain is a widely acknowledged occurrence in neurodegeneration, and 
structural changes identifiable using MRI are an accepted biomarker of AD (98). In this 
work, my collaborators at the UCL Centre for Medical Image Computing have 
employed two automated image processing techniques to characterise morphological 
differences between the mice cohorts. 
Badhwar et el. have previously characterised the J20 AD mouse at 6 months using atlas-
based structural analysis and identified significant volume increases in the 36 of the 64 
structures under investigation, including the cortex and hippocampal subfields (287). 
Badhwar et al. attributed these unexpected findings to neuroinflammation in the 
absence of atrophy (195), and increased neurogenesis in response to APP 
overexpression (318). In addition, there is growing evidence in support of 
neuroinflammation as a major contributing factor in AD pathogenesis (319): gliosis has 
previously been observed within the hippocampus of the J20 AD mouse at 6 months 
(290); this is known to activate inflammatory processes and may be the underlying cause 
of the hypertrophy observed by Badhwar et al. (290). PET tracers targeting the 18 kDa 
translocator protein have been identified as promising biomarkers of microglial 
activation (320), and may shed light on neuroinflammation in the J20 AD mouse. 
Our observation of atrophy within the cortex and CA1 hippocampal subfield at 16 
months, following plaque deposition from 6 months (104) therefore represents 
downstream findings in this model. Badhwar et al. performed additional voxel-wise 
analysis and observed local atrophy within the corpus callosum and cingulum bundle – 
findings which were replicated in our TBM analysis. Alterations within these white 
matter regions may serve as a precursor to the widespread cortical atrophy that I 
observed at 16 months. 
Atrophy within the olfactory bulb was also detected, a finding which has been observed 
within AD patients (321) and manifests clinically as difficulty identifying familiar odours 
using the Brief Small Identification Test (322). Previous work by Cao et al. in the J20 AD 
mouse found disrupted connectivity of the olfactory neuronal circuit (323) – deficits 
which may underpin our structural changes within the olfactory bulb.  
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Our TBM findings in the J20 AD mouse also identified marked atrophy occurring 
within the deeper cortical layers. This was unexpected, as it has been reported that the 
neurons of the deeper cortical layers are more resilient to the neurotoxic effects of 
amyloid-β deposition than the associated superficial neurons (324). Additionally, in 
clinical studies of AD patients, it has been reported that the superficial cortical layers are 
more vulnerable to plaque deposition (325, 326). Closer inspection of the distribution of 
4G8 staining within the cortex of the J20 AD mice did not reveal increased specificity 
of the antibody for the deeper cortical layers, suggesting an alternative mechanism 
producing this unique pattern of changes, which at this stage remains unknown.  
The Tc1 DS mouse presented with a pattern of TBM changes which mirror deficits 
previously observed within the DS population; this includes cerebellar alterations (327), 
which have been related to the motor disabilities observed in DS individuals (328). The 
Tc1 DS mice exhibited larger TIVs in comparison to the wildtype controls; this finding 
was unexpected, as reduced TBV has been reported in clinical studies of DS (329). It 
may be due to increased neurogenesis owing to trisomy of chromosome 21 genes. A 
large variation in the TBV measurements of the Tc1 DS mice was also observed; this is 
likely to be because the Tc1 DS mice are mosaic for chromosome 21, which is carried 
by different proportions of cells in different tissues (283). 
TBM analysis uncovered atrophy within the olfactory bulb of the Tc1 DS mice – a 
finding which has not previously been discussed in the literature. Deficits within the 
olfactory bulb  suggest impaired sense of smell in the Tc1 DS mouse – a finding which 
has previously been observed in DS individuals and attributed to AD-related changes 
within the DS population (330). A study of young DS adolescents did not identify any 
deficits in their ability to smell, further suggesting that this is an age-related decline in 
function (331). In the absence of AD neuropathology, our findings within the olfactory 
bulb suggest that deficits may be present in the DS population prior to the development 
of dementia. This, coupled with the vascular alterations within the olfactory artery, 
heavily implicate the olfactory bulb as a structure which is altered in DS. 
The introduction of amyloid pathology in the Tc1*J20 mouse amplified the atrophy 
observed within the olfactory bulb, suggesting that the deficits within this structure are 
influenced by the combination of chromosome 21 genes and mutant APP 
overexpression. 
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6.6 Conclusion 
In this chapter, I have used multi-parametric MRI to characterise the Tc1 DS mouse 
and the J20 AD mouse. Breeding these two mouse strains together produced the 
Tc1*J20 mouse, permitting the evaluation of AD-related changes both with and without 
APP trisomy. 
Our MRI findings revealed previously unexplored alterations in the Tc1 DS mouse 
model; this includes cerebrovascular alterations and structural changes in the absence of 
APP trisomy. Further work is required to explore whether these are 
neurodevelopmental or age-related alterations. The J20 AD mouse has been extensively 
characterised in the literature; this includes a number of MRI studies. I have echoed 
previous findings, and also identified novel cortical specificity of brain atrophy which 
has not previously been described. Finally, the Tc1*J20 mouse revealed a number of 
amplified deficits, highlighting the influence of chromosome 21 genes on AD 
neuropathology. This work supports ongoing efforts to understand early onset AD 
within DS individuals, and may shed light on the role of genes other than APP which 
contribute to this increased risk. 
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Chapter 7: General discussion 
According to the 2015 World Alzheimer report (332), there are an estimated 46.8 
million people worldwide living with dementia at a total cost of more than $818 billion 
globally. With no known cure for this debilitating disease, a collaboration of scientists 
across the world is united in their efforts to identify the cause of AD, and develop 
effective disease-modifying therapies. 
Mouse models of AD are valuable research tools, permitting the dissection of specific 
neuropathological events underpinning AD in highly controlled laboratory conditions. 
The most widely used AD mouse models are transgenic for human APP, and carry 
specific mutations associated with familial forms of the disease. These mice are reliable 
models of amyloid-β plaque formation; however they do not recapitulate the tau 
pathology in AD. In light of recent evidence in support of tau’s primary role in the 
neurodegenerative cascade (152), mouse models expressing mutant human tau are 
increasingly being used to explore the degenerative effects of NFT pathology. Robust 
biomarkers of tau pathology are required in order to identify novel deficits in these 
mice, in addition to supporting preclinical trials of candidate therapeutics.  
In Chapter 3, a sequence for high resolution in vivo mouse brain imaging was developed, 
for application in the rTg4510 mouse model of tauopathy. Scan parameters were 
carefully optimised for suitability for advanced image processing techniques; this 
included high resolution, isotropic voxels and whole brain coverage within a feasible in 
vivo imaging time of 90 minutes. It was found that a T2-weighted sequence, with a TE of 
43ms, would offer maximum contrast between the hippocampus and thalamus, whilst 
also retaining high contrast in the cortex and corpus callosum. 
The optimised structural sequence was subsequently implemented in a single timepoint 
study of the rTg4510 mouse model of tauopathy. Gross morphological differences were 
readily detectable by eye in agreement with a previous study (157), while further analysis 
identified a negative correlation between hippocampal volume (manually segmented) 
and NFT density. These findings highlight the sensitivity of structural MRI to 
neurodegenerative alterations occurring in this mouse model, with potential application 
for in vivo evaluation of other mouse models of AD.  
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In order to ease the burden of time-consuming manual delineation of ROIs and reduce 
user bias, TBM was employed for global analysis of morphological alterations in the 
rTg4510 mice. A bilateral pattern of atrophy was detected in regions susceptible to NFT 
deposition including the cortex, caudate putamen and hippocampus. These results 
support the suitability of the optimised structural sequence for advanced image 
processing techniques, which will facilitate high throughput analysis of future studies of 
the rTg4510 mouse. As there is no limit to the number of mouse brain data sets that 
may be registered, potential applications of this technique includes quantitative analysis 
of large (>100) data sets, with increasing statistical power of the TBM results.  
The development of this sequence laid the foundations for Chapter 4, where in vivo 
structural MRI was employed in a longitudinal study of neurodegeneration in the 
rTg4510 mouse. Atlas-based parcellation was employed alongside TBM for structural 
characterisation; this technique permitted the evaluation of absolute volume changes, in 
addition to those occurring disproportionately to TBV. The administration doxycycline 
to a subset of rTg4510 mice at discrete timepoints permitted the evaluation of two 
imaging paradigms: i) exploration of the longitudinal degenerative changes occurring in 
the rTg4510 mouse, and ii) assessment of the therapeutic impact of doxycycline. 
Additional biomarkers of AD neuropathology were recruited in order to explore their 
sensitivity to the accumulation and suppression of pathological tau. CEST, DTI and 
ASL were selected for their clinical translatability, in addition to their sensitivity to 
distinct pathological mechanisms implicated in AD.  
The results showed that high resolution structural MRI, when used in conjunction with 
advanced image processing techniques, yielded the highest sensitivity to pathological 
changes occurring in this model. Atlas-based parcellation was able to discriminate 
between the rTg4510 mice and wildtype controls as early as 3.5 months, with tau-driven 
atrophy (inferred by the proportional volume results) detectable from 5.5 months in this 
model. Atrophy was greater reduced in animals treated with doxycycline from 3.5 
months than from 4.5 months, highlighting the sensitivity of the structural MRI 
sequence to early therapeutic intervention. CEST, DTI and ASL provided insight into 
pathological mechanisms occurring within the disease process, and were also able to 
detect significant differences between treated and untreated rTg4510 animals as well as 
wildtype controls. These non-invasive MRI techniques offer insight into pathological 
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mechanisms underpinning AD that may be important when evaluating emerging 
therapeutics targeting one of more of these processes. 
Despite the increasing application of structural MRI to mouse models of 
neurodegeneration, the pros and cons of scanning a mouse alive or dead have yet to be 
fully explored in the literature. Chapter 5 explores the trade-offs between in vivo and ex 
vivo MRI, and the suitability of structural data sets for TBM analysis. 
It was observed that both in vivo and ex vivo MRI were able to detected a widespread 
bilateral pattern of severe atrophy in the rTg4510 mouse brain compared to wildtype 
controls at the 7.5 month timepoint; regions of atrophy were co-localised with neuronal 
loss and pathological tau accumulation demonstrated by immunohistochemistry. SNR 
measurements were greater in the in vivo data (likely primarily driven by the reduced 
spatial resolution), although CNR was greater in the ex vivo data sets; a finding that can 
be attributed to the strategic use of contrast agents during preparation of the ex vivo 
tissues. When TBM was employed to uncover differences in a cohort of doxycycline-
treated rTg4510 mice, ex vivo MRI detected extensive alterations, more sensitive than 
our in vivo findings. However, this increase in sensitivity should be considered against 
the disadvantages of ex vivo MRI which include the effects of formalin fixation on 
tissues, and the inability to image the same animal longitudinally, prohibiting studies of 
neurodegeneration in the same mouse cohort. The disparity between our TBM findings 
from in vivo and ex vivo MRI, underlines the importance of appropriate study design, 
given the trade-off between the two imaging approaches. Through my exploration of 
these factors, I hope this work will help support research groups working in the field of 
preclinical MRI, and shape their decision about the best way to image their transgenic 
mice. 
So far, the results chapters have focused on the sensitivity of structural and functional 
MRI techniques to tau pathology in the rTg4510 mouse. In the final results chapter, 
MRI techniques were employed to explore the role of genetics in AD, to uncover 
whether chromosome 21 genes other than APP influence the AD neuropathology seen 
universally among DS individuals.  
The results in the J20 mouse echoed previous findings in this mouse model, which has 
been extensively characterised in the literature. Novel blood flow alterations were 
identified in the Tc1 DS mouse, in the absence of APP trisomy; this included marked 
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hypoperfusion in all regions under investigation: the cortex, hippocampus and thalamus. 
Additional alterations were observed within the vasculature of the Tc1 DS mouse, 
which were detected by generating a groupwise average of the MR angiograms - a novel 
approach to the analysis of such data sets. These findings further support the use of 
voxel-wise techniques for analysis of mouse brain MRI data, to detect statistically 
significant findings which may be difficult to detect using laborious manual methods. 
By crossing the Tc1 DS mouse to the J20 AD mouse, the offspring developed 
characteristic amyloid-β plaques in the presence of additional chromosome 21 genes. 
The observed abnormalities in MRI biomarkers appeared to be exacerbated in the 
Tc1*J20 mouse, including CBF and histological assessment of plaque density, although 
none of these findings survived correction for multiple comparisons. Increasing the size 
of the Tc1*J20 cohort (n = 9) may have helped unambiguously demonstrate these 
differences.  
7.1 Limitations 
When interpreting the work presented in this thesis, a number of limitations must be 
taken into account when planning future studies. Firstly, it is important to consider that 
the work presented in Chapters 3, 5 and 6 is from late timepoint studies, where the 
pathology in these animals is fairly advanced. When planning these experiments, I chose 
an advanced timepoint in order to assess the sensitivity of the different imaging 
sequences to neuropathological alterations in the different models, and increase the 
likelihood of detecting significant correlations between histological assessment of NFT 
burden (which occur relatively late in the pathology) and imaging biomarkers. However, 
earlier timepoints are useful for investigating the sensitivity of imaging biomarkers to 
small discrete alterations occurring before the onset of gross neurodegeneration. This 
limitation has, to some extent, been addressed in Chapter 4, which describes the 
structural and functional changes occurring in the rTg4510 mouse from 3.5 months of 
age. It would be useful to characterise the J20 and Tc1 mice in a similar way, using 
multi-parametric MRI in a longitudinal study of neurodegeneration. 
In addition, the studies presented in this thesis also only focus on the development and 
application of different MRI biomarkers which offer sensitivity to AD-related changes. 
For future studies, it would be beneficial to consider behavioural assessment of the 
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transgenic mice (e.g. with a Morris water maze, which is sensitive to CA1 hippocampal 
subfield damage) in conjunction with MRI assessment. In addition to offering an 
alternative insight into cognitive alterations in the transgenic animals under 
investigation, behavioural assessment more closely mimic the current clinical AD 
diagnostic criteria, which relies on neuropsychological testing. 
It is also worth considering that the application of the multi-parametric MRI protocol is 
time-consuming, especially when performing longitudinal studies. Therefore, this 
protocol may not be feasible for groups with limited access to an MRI scanner. 
In Chapter 5, I attempt to address an important question within the preclinical imaging 
community and explore the advantages and disadvantages of in vivo and ex vivo high 
resolution structural imaging of the mouse brain. I implement a fully optimised in vivo 
and ex vivo acquisition and analysis  protocol respectively, in order to provide a 
meaningful comparison that is relevant to future studies of transgenic mice.  Although I 
have not explored all possible methodological combinations when making this 
comparison (e.g. imaging time, different RF coils etc.), I hope that this work will 
provide a useful starting point for future structural imaging studies of the mouse brain.  
7.2 Final conclusion 
This thesis has demonstrated the development and implementation of in vivo MRI 
biomarkers to characterise mouse models of neurodegeneration. This work supports 
ongoing efforts to reduce the number of mice sacrificed for scientific endeavour, by 
implementing non-invasive imaging techniques and demonstrating their use in 
longitudinal studies. 
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